

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
20 March 2003 (20.03.2003)

PCT

(10) International Publication Number  
**WO 03/022222 A2**

- (51) International Patent Classification<sup>7</sup>: **A61K**
- (21) International Application Number: PCT/US02/28870
- (22) International Filing Date:  
11 September 2002 (11.09.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
09/953,611 13 September 2001 (13.09.2001) US
- (71) Applicant: **ISIS PHARMACEUTICALS, INC.**  
[US/US]; 2292 Faraday Avenue, Carlsbad, CA 92008 (US).
- (72) Inventors: **WARD, Donna, T.**; 41349 Magnolia Street, Murrieta, CA 92562 (US). **WATT, Andrew, T.**; 1500 Shad-owridge Drive, Apartment 154, Vista, CA 92083 (US).
- (74) Agents: **LICATA, Jane, Massey et al.**; Licata & Tyrrel P.C., 66 E. Main Street, Marlton, NJ 08053 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: ANTISENSE MODULATION OF PROTEIN KINASE R EXPRESSION

(57) Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Protein Kinase R. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Protein Kinase R. Methods of using these compounds for modulation of Protein Kinase R expression and for treatment of diseases associated with expression of Protein Kinase R are provided.

WO 03/022222 A2

5           **ANTISENSE MODULATION OF PROTEIN KINASE R EXPRESSION**

**FIELD OF THE INVENTION**

10           The present invention provides compositions and methods for  
modulating the expression of Protein Kinase R. In particular,  
this invention relates to compounds, particularly  
oligonucleotides, specifically hybridizable with nucleic acids  
encoding Protein Kinase R. Such compounds have been shown to  
15 modulate the expression of Protein Kinase R.

**BACKGROUND OF THE INVENTION**

          In the family of extracellular cytokines, interferons are  
glycoprotein signaling molecules that are secreted in response  
20 to viral infection. Interferon synthesis is induced by the  
presence of RNA with double stranded character, which is a  
common intermediate in the replication of many viruses.  
Interferons bind to cell-surface receptors and stimulate an  
antiviral, antiproliferative, immunomodulatory response in host  
25 cells by inhibiting the replication of both RNA and DNA viruses  
and by activating the transcription of more than three-hundred  
interferon-stimulated genes (de Veer et al., *J. Leukoc. Biol.*,  
**2001**, 69, 912-920).

          Interferon induces the synthesis of antiviral 2'5'-  
30 oligoadenylate synthetases, enzymes that catalyze the production  
of an unusual nucleotide compound, pppA(2',5'A)<sub>n</sub>. These 2',5'-  
oligoadenylates then bind and activate a latent ribonuclease,  
RNase L, which degrades viral and cellular mRNA and ribosomal  
RNA, thereby halting protein synthesis (de Veer et al., *J.*  
35 *Leukoc. Biol.*, **2001**, 69, 912-920).

          Serving to prevent viral replication and infection, or to  
silence transposon hopping in the germline, is a natural  
biological process called double-stranded RNA-induced gene  
silencing, or RNA interference (RNAi). RNAi is a process in

-2-

which double-stranded RNA (dsRNA) corresponding to the sense and antisense sequence of an endogenous mRNA is introduced into a cell, and the cognate mRNA is degraded and the gene silenced (Bass, *Cell*, **2000**, *101*, 235-238; Montgomery and Fire, *Trends Genet.*, **1998**, *14*, 255-258).

Interferons also induce the production of a serine/threonine kinase, Protein Kinase R (also known as PKR, PRKR, interferon-induced double-stranded RNA-activated p68 kinase, DAI, dsI, and P1/eIF2 $\alpha$  protein kinase). Protein kinase R plays an important role in the anti-viral response mediated by interferons, and is activated following infection by influenza virus, adenovirus, hepatitis C virus, and human immunodeficiency virus type 1 (HIV-1) (Balachandran et al., *Embo J.*, **1998**, *17*, 6888-6902).

In the presence of double-stranded RNA (dsRNA), Protein Kinase R autophosphorylates, which activates its enzymatic activity, and Protein Kinase R then catalyzes phosphorylation of its substrates. Substrates for Protein Kinase R include the alpha subunit of eukaryotic protein synthesis initiation factor 2 (eIF-2 $\alpha$ ), nuclear factor-kappa B (NF- $\kappa$ B), and B56 $\alpha$  (the regulatory subunit of human protein phosphatase 2A). These substrates act in two separate dsRNA-triggered antiviral programs involving the production of antiviral interferons and other alarmone cytokines and the expression of antiapoptotic genes (Iordanov et al., *Mol. Cell. Biol.*, **2001**, *21*, 61-72; Xu and Williams, *Mol. Cell. Biol.*, **2000**, *20*, 5285-5299).

The phosphorylation of eIF-2 $\alpha$  inhibits the factor at the initiation stage of translation. Because eIF-2 $\alpha$  regulates protein synthesis in interferon-treated and virus-infected cells, Protein Kinase R is a central component of the interferon-induced antiviral response, and may play an important role in the control of cell growth and differentiation in uninfected cells (Kuhlen et al., *Gene*, **1996**, *178*, 191-193).

Protein kinase R was first isolated as lambda phage and P1 phage clones from a human genomic library (Kuhlen et al., *Gene*, **1996**, *178*, 191-193) and the organization of the regulatory and catalytic subdomains of the human and mouse gene products was found to be remarkably conserved (Kuhlen et al., *Genomics*, **1996**,

-3-

36, 197-201). By fluorescence *in situ* hybridization, the human Protein Kinase R gene was localized to the 2p21 chromosomal locus, and the mouse gene was mapped to chromosome 17 (band E2) (Barber et al., *Genomics*, **1993**, 16, 765-767). Clusters of  
5 nonrandom breakpoints, translocations, and other alterations near the 2p21 region of the human chromosome are associated with lipomas, large cell lymphomas, immunoblastic lymphomas, T cell leukemias, myelodysplastic syndrome, primary congenital  
10 glaucoma, and acute myeloid leukemia (Barber et al., *Genomics*, **1993**, 16, 765-767; Sarfarazi et al., *Genomics*, **1995**, 30, 171-177).

Homodimerization is required to activate Protein Kinase R, and heterodimerization between Protein Kinase R and other dsRNA-binding proteins can inhibit its kinase activity. One dsRNA-  
15 binding protein, p74, interacts with both Protein Kinase R and with a catalytically defective mutant of Protein Kinase R, and modulates cell growth (Coolidge and Patton, *Nucleic Acids Res.*, **2000**, 28, 1407-1417).

In hepatitis C virus infections, most viral isolates are  
20 resistant to treatment with interferon, and the virus is believed to have mechanisms of circumventing the antiviral effect of interferon. One such mechanism involves the hepatitis C virus envelope protein, E2, which bears a sequence identical to phosphorylation sites in Protein Kinase R and in the Protein  
25 Kinase R target, eIF-2 $\alpha$ . The viral E2 protein inhibits Protein Kinase R activity and blocks its inhibitory effect on protein synthesis and cell growth (Taylor et al., *Science*, **1999**, 285, 107-110).

Another potential outcome of Protein Kinase R inhibition by  
30 hepatitis C viral protein E2 is the promotion of cell growth, which may contribute to the development of hepatitis C virus-associated hepatocellular carcinoma (He et al., *J. Virol.*, **2001**, 75, 5090-5098).

Protein kinase R has also been proposed to play a role in  
35 the induction of cell death. Apoptosis, or programmed cell death, occurs in response to cellular stresses such as growth factor deprivation, UV light, inflammatory cytokine production, and viral infection. Apoptosis is also induced in murine 3T3 L1 cells by overexpression of wild type Protein Kinase R when

-4-

treated with dsRNA. Conversely, overexpression of a catalytically inactive dominant-negative mutant Protein Kinase R causes malignant transformation and resistance to apoptosis, indicating the importance of this kinase in regulation of cellular proliferation (Balachandran et al., *Embo J.*, **1998**, *17*, 6888-6902).

Mice with a targeted deletion in the Protein Kinase R gene develop normally with no phenotypic defects, but have an impaired antiviral response upon dsRNA or interferon treatment, and murine embryonic fibroblasts (MEFs) derived from these Protein Kinase R null mice are less sensitive to apoptotic stimuli than MEFs obtained from isogenic normal mice (Der et al., *Proc. Natl. Acad. Sci. U. S. A.*, **1997**, *94*, 3279-3283). These mice are also more susceptible to infection by influenza virus, which may result from a failure to halt protein synthesis and an increase in viral replication, from a reduction of apoptosis (allowing the virus to replicate to higher levels during infection), or from a defect in Protein Kinase R-mediated stimulation of the immune system (de Veer et al., *J. Leukoc. Biol.*, **2001**, *69*, 912-920).

The pharmacological modulation of Protein Kinase R activity and/or expression is therefore believed to be an appropriate point of therapeutic intervention in viral infections, in pathological conditions such as cancer, in diseases affected by the misregulation of apoptotic pathways, as well as a target for the functional elucidation and/or the regulation of alternate RNA processing mechanisms such as RNAi.

Antisense-mediated inhibition of Protein Kinase R has been utilized as a tool to elucidate mechanisms of the interferon signal transduction pathway. The vaccinia virus has been used to infect cultured African green monkey kidney (BSC-40) cells, causing induction of the expression of an antisense mRNA transcript of Protein Kinase R, demonstrating that Protein Kinase R potently inhibits protein synthesis (Lee et al., *Virology*, **1993**, *192*, 380-385). Similarly, an eukaryotic expression vector was used to stably transform U-937 cells and inhibit expression of Protein Kinase R with antisense mRNA transcripts of the cDNA (Der and Lau, *Proc. Natl. Acad. Sci. U. S. A.*, **1995**, *92*, 8841-8845).

-5-

Disclosed and claimed in PCT Publication WO 97/08292 are methods for production of viral vaccines comprising infection of a cell culture deficient in Protein Kinase R activity, wherein said cells are obtained by transfection with or culturing cells in the presence of a Protein Kinase R antisense polynucleotide (Lau, 1997).

An antisense oligonucleotide, 19 nucleotides in length, was used to show that Protein Kinase R has an essential role in mediating the induction of apoptosis by tumor necrosis factor (TNF) (Yeung et al., *Proc. Natl. Acad. Sci. U. S. A.*, 1996, 93, 12451-12455).

A phosphorothioate antisense oligonucleotide, 18 nucleotides in length, complementary to the 5' end of the mRNA transcript, was used to show that inhibition of expression of Protein Kinase R blocked the induction of several immediate early genes (Mundschau and Faller, *J. Biol. Chem.*, 1995, 270, 3100-3106).

Because Protein Kinase R is activated by dsRNA, chimeric antisense oligonucleotides have been designed based on the binding site for 2',5'-oligoadenylates, 55-73 nucleotides down from the start codon of the Protein Kinase R mRNA (Cramer et al., *Bioorg. Med. Chem. Lett.*, 1999, 9, 1049-1054; Deb et al., *J. Immunol.*, 2001, 166, 6170-6180; Maitra et al., *J. Biol. Chem.*, 1995, 270, 15071-15075; Maran et al., *Science*, 1994, 265, 789-792; Xiao et al., *J. Med. Chem.*, 1997, 40, 1195-1200; Xiao et al., *J. Med. Chem.*, 1998, 41, 1531-1539). For example, the chimeric antisense oligonucleotide 5'-S<sub>p</sub>(A2'),A-linker-GTACTACTCCCTGCTTCTG-3'-3'tail(dC)-5' was used to show that Protein Kinase R is required for interferon gamma signaling to NF- $\kappa$ B (Deb et al., *J. Immunol.*, 2001, 166, 6170-6180).

Disclosed and claimed in US Patent 5,677,289 is an improvement in a method wherein an antisense oligonucleotide complementary to a target strand of mRNA is administered to a mammal, wherein the mammal is human, to reduce or inhibit the activity of the mRNA, the improvement comprising attaching an activator of ribonuclease L to an oligonucleotide, wherein the activator is an antisense oligonucleotide complementary to the Protein Kinase R mRNA (Torrence et al., 1997).

Disclosed and claimed in US Patent 5,837,503 is a

-6-

recombinant vector containing a cassette for transcription by RNA polymerase III, into which an oligonucleotide has been inserted, and used as a medicinal product. In one embodiment of the invention, the inserted oligonucleotide includes nucleotides encoding an antisense molecule that inhibits Protein Kinase R (Doglio et al., 1998).

However, these strategies are untested as therapeutic protocols, and currently, there are no known therapeutic agents which effectively inhibit the synthesis of Protein Kinase R.

Consequently, the need for additional agents capable of effectively inhibiting Protein Kinase R function remains.

Antisense technology is emerging as an effective means for reducing the expression of specific gene products and may therefore prove to be uniquely useful in a number of therapeutic, diagnostic, and research applications for the modulation of Protein Kinase R expression.

The present invention provides compositions and methods for modulating Protein Kinase R expression.

## SUMMARY OF THE INVENTION

The present invention is directed to compounds, particularly antisense oligonucleotides, which are targeted to a nucleic acid encoding Protein Kinase R, and which modulate the expression of Protein Kinase R. Pharmaceutical and other compositions comprising the compounds of the invention are also provided. Further provided are methods of modulating the expression of Protein Kinase R in cells or tissues comprising contacting said cells or tissues with one or more of the antisense compounds or compositions of the invention. Further provided are methods of treating an animal, particularly a human, suspected of having or being prone to a disease or condition associated with expression of Protein Kinase R by administering a therapeutically or prophylactically effective amount of one or more of the antisense compounds or compositions of the invention.

## DETAILED DESCRIPTION OF THE INVENTION

The present invention employs oligomeric compounds, particularly antisense oligonucleotides, for use in modulating

-7-

the function of nucleic acid molecules encoding Protein Kinase R, ultimately modulating the amount of Protein Kinase R produced. This is accomplished by providing antisense compounds which specifically hybridize with one or more nucleic acids encoding Protein Kinase R. As used herein, the terms "target nucleic acid" and "nucleic acid encoding Protein Kinase R" encompass DNA encoding Protein Kinase R, RNA (including pre-mRNA and mRNA) transcribed from such DNA, and also cDNA derived from such RNA. The specific hybridization of an oligomeric compound with its target nucleic acid interferes with the normal function of the nucleic acid. This modulation of function of a target nucleic acid by compounds which specifically hybridize to it is generally referred to as "antisense". The functions of DNA to be interfered with include replication and transcription. The functions of RNA to be interfered with include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA. The overall effect of such interference with target nucleic acid function is modulation of the expression of Protein Kinase R. In the context of the present invention, "modulation" means either an increase (stimulation) or a decrease (inhibition) in the expression of a gene. In the context of the present invention, inhibition is the preferred form of modulation of gene expression and mRNA is a preferred target.

It is preferred to target specific nucleic acids for antisense. "Targeting" an antisense compound to a particular nucleic acid, in the context of this invention, is a multistep process. The process usually begins with the identification of a nucleic acid sequence whose function is to be modulated. This may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. In the present invention, the target is a nucleic acid molecule encoding Protein Kinase R. The targeting process also includes determination of a site or sites within this gene for the antisense interaction to occur such that the desired effect, e.g., detection or modulation of expression of



-8-

the protein, will result. Within the context of the present invention, a preferred intragenic site is the region encompassing the translation initiation or termination codon of the open reading frame (ORF) of the gene. Since, as is known in the art, the translation initiation codon is typically 5'-AUG (in transcribed mRNA molecules; 5'-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the "AUG codon," the "start codon" or the "AUG start codon". A minority of genes have a translation initiation codon having the RNA sequence 5'-GUG, 5'-UUG or 5'-CUG, and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function in vivo. Thus, the terms "translation initiation codon" and "start codon" can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, "start codon" and "translation initiation codon" refer to the codon or codons that are used in vivo to initiate translation of an mRNA molecule transcribed from a gene encoding Protein Kinase R, regardless of the sequence(s) of such codons.

It is also known in the art that a translation termination codon (or "stop codon") of a gene may have one of three sequences, i.e., 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively). The terms "start codon region" and "translation initiation codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation initiation codon. Similarly, the terms "stop codon region" and "translation termination codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation termination codon.

The open reading frame (ORF) or "coding region," which is known in the art to refer to the region between the translation

-9-

initiation codon and the translation termination codon, is also a region which may be targeted effectively. Other target regions include the 5' untranslated region (5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation codon of an mRNA or corresponding nucleotides on the gene, and the 3' untranslated region (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3' end of an mRNA or corresponding nucleotides on the gene. The 5' cap of an mRNA comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap region of an mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides adjacent to the cap. The 5' cap region may also be a preferred target region.

Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as "introns," which are excised from a transcript before it is translated. The remaining (and therefore translated) regions are known as "exons" and are spliced together to form a continuous mRNA sequence. mRNA splice sites, i.e., intron-exon junctions, may also be preferred target regions, and are particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular mRNA splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions are also preferred targets. It has also been found that introns can also be effective, and therefore preferred, target regions for antisense compounds targeted, for example, to DNA or pre-mRNA.

Once one or more target sites have been identified, oligonucleotides are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect.

In the context of this invention, "hybridization" means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary

-10-

nucleoside or nucleotide bases. For example, adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds. "Complementary," as used herein, refers to the capacity for precise pairing between two nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of a DNA or RNA molecule, then the oligonucleotide and the DNA or RNA are considered to be complementary to each other at that position. The oligonucleotide and the DNA or RNA are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides which can hydrogen bond with each other. Thus, "specifically hybridizable" and "complementary" are terms which are used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the oligonucleotide and the DNA or RNA target. It is understood in the art that the sequence of an antisense compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. An antisense compound is specifically hybridizable when binding of the compound to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed.

Antisense and other compounds of the invention which hybridize to the target and inhibit expression of the target are identified through experimentation, and the sequences of these compounds are hereinbelow identified as preferred embodiments of the invention. The target sites to which these preferred sequences are complementary are hereinbelow referred to as "active sites" and are therefore preferred sites for targeting. Therefore another embodiment of the invention encompasses compounds which hybridize to these active sites.

Antisense compounds are commonly used as research reagents

-11-

and diagnostics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes. Antisense compounds are also  
5 used, for example, to distinguish between functions of various members of a biological pathway. Antisense modulation has, therefore, been harnessed for research use.

For use in kits and diagnostics, the antisense compounds of the present invention, either alone or in combination with other  
10 antisense compounds or therapeutics, can be used as tools in differential and/or combinatorial analyses to elucidate expression patterns of a portion or the entire complement of genes expressed within cells and tissues.

Expression patterns within cells or tissues treated with  
15 one or more antisense compounds are compared to control cells or tissues not treated with antisense compounds and the patterns produced are analyzed for differential levels of gene expression as they pertain, for example, to disease association, signaling pathway, cellular localization, expression level, size,  
20 structure or function of the genes examined. These analyses can be performed on stimulated or unstimulated cells and in the presence or absence of other compounds which affect expression patterns.

Examples of methods of gene expression analysis known in  
25 the art include DNA arrays or microarrays (Brazma and Vilo, *FEBS Lett.*, **2000**, 480, 17-24; Celis, et al., *FEBS Lett.*, **2000**, 480, 2-16), SAGE (serial analysis of gene expression) (Madden, et al., *Drug Discov. Today*, **2000**, 5, 415-425), READS (restriction enzyme amplification of digested cDNAs) (Prashar and Weissman, *Methods*  
30 *Enzymol.*, **1999**, 303, 258-72), TOGA (total gene expression analysis) (Sutcliffe, et al., *Proc. Natl. Acad. Sci. U. S. A.*, **2000**, 97, 1976-81), protein arrays and proteomics (Celis, et al., *FEBS Lett.*, **2000**, 480, 2-16; Jungblut, et al., *Electrophoresis*, **1999**, 20, 2100-10), expressed sequence tag  
35 (EST) sequencing (Celis, et al., *FEBS Lett.*, **2000**, 480, 2-16; Larsson, et al., *J. Biotechnol.*, **2000**, 80, 143-57), subtractive RNA fingerprinting (SuRF) (Fuchs, et al., *Anal. Biochem.*, **2000**, 286, 91-98; Larson, et al., *Cytometry*, **2000**, 41, 203-208), subtractive cloning, differential display (DD) (Jurecic and

-12-

Belmont, *Curr. Opin. Microbiol.*, **2000**, 3, 316-21), comparative genomic hybridization (Carulli, et al., *J. Cell Biochem. Suppl.*, **1998**, 31, 286-96), FISH (fluorescent in situ hybridization) techniques (Going and Gusterson, *Eur. J. Cancer*, **1999**, 35, 1895-904) and mass spectrometry methods (reviewed in (To, *Comb. Chem. High Throughput Screen*, **2000**, 3, 235-41)).

The specificity and sensitivity of antisense is also harnessed by those of skill in the art for therapeutic uses. Antisense oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals and man. Antisense oligonucleotide drugs, including ribozymes, have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes for treatment of cells, tissues and animals, especially humans.

In the context of this invention, the term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally-occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid target and increased stability in the presence of nucleases.

While antisense oligonucleotides are a preferred form of antisense compound, the present invention comprehends other oligomeric antisense compounds, including but not limited to oligonucleotide mimetics such as are described below. The antisense compounds in accordance with this invention preferably comprise from about 8 to about 50 nucleobases (i.e. from about 8 to about 50 linked nucleosides). Particularly preferred antisense compounds are antisense oligonucleotides, even more preferably those comprising from about 12 to about 30 nucleobases. Antisense compounds include ribozymes, external guide sequence (EGS) oligonucleotides (oligozymes), and other

-13-

short catalytic RNAs or catalytic oligonucleotides which hybridize to the target nucleic acid and modulate its expression.

As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2', 3' or 5' hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn the respective ends of this linear polymeric structure can be further joined to form a circular structure, however, open linear structures are generally preferred. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.

Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.

Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates, 5'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, selenophosphates and

-14-

boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein one or more internucleotide linkages is a 3' to 3', 5' to 5' or 2' to 2' linkage. Preferred oligonucleotides having inverted polarity comprise a single 3' to 3' linkage at the 3'-most internucleotide linkage i.e. a single inverted nucleoside residue which may be abasic (the nucleobase is missing or has a hydroxyl group in place thereof). Various salts, mixed salts and free acid forms are also included.

Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S.: 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,194,599; 5,565,555; 5,527,899; 5,721,218; 5,672,697 and 5,625,050, certain of which are commonly owned with this application, and each of which is herein incorporated by reference.

Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; riboacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH<sub>2</sub> component parts.

Representative United States patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S.: 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307;

-15-

5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240;  
5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312;  
5,633,360; 5,677,437; 5,792,608; 5,646,269 and 5,677,439,  
certain of which are commonly owned with this application, and  
5 each of which is herein incorporated by reference.

In other preferred oligonucleotide mimetics, both the sugar  
and the internucleoside linkage, i.e., the backbone, of the  
nucleotide units are replaced with novel groups. The base units  
are maintained for hybridization with an appropriate nucleic  
10 acid target compound. One such oligomeric compound, an  
oligonucleotide mimetic that has been shown to have excellent  
hybridization properties, is referred to as a peptide nucleic  
acid (PNA). In PNA compounds, the sugar-backbone of an  
oligonucleotide is replaced with an amide containing backbone,  
15 in particular an aminoethylglycine backbone. The nucleobases  
are retained and are bound directly or indirectly to aza  
nitrogen atoms of the amide portion of the backbone.

Representative United States patents that teach the preparation  
of PNA compounds include, but are not limited to, U.S.:

20 5,539,082; 5,714,331; and 5,719,262, each of which is herein  
incorporated by reference. Further teaching of PNA compounds  
can be found in Nielsen et al., *Science*, **1991**, 254, 1497-1500.

Most preferred embodiments of the invention are  
oligonucleotides with phosphorothioate backbones and  
25 oligonucleosides with heteroatom backbones, and in particular -  
CH<sub>2</sub>-NH-O-CH<sub>2</sub>-, -CH<sub>2</sub>-N(CH<sub>3</sub>)-O-CH<sub>2</sub>- [known as a methylene  
(methylinino) or MMI backbone], -CH<sub>2</sub>-O-N(CH<sub>3</sub>)-CH<sub>2</sub>-, -CH<sub>2</sub>-N(CH<sub>3</sub>)-  
N(CH<sub>3</sub>)-CH<sub>2</sub>- and -O-N(CH<sub>3</sub>)-CH<sub>2</sub>-CH<sub>2</sub>- [wherein the native  
phosphodiester backbone is represented as -O-P-O-CH<sub>2</sub>-] of the  
30 above referenced U.S. patent 5,489,677, and the amide backbones  
of the above referenced U.S. patent 5,602,240. Also preferred  
are oligonucleotides having morpholino backbone structures of  
the above-referenced U.S. patent 5,034,506.

Modified oligonucleotides may also contain one or more  
35 substituted sugar moieties. Preferred oligonucleotides comprise  
one of the following at the 2' position: OH; F; O-, S-, or N-  
alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-  
alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted  
or unsubstituted C<sub>1</sub> to C<sub>10</sub> alkyl or C<sub>2</sub> to C<sub>10</sub> alkenyl and alkynyl.



-16-

Particularly preferred are  $O[(CH_2)_nO]_mCH_3$ ,  $O(CH_2)_nOCH_3$ ,  $O(CH_2)_nNH_2$ ,  $O(CH_2)_nCH_3$ ,  $O(CH_2)_nONH_2$ , and  $O(CH_2)_nON[(CH_2)_mCH_3]_2$ , where  $n$  and  $m$  are from 1 to about 10. Other preferred oligonucleotides comprise one of the following at the 2' position:  $C_1$  to  $C_{10}$  lower alkyl, substituted lower alkyl, alkenyl, alkynyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH,  $SCH_3$ , OCN, Cl, Br, CN,  $CF_3$ ,  $OCF_3$ ,  $SOCH_3$ ,  $SO_2CH_3$ ,  $ONO_2$ ,  $NO_2$ ,  $N_3$ ,  $NH_2$ , heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification includes 2'-methoxyethoxy (2'-O- $CH_2CH_2OCH_3$ , also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., *Helv. Chim. Acta*, **1995**, 78, 486-504) i.e., an alkoxyalkoxy group. A further preferred modification includes 2'-dimethylaminooxyethoxy, i.e., a  $O(CH_2)_2ON(CH_3)_2$  group, also known as 2'-DMAOE, as described in examples hereinbelow, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethylaminoethoxyethyl or 2'-DMAEOE), i.e., 2'-O- $CH_2$ -O- $CH_2$ - $N(CH_3)_2$ , also described in examples hereinbelow.

A further preferred modification includes Locked Nucleic Acids (LNAs) in which the 2'-hydroxyl group is linked to the 3' or 4' carbon atom of the sugar ring thereby forming a bicyclic sugar moiety. The linkage is preferably a methylene ( $-CH_2-$ ) group bridging the 2' oxygen atom and the 4' carbon atom wherein  $n$  is 1 or 2. LNAs and preparation thereof are described in WO 98/39352 and WO 99/14226.

Other preferred modifications include 2'-methoxy (2'-O- $CH_3$ ), 2'-aminopropoxy (2'-O $CH_2CH_2CH_2NH_2$ ), 2'-allyl (2'- $CH_2$ - $CH=CH_2$ ), 2'-O-allyl (2'-O- $CH_2$ - $CH=CH_2$ ) and 2'-fluoro (2'-F). The 2'-modification may be in the arabino (up) position or ribo (down) position. A preferred 2'-arabino modification is 2'-F. Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States

-17-

patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S.: 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; 5,792,747; and 5,700,920, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

10 Oligonucleotides may also include nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and  
15 uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and  
20 cytosine, 5-propynyl ( $-C\equiv C-CH_3$ ) uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted  
25 adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further  
30 modified nucleobases include tricyclic pyrimidines such as phenoxazine cytidine (1H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), phenothiazine cytidine (1H-pyrimido[5,4-b][1,4]benzothiazin-2(3H)-one), G-clamps such as a substituted phenoxazine cytidine (e.g. 9-(2-aminoethoxy)-H-pyrimido[5,4-  
35 b][1,4]benzoxazin-2(3H)-one), carbazole cytidine (2H-pyrimido[4,5-b]indol-2-one), pyridoindole cytidine (H-pyrido[3',2':4,5]pyrrolo[2,3-d]pyrimidin-2-one). Modified nucleobases may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example

-18-

7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. Further nucleobases include those disclosed in United States Patent No. 3,687,808, those disclosed in *The Concise Encyclopedia Of Polymer Science And Engineering*, pages 858-859, Kroschwitz, J.I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., *Angewandte Chemie*, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y.S., Chapter 15, *Antisense Research and Applications*, pages 289-302, Crooke, S.T. and Lebleu, B., ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y.S., Crooke, S.T. and Lebleu, B., eds., *Antisense Research and Applications*, CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

Representative United States patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. 3,687,808, as well as U.S.: 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; 5,645,985; 5,830,653; 5,763,588; 6,005,096; and 5,681,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference, and United States patent 5,750,692, which is commonly owned with the instant application and also herein incorporated by reference.

Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. The compounds of the invention can include conjugate groups covalently bound to functional groups such as primary or

-19-

secondary hydroxyl groups. Conjugate groups of the invention include intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, polyethers, groups that enhance the pharmacodynamic properties of oligomers, and groups that enhance the pharmacokinetic properties of oligomers. Typical conjugates groups include cholesterols, lipids, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes. Groups that enhance the pharmacodynamic properties, in the context of this invention, include groups that improve oligomer uptake, enhance oligomer resistance to degradation, and/or strengthen sequence-specific hybridization with RNA. Groups that enhance the pharmacokinetic properties, in the context of this invention, include groups that improve oligomer uptake, distribution, metabolism or excretion. Representative conjugate groups are disclosed in International Patent Application PCT/US92/09196, filed October 23, 1992 the entire disclosure of which is incorporated herein by reference. Conjugate moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., *Proc. Natl. Acad. Sci. USA*, **1989**, 86, 6553-6556), cholic acid (Manoharan et al., *Bioorg. Med. Chem. Lett.*, **1994**, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., *Ann. N.Y. Acad. Sci.*, **1992**, 660, 306-309; Manoharan et al., *Bioorg. Med. Chem. Lett.*, **1993**, 3, 2765-2770), a thiocholesterol (Oberhauser et al., *Nucl. Acids Res.*, **1992**, 20, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., *EMBO J.*, **1991**, 10, 1111-1118; Kabanov et al., *FEBS Lett.*, **1990**, 259, 327-330; Svinarchuk et al., *Biochimie*, **1993**, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., *Tetrahedron Lett.*, **1995**, 36, 3651-3654; Shea et al., *Nucl. Acids Res.*, **1990**, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., *Nucleosides & Nucleotides*, **1995**, 14, 969-973), or adamantane acetic acid (Manoharan et al., *Tetrahedron Lett.*, **1995**, 36, 3651-3654), a palmityl moiety (Mishra et al., *Biochim. Biophys. Acta*, **1995**, 1264, 229-237), or an octadecylamine or hexylamino-carbonyloxycholesterol moiety (Crooke et al., *J. Pharmacol. Exp. Ther.*,

-20-

1996, 277, 923-937. Oligonucleotides of the invention may also be conjugated to active drug substances, for example, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fenbufen, ketoprofen, (S)-(+)-pranoprofen, carprofen, dansylsarcosine, 2,3,5-triiodobenzoic acid, flufenamic acid, folinic acid, a benzothiadiazide, chlorothiazide, a diazepine, indomethacin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic. Oligonucleotide-drug conjugates and their preparation are described in United States Patent Application 09/334,130 (filed June 15, 1999) which is incorporated herein by reference in its entirety.

Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U.S.: 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717; 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241; 5,391,723; 5,416,203; 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference.

It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide. The present invention also includes antisense compounds which are chimeric compounds. "Chimeric" antisense compounds or "chimeras," in the context of this invention, are antisense compounds, particularly oligonucleotides, which contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotide compound. These oligonucleotides typically

-21-

contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid.

- 5 An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, 10 thereby greatly enhancing the efficiency of oligonucleotide inhibition of gene expression. Consequently, comparable results can often be obtained with shorter oligonucleotides when chimeric oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides hybridizing to the same target region.
- 15 Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

Chimeric antisense compounds of the invention may be formed as composite structures of two or more oligonucleotides, 20 modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S.: 25 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

30 The antisense compounds used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, CA). Any other means 35 for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives.

The antisense compounds of the invention are synthesized in

-22-

vitro and do not include antisense compositions of biological origin, or genetic vector constructs designed to direct the in vivo synthesis of antisense molecules.

The compounds of the invention may also be admixed,

5 encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative United States  
10 patents that teach the preparation of such uptake, distribution and/or absorption assisting formulations include, but are not limited to, U.S.: 5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,158; 5,547,932; 5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556; 5,108,921; 5,213,804;  
15 5,227,170; 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978; 5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259; 5,543,152; 5,556,948; 5,580,575; and 5,595,756, each of which is herein incorporated by reference.

The antisense compounds of the invention encompass any  
20 pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn  
25 to prodrugs and pharmaceutically acceptable salts of the compounds of the invention, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents.

The term "prodrug" indicates a therapeutic agent that is prepared in an inactive form that is converted to an active form  
30 (i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/or conditions. In particular, prodrug versions of the oligonucleotides of the invention are prepared as SATE [(S-acetyl-2-thioethyl) phosphate] derivatives according to the methods disclosed in WO  
35 93/24510 to Gosselin et al., published December 9, 1993 or in WO 94/26764 and U.S. 5,770,713 to Imbach et al.

The term "pharmaceutically acceptable salts" refers to physiologically and pharmaceutically acceptable salts of the compounds of the invention: i.e., salts that retain the desired

-23-

biological activity of the parent compound and do not impart undesired toxicological effects thereto.

Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge et al., "Pharmaceutical Salts," *J. of Pharma Sci.*, **1977**, 66, 1-19). The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner. The free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention. As used herein, a "pharmaceutical addition salt" includes a pharmaceutically acceptable salt of an acid form of one of the components of the compositions of the invention. These include organic or inorganic acid salts of the amines. Preferred acid salts are the hydrochlorides, acetates, salicylates, nitrates and phosphates. Other suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of a variety of inorganic and organic acids, such as, for example, with inorganic acids, such as for example hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid; with organic carboxylic, sulfonic, sulfo or phospho acids or N-substituted sulfamic acids, for example acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylemaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, embonic acid, nicotinic acid or isonicotinic acid; and with amino acids, such



-24-

as the 20 alpha-amino acids involved in the synthesis of proteins in nature, for example glutamic acid or aspartic acid, and also with phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 2- or 3-phosphoglycerate, glucose-6-phosphate, N-cyclohexylsulfamic acid (with the formation of cyclamates), or with other acid organic compounds, such as ascorbic acid. Pharmaceutically acceptable salts of compounds may also be prepared with a pharmaceutically acceptable cation. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. Carbonates or hydrogen carbonates are also possible.

For oligonucleotides, preferred examples of pharmaceutically acceptable salts include but are not limited to (a) salts formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as spermine and spermidine, etc.; (b) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; (c) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (d) salts formed from elemental anions such as chlorine, bromine, and iodine.

The antisense compounds of the present invention can be utilized for diagnostics, therapeutics, prophylaxis and as research reagents and kits. For therapeutics, an animal, preferably a human, suspected of having a disease or disorder which can be treated by modulating the expression of Protein Kinase R is treated by administering antisense compounds in accordance with this invention. The compounds of the invention can be utilized in pharmaceutical compositions by adding an effective amount of an antisense compound to a suitable

-25-

pharmaceutically acceptable diluent or carrier. Use of the antisense compounds and methods of the invention may also be useful prophylactically, e.g., to prevent or delay infection, inflammation or tumor formation, for example.

5       The antisense compounds of the invention are useful for research and diagnostics, because these compounds hybridize to nucleic acids encoding Protein Kinase R, enabling sandwich and other assays to easily be constructed to exploit this fact. Hybridization of the antisense oligonucleotides of the invention  
10 with a nucleic acid encoding Protein Kinase R can be detected by means known in the art. Such means may include conjugation of an enzyme to the oligonucleotide, radiolabelling of the oligonucleotide or any other suitable detection means. Kits using such detection means for detecting the level of Protein  
15 Kinase R in a sample may also be prepared.

      The present invention also includes pharmaceutical compositions and formulations which include the antisense compounds of the invention. The pharmaceutical compositions of the present invention may be administered in a number of ways  
20 depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer;  
25 intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Oligonucleotides with at  
30 least one 2'-O-methoxyethyl modification are believed to be particularly useful for oral administration.

      Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and  
35 powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful. Preferred topical formulations include those in which the oligonucleotides of the invention are in admixture with a

-26-

topical delivery agent such as lipids, liposomes, fatty acids, fatty acid esters, steroids, chelating agents and surfactants. Preferred lipids and liposomes include neutral (e.g. dioleoylphosphatidyl DOPE ethanolamine, dimyristoylphosphatidyl choline DMPC, distearoylphosphatidyl choline) negative (e.g. dimyristoylphosphatidyl glycerol DMPG) and cationic (e.g. dioleoyltetramethylaminopropyl DOTAP and dioleoylphosphatidyl ethanolamine DOTMA). Oligonucleotides of the invention may be encapsulated within liposomes or may form complexes thereto, in particular to cationic liposomes. Alternatively, oligonucleotides may be complexed to lipids, in particular to cationic lipids. Preferred fatty acids and esters include but are not limited arachidonic acid, oleic acid, eicosanoic acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an acylcholine, or a C<sub>1-10</sub> alkyl ester (e.g. isopropylmyristate IPM), monoglyceride, diglyceride or pharmaceutically acceptable salt thereof. Topical formulations are described in detail in United States patent application 09/315,298 filed on May 20, 1999 which is incorporated herein by reference in its entirety.

Compositions and formulations for oral administration include powders or granules, microparticulates, nanoparticulates, suspensions or solutions in water or non-aqueous media, capsules, gel capsules, sachets, tablets or minitables. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable. Preferred oral formulations are those in which oligonucleotides of the invention are administered in conjunction with one or more penetration enhancers surfactants and chelators. Preferred surfactants include fatty acids and/or esters or salts thereof, bile acids and/or salts thereof. Preferred bile acids/salts include chenodeoxycholic acid (CDCA) and ursodeoxychenodeoxycholic acid (UDCA), cholic acid, dehydrocholic acid, deoxycholic acid, glucolic acid, glycholic acid, glycodeoxycholic acid, taurocholic acid, taurodeoxycholic acid, sodium tauro-24,25-dihydro-fusidate, sodium glycodihydrofusidate, . Preferred fatty acids include arachidonic

-27-

acid, undecanoic acid, oleic acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprato, tricaprato, monoolein, dilaurin, glyceryl 1-monocaprato, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an acylcholine, or a monoglyceride, a diglyceride or a pharmaceutically acceptable salt thereof (e.g. sodium). Also preferred are combinations of penetration enhancers, for example, fatty acids/salts in combination with bile acids/salts. A particularly preferred combination is the sodium salt of lauric acid, capric acid and UDCA. Further penetration enhancers include polyoxyethylene-9-lauryl ether, polyoxyethylene-20-cetyl ether. Oligonucleotides of the invention may be delivered orally in granular form including sprayed dried particles, or complexed to form micro or nanoparticles. Oligonucleotide complexing agents include poly-amino acids; polyimines; polyacrylates; polyalkylacrylates, polyoxethanes, polyalkylcyanoacrylates; cationized gelatins, albumins, starches, acrylates, polyethyleneglycols (PEG) and starches; polyalkylcyanoacrylates; DEAE-derivatized polyimines, pollulans, celluloses and starches. Particularly preferred complexing agents include chitosan, N-trimethylchitosan, poly-L-lysine, polyhistidine, polyornithine, polyspermines, protamine, polyvinylpyridine, polythiodiethylamino-methylethylene P(TDAE), polyaminostyrene (e.g. p-amino), poly(methylcyanoacrylate), poly(ethylcyanoacrylate), poly(butylcyanoacrylate), poly(isobutylcyanoacrylate), poly(isohexylcyanoacrylate), DEAE-methacrylate, DEAE-hexylacrylate, DEAE-acrylamide, DEAE-albumin and DEAE-dextran, polymethylacrylate, polyhexylacrylate, poly(D,L-lactic acid), poly(DL-lactic-co-glycolic acid (PLGA), alginate, and polyethyleneglycol (PEG). Oral formulations for oligonucleotides and their preparation are described in detail in United States applications 08/886,829 (filed July 1, 1997), 09/108,673 (filed July 1, 1998), 09/256,515 (filed February 23, 1999), 09/082,624 (filed May 21, 1998) and 09/315,298 (filed May 20, 1999) each of which is incorporated herein by reference in their entirety.

Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents and other

-28-

suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions may be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids.

The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

The compositions of the present invention may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, gel capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention may also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

In one embodiment of the present invention the pharmaceutical compositions may be formulated and used as foams. Pharmaceutical foams include formulations such as, but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature these formulations vary in the components and the consistency of the final product. The preparation of such compositions and formulations is generally known to those skilled in the pharmaceutical and formulation arts and may be applied to the formulation of the compositions of the present invention.

-29-

## Emulsions

The compositions of the present invention may be prepared and formulated as emulsions. Emulsions are typically heterogenous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1  $\mu\text{m}$  in diameter. (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199; Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., Volume 1, p. 245; Block in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 2, p. 335; Higuchi et al., in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, 1985, p. 301). Emulsions are often biphasic systems comprising of two immiscible liquid phases intimately mixed and dispersed with each other. In general, emulsions may be either water-in-oil (w/o) or of the oil-in-water (o/w) variety. When an aqueous phase is finely divided into and dispersed as minute droplets into a bulk oily phase the resulting composition is called a water-in-oil (w/o) emulsion. Alternatively, when an oily phase is finely divided into and dispersed as minute droplets into a bulk aqueous phase the resulting composition is called an oil-in-water (o/w) emulsion. Emulsions may contain additional components in addition to the dispersed phases and the active drug which may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase. Pharmaceutical excipients such as emulsifiers, stabilizers, dyes, and anti-oxidants may also be present in emulsions as needed. Pharmaceutical emulsions may also be multiple emulsions that are comprised of more than two phases such as, for example, in the case of oil-in-water-in-oil (o/w/o) and water-in-oil-in-water (w/o/w) emulsions. Such complex formulations often provide certain advantages that simple binary emulsions do not. Multiple emulsions in which individual oil droplets of an o/w emulsion enclose small water droplets constitute a w/o/w emulsion. Likewise a system of oil droplets enclosed in globules of water stabilized in an oily continuous provides an o/w/o emulsion.

-30-

Emulsions are characterized by little or no thermodynamic stability. Often, the dispersed or discontinuous phase of the emulsion is well dispersed into the external or continuous phase and maintained in this form through the means of emulsifiers or the viscosity of the formulation. Either of the phases of the emulsion may be a semisolid or a solid, as is the case of emulsion-style ointment bases and creams. Other means of stabilizing emulsions entail the use of emulsifiers that may be incorporated into either phase of the emulsion. Emulsifiers may broadly be classified into four categories: synthetic surfactants, naturally occurring emulsifiers, absorption bases, and finely dispersed solids (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Synthetic surfactants, also known as surface active agents, have found wide applicability in the formulation of emulsions and have been reviewed in the literature (Rieger, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), Marcel Dekker, Inc., New York, N.Y., 1988, volume 1, p. 199). Surfactants are typically amphiphilic and comprise a hydrophilic and a hydrophobic portion. The ratio of the hydrophilic to the hydrophobic nature of the surfactant has been termed the hydrophile/lipophile balance (HLB) and is a valuable tool in categorizing and selecting surfactants in the preparation of formulations. Surfactants may be classified into different classes based on the nature of the hydrophilic group: nonionic, anionic, cationic and amphoteric (Rieger, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285).

Naturally occurring emulsifiers used in emulsion formulations include lanolin, beeswax, phosphatides, lecithin and acacia. Absorption bases possess hydrophilic properties such that they can soak up water to form w/o emulsions yet retain their semisolid consistencies, such as anhydrous lanolin and hydrophilic petrolatum. Finely divided solids have also been used as good emulsifiers especially in combination with

-31-

surfactants and in viscous preparations. These include polar inorganic solids, such as heavy metal hydroxides, nonswelling clays such as bentonite, attapulgite, hectorite, kaolin, montmorillonite, colloidal aluminum silicate and colloidal magnesium aluminum silicate, pigments and nonpolar solids such as carbon or glyceryl tristearate.

A large variety of non-emulsifying materials are also included in emulsion formulations and contribute to the properties of emulsions. These include fats, oils, waxes, fatty acids, fatty alcohols, fatty esters, humectants, hydrophilic colloids, preservatives and antioxidants (Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Hydrophilic colloids or hydrocolloids include naturally occurring gums and synthetic polymers such as polysaccharides (for example, acacia, agar, alginic acid, carrageenan, guar gum, karaya gum, and tragacanth), cellulose derivatives (for example, carboxymethylcellulose and carboxypropylcellulose), and synthetic polymers (for example, carbomers, cellulose ethers, and carboxyvinyl polymers). These disperse or swell in water to form colloidal solutions that stabilize emulsions by forming strong interfacial films around the dispersed-phase droplets and by increasing the viscosity of the external phase.

Since emulsions often contain a number of ingredients such as carbohydrates, proteins, sterols and phosphatides that may readily support the growth of microbes, these formulations often incorporate preservatives. Commonly used preservatives included in emulsion formulations include methyl paraben, propyl paraben, quaternary ammonium salts, benzalkonium chloride, esters of p-hydroxybenzoic acid, and boric acid. Antioxidants are also commonly added to emulsion formulations to prevent deterioration of the formulation. Antioxidants used may be free radical scavengers such as tocopherols, alkyl gallates, butylated hydroxyanisole, butylated hydroxytoluene, or reducing agents such as ascorbic acid and sodium metabisulfite, and antioxidant synergists such as citric acid, tartaric acid, and lecithin.



-32-

The application of emulsion formulations via dermatological, oral and parenteral routes and methods for their manufacture have been reviewed in the literature (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Emulsion formulations for oral delivery have been very widely used because of reasons of ease of formulation, efficacy from an absorption and bioavailability standpoint. (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Mineral-oil base laxatives, oil-soluble vitamins and high fat nutritive preparations are among the materials that have commonly been administered orally as o/w emulsions.

In one embodiment of the present invention, the compositions of oligonucleotides and nucleic acids are formulated as microemulsions. A microemulsion may be defined as a system of water, oil and amphiphile which is a single optically isotropic and thermodynamically stable liquid solution (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Typically microemulsions are systems that are prepared by first dispersing an oil in an aqueous surfactant solution and then adding a sufficient amount of a fourth component, generally an intermediate chain-length alcohol to form a transparent system. Therefore, microemulsions have also been described as thermodynamically stable, isotropically clear dispersions of two immiscible liquids that are stabilized by interfacial films of surface-active molecules (Leung and Shah, in: *Controlled Release of Drugs: Polymers and Aggregate Systems*, Rosoff, M., Ed., 1989, VCH Publishers, New York, pages 185-215). Microemulsions commonly are prepared via a combination of three to five components that include oil, water, surfactant, cosurfactant and electrolyte. Whether the microemulsion is of the water-in-oil (w/o) or an oil-in-water (o/w) type is dependent on the properties of the oil and surfactant used and on the structure and geometric packing of the polar heads and

-33-

hydrocarbon tails of the surfactant molecules (Schott, in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, 1985, p. 271).

The phenomenological approach utilizing phase diagrams has been extensively studied and has yielded a comprehensive knowledge, to one skilled in the art, of how to formulate microemulsions (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335). Compared to conventional emulsions, microemulsions offer the advantage of solubilizing water-insoluble drugs in a formulation of thermodynamically stable droplets that are formed spontaneously.

Surfactants used in the preparation of microemulsions include, but are not limited to, ionic surfactants, non-ionic surfactants, Brij 96, polyoxyethylene oleyl ethers, polyglycerol fatty acid esters, tetraglycerol monolaurate (ML310), tetraglycerol monooleate (MO310), hexaglycerol monooleate (PO310), hexaglycerol pentaoleate (PO500), decaglycerol monocaprates (MCA750), decaglycerol monooleate (MO750), decaglycerol sequioleate (SO750), decaglycerol decaoleate (DAO750), alone or in combination with cosurfactants. The cosurfactant, usually a short-chain alcohol such as ethanol, 1-propanol, and 1-butanol, serves to increase the interfacial fluidity by penetrating into the surfactant film and consequently creating a disordered film because of the void space generated among surfactant molecules. Microemulsions may, however, be prepared without the use of cosurfactants and alcohol-free self-emulsifying microemulsion systems are known in the art. The aqueous phase may typically be, but is not limited to, water, an aqueous solution of the drug, glycerol, PEG300, PEG400, polyglycerols, propylene glycols, and derivatives of ethylene glycol. The oil phase may include, but is not limited to, materials such as Captex 300, Captex 355, Capmul MCM, fatty acid esters, medium chain (C8-C12) mono, di, and tri-glycerides, polyoxyethylated glyceryl fatty acid esters, fatty alcohols, polyglycolized glycerides, saturated polyglycolized C8-C10 glycerides, vegetable oils and silicone oil.

-34-

Microemulsions are particularly of interest from the standpoint of drug solubilization and the enhanced absorption of drugs. Lipid based microemulsions (both o/w and w/o) have been proposed to enhance the oral bioavailability of drugs, including peptides (Constantinides et al., *Pharmaceutical Research*, **1994**, 11, 1385-1390; Ritschel, *Meth. Find. Exp. Clin. Pharmacol.*, **1993**, 13, 205). Microemulsions afford advantages of improved drug solubilization, protection of drug from enzymatic hydrolysis, possible enhancement of drug absorption due to surfactant-induced alterations in membrane fluidity and permeability, ease of preparation, ease of oral administration over solid dosage forms, improved clinical potency, and decreased toxicity (Constantinides et al., *Pharmaceutical Research*, **1994**, 11, 1385; Ho et al., *J. Pharm. Sci.*, **1996**, 85, 138-143). Often microemulsions may form spontaneously when their components are brought together at ambient temperature. This may be particularly advantageous when formulating thermolabile drugs, peptides or oligonucleotides. Microemulsions have also been effective in the transdermal delivery of active components in both cosmetic and pharmaceutical applications. It is expected that the microemulsion compositions and formulations of the present invention will facilitate the increased systemic absorption of oligonucleotides and nucleic acids from the gastrointestinal tract, as well as improve the local cellular uptake of oligonucleotides and nucleic acids within the gastrointestinal tract, vagina, buccal cavity and other areas of administration.

Microemulsions of the present invention may also contain additional components and additives such as sorbitan monostearate (Grill 3), Labrasol, and penetration enhancers to improve the properties of the formulation and to enhance the absorption of the oligonucleotides and nucleic acids of the present invention. Penetration enhancers used in the microemulsions of the present invention may be classified as belonging to one of five broad categories - surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, **1991**, p. 92). Each of these classes has been discussed above.

-35-

## Liposomes

There are many organized surfactant structures besides microemulsions that have been studied and used for the formulation of drugs. These include monolayers, micelles, bilayers and vesicles. Vesicles, such as liposomes, have attracted great interest because of their specificity and the duration of action they offer from the standpoint of drug delivery. As used in the present invention, the term "liposome" means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers.

Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the composition to be delivered. Cationic liposomes possess the advantage of being able to fuse to the cell wall. Non-cationic liposomes, although not able to fuse as efficiently with the cell wall, are taken up by macrophages *in vivo*.

In order to cross intact mammalian skin, lipid vesicles must pass through a series of fine pores, each with a diameter less than 50 nm, under the influence of a suitable transdermal gradient. Therefore, it is desirable to use a liposome which is highly deformable and able to pass through such fine pores.

Further advantages of liposomes include; liposomes obtained from natural phospholipids are biocompatible and biodegradable; liposomes can incorporate a wide range of water and lipid soluble drugs; liposomes can protect encapsulated drugs in their internal compartments from metabolism and degradation (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Important considerations in the preparation of liposome formulations are the lipid surface charge, vesicle size and the aqueous volume of the liposomes.

Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposomal membrane is structurally similar to biological membranes, when liposomes are applied to a tissue, the liposomes start to merge with the cellular membranes. As the merging of the liposome and

-36-

cell progresses, the liposomal contents are emptied into the cell where the active agent may act.

Liposomal formulations have been the focus of extensive investigation as the mode of delivery for many drugs. There is  
5 growing evidence that for topical administration, liposomes present several advantages over other formulations. Such advantages include reduced side-effects related to high systemic absorption of the administered drug, increased accumulation of the administered drug at the desired target, and the ability to  
10 administer a wide variety of drugs, both hydrophilic and hydrophobic, into the skin.

Several reports have detailed the ability of liposomes to deliver agents including high-molecular weight DNA into the skin. Compounds including analgesics, antibodies, hormones and  
15 high-molecular weight DNAs have been administered to the skin. The majority of applications resulted in the targeting of the upper epidermis.

Liposomes fall into two broad classes. Cationic liposomes are positively charged liposomes which interact with the  
20 negatively charged DNA molecules to form a stable complex. The positively charged DNA/liposome complex binds to the negatively charged cell surface and is internalized in an endosome. Due to the acidic pH within the endosome, the liposomes are ruptured, releasing their contents into the cell cytoplasm (Wang *et al.*,  
25 *Biochem. Biophys. Res. Commun.*, **1987**, 147, 980-985).

Liposomes which are pH-sensitive or negatively-charged, entrap DNA rather than complex with it. Since both the DNA and the lipid are similarly charged, repulsion rather than complex formation occurs. Nevertheless, some DNA is entrapped within the  
30 aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver DNA encoding the thymidine kinase gene to cell monolayers in culture. Expression of the exogenous gene was detected in the target cells (Zhou *et al.*, *Journal of Controlled Release*, **1992**, 19, 269-274).

35 One major type of liposomal composition includes phospholipids other than naturally-derived phosphatidylcholine. Neutral liposome compositions, for example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC). Anionic liposome compositions

-37-

generally are formed from dimyristoyl phosphatidylglycerol, while anionic fusogenic liposomes are formed primarily from dioleoyl phosphatidylethanolamine (DOPE). Another type of liposomal composition is formed from phosphatidylcholine (PC) such as, for example, soybean PC, and egg PC. Another type is formed from mixtures of phospholipid and/or phosphatidylcholine and/or cholesterol.

Several studies have assessed the topical delivery of liposomal drug formulations to the skin. Application of liposomes containing interferon to guinea pig skin resulted in a reduction of skin herpes sores while delivery of interferon via other means (e.g. as a solution or as an emulsion) were ineffective (Weiner et al., *Journal of Drug Targeting*, **1992**, *2*, 405-410). Further, an additional study tested the efficacy of interferon administered as part of a liposomal formulation to the administration of interferon using an aqueous system, and concluded that the liposomal formulation was superior to aqueous administration (du Plessis et al., *Antiviral Research*, **1992**, *18*, 259-265).

Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin, in particular systems comprising non-ionic surfactant and cholesterol. Non-ionic liposomal formulations comprising Novasome™ I (glyceryl dilaurate/cholesterol/polyoxyethylene-10-stearyl ether) and Novasome™ II (glyceryl distearate/cholesterol/polyoxyethylene-10-stearyl ether) were used to deliver cyclosporin-A into the dermis of mouse skin. Results indicated that such non-ionic liposomal systems were effective in facilitating the deposition of cyclosporin-A into different layers of the skin (Hu et al. *S.T.P. Pharma. Sci.*, **1994**, *4*, *6*, 466).

Liposomes also include "sterically stabilized" liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome (A) comprises one

-38-

or more glycolipids, such as monosialoganglioside  $G_{M1}$ , or (B) is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. While not wishing to be bound by any particular theory, it is thought in the art that, at least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these sterically stabilized liposomes derives from a reduced uptake into cells of the reticuloendothelial system (RES) (Allen et al., *FEBS Letters*, 1987, 223, 42; Wu et al., *Cancer Research*, 1993, 53, 3765).

Various liposomes comprising one or more glycolipids are known in the art. Papahadjopoulos et al. (*Ann. N.Y. Acad. Sci.*, 1987, 507, 64) reported the ability of monosialoganglioside  $G_{M1}$ , galactocerebroside sulfate and phosphatidylinositol to improve blood half-lives of liposomes. These findings were expounded upon by Gabizon et al. (*Proc. Natl. Acad. Sci. U.S.A.*, 1988, 85, 6949). U.S. Patent No. 4,837,028 and WO 88/04924, both to Allen et al., disclose liposomes comprising (1) sphingomyelin and (2) the ganglioside  $G_{M1}$  or a galactocerebroside sulfate ester. U.S. Patent No. 5,543,152 (Webb et al.) discloses liposomes comprising sphingomyelin. Liposomes comprising 1,2-sn-dimyristoylphosphatidylcholine are disclosed in WO 97/13499 (Lim et al.).

Many liposomes comprising lipids derivatized with one or more hydrophilic polymers, and methods of preparation thereof, are known in the art. Sunamoto et al. (*Bull. Chem. Soc. Jpn.*, 1980, 53, 2778) described liposomes comprising a nonionic detergent, 2C<sub>12</sub>15G, that contains a PEG moiety. Illum et al. (*FEBS Lett.*, 1984, 167, 79) noted that hydrophilic coating of polystyrene particles with polymeric glycols results in significantly enhanced blood half-lives. Synthetic phospholipids modified by the attachment of carboxylic groups of polyalkylene glycols (e.g., PEG) are described by Sears (U.S. Patent Nos. 4,426,330 and 4,534,899). Klibanov et al. (*FEBS Lett.*, 1990, 268, 235) described experiments demonstrating that liposomes comprising phosphatidylethanolamine (PE) derivatized with PEG or PEG stearate have significant increases in blood circulation half-lives. Blume et al. (*Biochimica et Biophysica Acta*, 1990, 1029, 91) extended such observations to other PEG-

-39-

derivatized phospholipids, e.g., DSPE-PEG, formed from the combination of distearoylphosphatidylethanolamine (DSPE) and PEG. Liposomes having covalently bound PEG moieties on their external surface are described in European Patent No. EP 0 445 131 B1 and WO 90/04384 to Fisher. Liposome compositions containing 1-20 mole percent of PE derivatized with PEG, and methods of use thereof, are described by Woodle et al. (U.S. Patent Nos. 5,013,556 and 5,356,633) and Martin et al. (U.S. Patent No. 5,213,804 and European Patent No. EP 0 496 813 B1). Liposomes comprising a number of other lipid-polymer conjugates are disclosed in WO 91/05545 and U.S. Patent No. 5,225,212 (both to Martin et al.) and in WO 94/20073 (Zalipsky et al.) Liposomes comprising PEG-modified ceramide lipids are described in WO 96/10391 (Choi et al.). U.S. Patent Nos. 5,540,935 (Miyazaki et al.) and 5,556,948 (Tagawa et al.) describe PEG-containing liposomes that can be further derivatized with functional moieties on their surfaces.

A limited number of liposomes comprising nucleic acids are known in the art. WO 96/40062 to Thierry et al. discloses methods for encapsulating high molecular weight nucleic acids in liposomes. U.S. Patent No. 5,264,221 to Tagawa et al. discloses protein-bonded liposomes and asserts that the contents of such liposomes may include an antisense RNA. U.S. Patent No. 5,665,710 to Rahman et al. describes certain methods of encapsulating oligodeoxynucleotides in liposomes. WO 97/04787 to Love et al. discloses liposomes comprising antisense oligonucleotides targeted to the raf gene.

Transfersomes are yet another type of liposomes, and are highly deformable lipid aggregates which are attractive candidates for drug delivery vehicles. Transfersomes may be described as lipid droplets which are so highly deformable that they are easily able to penetrate through pores which are smaller than the droplet. Transfersomes are adaptable to the environment in which they are used, e.g. they are self-optimizing (adaptive to the shape of pores in the skin), self-repairing, frequently reach their targets without fragmenting, and often self-loading. To make transfersomes it is possible to add surface edge-activators, usually surfactants, to a standard liposomal composition. Transfersomes have been used to deliver



-40-

serum albumin to the skin. The transfersome-mediated delivery of serum albumin has been shown to be as effective as subcutaneous injection of a solution containing serum albumin.

Surfactants find wide application in formulations such as emulsions (including microemulsions) and liposomes. The most common way of classifying and ranking the properties of the many different types of surfactants, both natural and synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group (also known as the "head") provides the most useful means for categorizing the different surfactants used in formulations (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, NY, 1988, p. 285).

If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical and cosmetic products and are usable over a wide range of pH values. In general their HLB values range from 2 to about 18 depending on their structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this class. The polyoxyethylene surfactants are the most popular members of the nonionic surfactant class.

If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most important members of the anionic surfactant class are the alkyl sulfates and the soaps.

If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. The quaternary ammonium salts are the most used members of this class.

-41-

If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides.

The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, NY, 1988, p. 285).

#### 10 Penetration Enhancers

In one embodiment, the present invention employs various penetration enhancers to effect the efficient delivery of nucleic acids, particularly oligonucleotides, to the skin of animals. Most drugs are present in solution in both ionized and nonionized forms. However, usually only lipid soluble or lipophilic drugs readily cross cell membranes. It has been discovered that even non-lipophilic drugs may cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs.

Penetration enhancers may be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92). Each of the above mentioned classes of penetration enhancers are described below in greater detail.

Surfactants: In connection with the present invention, surfactants (or "surface-active agents") are chemical entities which, when dissolved in an aqueous solution, reduce the surface tension of the solution or the interfacial tension between the aqueous solution and another liquid, with the result that absorption of oligonucleotides through the mucosa is enhanced. In addition to bile salts and fatty acids, these penetration enhancers include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier*

-42-

Systems, 1991, p.92); and perfluorochemical emulsions, such as FC-43. Takahashi et al., *J. Pharm. Pharmacol.*, 1988, 40, 252).

Fatty acids: Various fatty acids and their derivatives which act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid (n-decanoic acid), myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein (1-monooleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glycerol 1-monocaprate, 1-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, C<sub>1-10</sub> alkyl esters thereof (e.g., methyl, isopropyl and t-butyl), and mono- and di-glycerides thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; El Hariri et al., *J. Pharm. Pharmacol.*, 1992, 44, 651-654).

Bile salts: The physiological role of bile includes the facilitation of dispersion and absorption of lipids and fat-soluble vitamins (Brunton, Chapter 38 in: Goodman & Gilman's *The Pharmacological Basis of Therapeutics*, 9th Ed., Hardman et al. Eds., McGraw-Hill, New York, 1996, pp. 934-935). Various natural bile salts, and their synthetic derivatives, act as penetration enhancers. Thus the term "bile salts" includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. The bile salts of the invention include, for example, cholic acid (or its pharmaceutically acceptable sodium salt, sodium cholate), dehydrocholic acid (sodium dehydrocholate), deoxycholic acid (sodium deoxycholate), glucolic acid (sodium glucolate), glycholic acid (sodium glycholate), glycodeoxycholic acid (sodium glycodeoxycholate), taurocholic acid (sodium taurocholate), taurodeoxycholic acid (sodium taurodeoxycholate), chenodeoxycholic acid (sodium chenodeoxycholate), ursodeoxycholic acid (UDCA), sodium tauro-24,25-dihydro-fusidate (STDHF), sodium glycodihydrofusidate and polyoxyethylene-9-lauryl ether (POE) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92; Swinyard, Chapter 39 In: *Remington's Pharmaceutical Sciences*, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, PA, 1990,

-43-

pages 782-783; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, **1990**, 7, 1-33; Yamamoto et al., *J. Pharm. Exp. Ther.*, **1992**, 263, 25; Yamashita et al., *J. Pharm. Sci.*, **1990**, 79, 579-583).

5

Chelating Agents: Chelating agents, as used in connection with the present invention, can be defined as compounds that remove metallic ions from solution by forming complexes therewith, with the result that absorption of oligonucleotides through the mucosa is enhanced. With regards to their use as penetration enhancers in the present invention, chelating agents have the added advantage of also serving as DNase inhibitors, as most characterized DNA nucleases require a divalent metal ion for catalysis and are thus inhibited by chelating agents (Jarrett, *J. Chromatogr.*, **1993**, 618, 315-339). Chelating agents of the invention include but are not limited to disodium ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g., sodium salicylate, 5-methoxysalicylate and homovanilate), N-acyl derivatives of collagen, laureth-9 and N-amino acyl derivatives of beta-diketones (enamines) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, **1991**, page 92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, **1990**, 7, 1-33; Buur et al., *J. Control Rel.*, **1990**, 14, 43-51).

25

Non-chelating non-surfactants: As used herein, non-chelating non-surfactant penetration enhancing compounds can be defined as compounds that demonstrate insignificant activity as chelating agents or as surfactants but that nonetheless enhance absorption of oligonucleotides through the alimentary mucosa (Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, **1990**, 7, 1-33). This class of penetration enhancers include, for example, unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacyclo-alkanone derivatives (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, **1991**, page 92); and non-steroidal anti-inflammatory agents such as diclofenac sodium, indomethacin and phenylbutazone (Yamashita et al., *J. Pharm. Pharmacol.*, **1987**, 39, 621-626).

35

Agents that enhance uptake of oligonucleotides at the cellular level may also be added to the pharmaceutical and other

-44-

compositions of the present invention. For example, cationic lipids, such as lipofectin (Junichi et al, U.S. Patent No. 5,705,188), cationic glycerol derivatives, and polycationic molecules, such as polylysine (Lollo et al., PCT Application WO 97/30731), are also known to enhance the cellular uptake of oligonucleotides.

Other agents may be utilized to enhance the penetration of the administered nucleic acids, including glycols such as ethylene glycol and propylene glycol, pyrrols such as 2-pyrrol, azones, and terpenes such as limonene and menthone.

### Carriers

Certain compositions of the present invention also incorporate carrier compounds in the formulation. As used herein, "carrier compound" or "carrier" can refer to a nucleic acid, or analog thereof, which is inert (*i.e.*, does not possess biological activity *per se*) but is recognized as a nucleic acid by *in vivo* processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common receptor. For example, the recovery of a partially phosphorothioate oligonucleotide in hepatic tissue can be reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-4'-isothiocyano-stilbene-2,2'-disulfonic acid (Miyao et al., *Antisense Res. Dev.*, 1995, 5, 115-121; Takakura et al., *Antisense & Nucl. Acid Drug Dev.*, 1996, 6, 177-183).

### Excipients

In contrast to a carrier compound, a "pharmaceutical carrier" or "excipient" is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal.

-45-

The excipient may be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutical carriers include, but are not limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrants (e.g., starch, sodium starch glycolate, etc.); and wetting agents (e.g., sodium lauryl sulphate, etc.).

Pharmaceutically acceptable organic or inorganic excipient suitable for non-parenteral administration which do not deleteriously react with nucleic acids can also be used to formulate the compositions of the present invention. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Formulations for topical administration of nucleic acids may include sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohols, or solutions of the nucleic acids in liquid or solid oil bases. The solutions may also contain buffers, diluents and other suitable additives. Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration which do not deleteriously react with nucleic acids can be used.

Suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

-46-

## Other Components

The compositions of the present invention may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the present invention.

The formulations can be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously interact with the nucleic acid(s) of the formulation.

Aqueous suspensions may contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

Certain embodiments of the invention provide pharmaceutical compositions containing (a) one or more antisense compounds and (b) one or more other chemotherapeutic agents which function by a non-antisense mechanism. Examples of such chemotherapeutic agents include but are not limited to daunorubicin, daunomycin, dactinomycin, doxorubicin, epirubicin, idarubicin, esorubicin, bleomycin, mafosfamide, ifosfamide, cytosine arabinoside, bis-chloroethylnitrosurea, busulfan, mitomycin C, actinomycin D, mithramycin, prednisone, hydroxyprogesterone, testosterone, tamoxifen, dacarbazine, procarbazine, hexamethylmelamine, pentamethylmelamine, mitoxantrone, amsacrine, chlorambucil, methylcyclohexylnitrosurea, nitrogen mustards, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-azacytidine, hydroxyurea, deoxycoformycin, 4-hydroxyperoxycyclophosphoramide, 5-fluorouracil (5-FU), 5-

-47-

fluorodeoxyuridine (5-FUdR), methotrexate (MTX), colchicine, taxol, vincristine, vinblastine, etoposide (VP-16), trimetrexate, irinotecan, topotecan, gemcitabine, teniposide, cisplatin and diethylstilbestrol (DES). See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed. 1987, pp. 1206-1228, Berkow et al., eds., Rahway, N.J. When used with the compounds of the invention, such chemotherapeutic agents may be used individually (e.g., 5-FU and oligonucleotide), sequentially (e.g., 5-FU and oligonucleotide for a period of time followed by MTX and oligonucleotide), or in combination with one or more other such chemotherapeutic agents (e.g., 5-FU, MTX and oligonucleotide, or 5-FU, radiotherapy and oligonucleotide). Anti-inflammatory drugs, including but not limited to nonsteroidal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including but not limited to ribivirin, vidarabine, acyclovir and ganciclovir, may also be combined in compositions of the invention. See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed., Berkow et al., eds., 1987, Rahway, N.J., pages 2499-2506 and 46-49, respectively). Other non-antisense chemotherapeutic agents are also within the scope of this invention. Two or more combined compounds may be used together or sequentially.

In another related embodiment, compositions of the invention may contain one or more antisense compounds, particularly oligonucleotides, targeted to a first nucleic acid and one or more additional antisense compounds targeted to a second nucleic acid target. Numerous examples of antisense compounds are known in the art. Two or more combined compounds may be used together or sequentially.

The formulation of therapeutic compositions and their subsequent administration is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may



-48-

vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on  $EC_{50}$ s found to be effective in in vitro and in vivo animal models. In general, dosage is from 0.01 ug to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 ug to 100 g per kg of body weight, once or more daily, to once every 20 years.

While the present invention has been described with specificity in accordance with certain of its preferred embodiments, the following examples serve only to illustrate the invention and are not intended to limit the same.

-49-

**EXAMPLES****Example 1****5 Nucleoside Phosphoramidites for Oligonucleotide Synthesis  
Deoxy and 2'-alkoxy amidites**

2'-Deoxy and 2'-methoxy beta-cyanoethyldiisopropyl phosphoramidites were purchased from commercial sources (e.g. Chemgenes, Needham MA or Glen Research, Inc. Sterling VA).

10 Other 2'-O-alkoxy substituted nucleoside amidites are prepared as described in U.S. Patent 5,506,351, herein incorporated by reference. For oligonucleotides synthesized using 2'-alkoxy amidites, the standard cycle for unmodified oligonucleotides was utilized, except the wait step after pulse delivery of tetrazole  
15 and base was increased to 360 seconds.

Oligonucleotides containing 5-methyl-2'-deoxycytidine (5-Me-C) nucleotides were synthesized according to published methods [Sanghvi, et. al., *Nucleic Acids Research*, **1993**, 21, 3197-3203] using commercially available phosphoramidites (Glen  
20 Research, Sterling VA or ChemGenes, Needham MA).

**2'-Fluoro amidites****2'-Fluorodeoxyadenosine amidites**

2'-fluoro oligonucleotides were synthesized as described  
25 previously [Kawasaki, et. al., *J. Med. Chem.*, **1993**, 36, 831-841] and United States patent 5,670,633, herein incorporated by reference. Briefly, the protected nucleoside N6-benzoyl-2'-deoxy-2'-fluoroadenosine was synthesized utilizing commercially available 9-beta-D-arabinofuranosyladenine as starting material  
30 and by modifying literature procedures whereby the 2'-alpha-fluoro atom is introduced by a S<sub>N</sub>2-displacement of a 2'-beta-trityl group. Thus N6-benzoyl-9-beta-D-arabinofuranosyladenine was selectively protected in moderate yield as the 3',5'-ditetrahydropyranyl (THP) intermediate. Deprotection of the THP  
35 and N6-benzoyl groups was accomplished using standard methodologies and standard methods were used to obtain the 5'-dimethoxytrityl-(DMT) and 5'-DMT-3'-phosphoramidite intermediates.

-50-

**2'-Fluorodeoxyguanosine**

The synthesis of 2'-deoxy-2'-fluoroguanosine was accomplished using tetraisopropylidisiloxanyl (TPDS) protected 9-beta-D-arabinofuranosylguanine as starting material, and  
5 conversion to the intermediate diisobutyryl-arabinofuranosylguanosine. Deprotection of the TPDS group was followed by protection of the hydroxyl group with THP to give diisobutyryl di-THP protected arabinofuranosylguanine. Selective O-deacylation and triflation was followed by treatment  
10 of the crude product with fluoride, then deprotection of the THP groups. Standard methodologies were used to obtain the 5'-DMT- and 5'-DMT-3'-phosphoramidites.

**2'-Fluorouridine**

15 Synthesis of 2'-deoxy-2'-fluorouridine was accomplished by the modification of a literature procedure in which 2,2'-anhydro-1-beta-D-arabinofuranosyluracil was treated with 70% hydrogen fluoride-pyridine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

20

**2'-Fluorodeoxycytidine**

2'-deoxy-2'-fluorocytidine was synthesized via amination of 2'-deoxy-2'-fluorouridine, followed by selective protection to give N4-benzoyl-2'-deoxy-2'-fluorocytidine. Standard procedures  
25 were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

**2'-O-(2-Methoxyethyl) modified amidites**

2'-O-Methoxyethyl-substituted nucleoside amidites are prepared as follows, or alternatively, as per the methods of  
30 Martin, P., *Helvetica Chimica Acta*, 1995, 78, 486-504.

**2,2'-Anhydro[1-(beta-D-arabinofuranosyl)-5-methyluridine]**

5-Methyluridine (ribosylthymine, commercially available through Yamasa, Choshi, Japan) (72.0 g, 0.279 M), diphenyl-  
35 carbonate (90.0 g, 0.420 M) and sodium bicarbonate (2.0 g, 0.024 M) were added to DMF (300 mL). The mixture was heated to reflux, with stirring, allowing the evolved carbon dioxide gas to be released in a controlled manner. After 1 hour, the slightly darkened solution was concentrated under reduced

-51-

pressure. The resulting syrup was poured into diethylether (2.5 L), with stirring. The product formed a gum. The ether was decanted and the residue was dissolved in a minimum amount of methanol (ca. 400 mL). The solution was poured into fresh ether (2.5 L) to yield a stiff gum. The ether was decanted and the gum was dried in a vacuum oven (60°C at 1 mm Hg for 24 h) to give a solid that was crushed to a light tan powder (57 g, 85% crude yield). The NMR spectrum was consistent with the structure, contaminated with phenol as its sodium salt (ca. 5%). The material was used as is for further reactions (or it can be purified further by column chromatography using a gradient of methanol in ethyl acetate (10-25%) to give a white solid, mp 222-4°C).

#### **2'-O-Methoxyethyl-5-methyluridine**

2,2'-Anhydro-5-methyluridine (195 g, 0.81 M), tris(2-methoxyethyl)borate (231 g, 0.98 M) and 2-methoxyethanol (1.2 L) were added to a 2 L stainless steel pressure vessel and placed in a pre-heated oil bath at 160°C. After heating for 48 hours at 155-160°C, the vessel was opened and the solution evaporated to dryness and triturated with MeOH (200 mL). The residue was suspended in hot acetone (1 L). The insoluble salts were filtered, washed with acetone (150 mL) and the filtrate evaporated. The residue (280 g) was dissolved in CH<sub>3</sub>CN (600 mL) and evaporated. A silica gel column (3 kg) was packed in CH<sub>2</sub>Cl<sub>2</sub>/acetone/MeOH (20:5:3) containing 0.5% Et<sub>3</sub>NH. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (250 mL) and adsorbed onto silica (150 g) prior to loading onto the column. The product was eluted with the packing solvent to give 160 g (63%) of product. Additional material was obtained by reworking impure fractions.

#### **2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine**

2'-O-Methoxyethyl-5-methyluridine (160 g, 0.506 M) was co-evaporated with pyridine (250 mL) and the dried residue dissolved in pyridine (1.3 L). A first aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the mixture stirred at room temperature for one hour. A second aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added

-52-

and the reaction stirred for an additional one hour. Methanol (170 mL) was then added to stop the reaction. HPLC showed the presence of approximately 70% product. The solvent was evaporated and triturated with  $\text{CH}_3\text{CN}$  (200 mL). The residue was dissolved in  $\text{CHCl}_3$  (1.5 L) and extracted with 2x500 mL of saturated  $\text{NaHCO}_3$  and 2x500 mL of saturated  $\text{NaCl}$ . The organic phase was dried over  $\text{Na}_2\text{SO}_4$ , filtered and evaporated. 275 g of residue was obtained. The residue was purified on a 3.5 kg silica gel column, packed and eluted with  $\text{EtOAc}$ /hexane/acetone (5:5:1) containing 0.5%  $\text{Et}_3\text{NH}$ . The pure fractions were evaporated to give 164 g of product. Approximately 20 g additional was obtained from the impure fractions to give a total yield of 183 g (57%).

**3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine**

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (106 g, 0.167 M),  $\text{DMF}$ /pyridine (750 mL of a 3:1 mixture prepared from 562 mL of  $\text{DMF}$  and 188 mL of pyridine) and acetic anhydride (24.38 mL, 0.258 M) were combined and stirred at room temperature for 24 hours. The reaction was monitored by TLC by first quenching the TLC sample with the addition of  $\text{MeOH}$ . Upon completion of the reaction, as judged by TLC,  $\text{MeOH}$  (50 mL) was added and the mixture evaporated at  $35^\circ\text{C}$ . The residue was dissolved in  $\text{CHCl}_3$  (800 mL) and extracted with 2x200 mL of saturated sodium bicarbonate and 2x200 mL of saturated  $\text{NaCl}$ . The water layers were back extracted with 200 mL of  $\text{CHCl}_3$ . The combined organics were dried with sodium sulfate and evaporated to give 122 g of residue (approx. 90% product). The residue was purified on a 3.5 kg silica gel column and eluted using  $\text{EtOAc}$ /hexane(4:1). Pure product fractions were evaporated to yield 96 g (84%). An additional 1.5 g was recovered from later fractions.

**3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine**

A first solution was prepared by dissolving 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (96 g, 0.144 M) in  $\text{CH}_3\text{CN}$  (700 mL) and set aside. Triethylamine (189 mL, 1.44

-53-

M) was added to a solution of triazole (90 g, 1.3 M) in  $\text{CH}_3\text{CN}$  (1 L), cooled to  $-5^\circ\text{C}$  and stirred for 0.5 h using an overhead stirrer.  $\text{POCl}_3$  was added dropwise, over a 30 minute period, to the stirred solution maintained at  $0-10^\circ\text{C}$ , and the resulting mixture stirred for an additional 2 hours. The first solution was added dropwise, over a 45 minute period, to the latter solution. The resulting reaction mixture was stored overnight in a cold room. Salts were filtered from the reaction mixture and the solution was evaporated. The residue was dissolved in EtOAc (1 L) and the insoluble solids were removed by filtration. The filtrate was washed with 1x300 mL of  $\text{NaHCO}_3$  and 2x300 mL of saturated  $\text{NaCl}$ , dried over sodium sulfate and evaporated. The residue was triturated with EtOAc to give the title compound.

**2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine**

A solution of 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine (103 g, 0.141 M) in dioxane (500 mL) and  $\text{NH}_4\text{OH}$  (30 mL) was stirred at room temperature for 2 hours. The dioxane solution was evaporated and the residue azeotroped with MeOH (2x200 mL). The residue was dissolved in MeOH (300 mL) and transferred to a 2 liter stainless steel pressure vessel. MeOH (400 mL) saturated with  $\text{NH}_3$  gas was added and the vessel heated to  $100^\circ\text{C}$  for 2 hours (TLC showed complete conversion). The vessel contents were evaporated to dryness and the residue was dissolved in EtOAc (500 mL) and washed once with saturated  $\text{NaCl}$  (200 mL). The organics were dried over sodium sulfate and the solvent was evaporated to give 85 g (95%) of the title compound.

**N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine**

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (85 g, 0.134 M) was dissolved in DMF (800 mL) and benzoic anhydride (37.2 g, 0.165 M) was added with stirring. After stirring for 3 hours, TLC showed the reaction to be approximately 95% complete. The solvent was evaporated and the residue azeotroped with MeOH (200 mL). The residue was dissolved in  $\text{CHCl}_3$  (700 mL) and extracted with saturated  $\text{NaHCO}_3$  (2x300 mL) and saturated  $\text{NaCl}$

-54-

(2x300 mL), dried over  $\text{MgSO}_4$  and evaporated to give a residue (96 g). The residue was chromatographed on a 1.5 kg silica column using EtOAc/hexane (1:1) containing 0.5%  $\text{Et}_3\text{NH}$  as the eluting solvent. The pure product fractions were evaporated to give 90 g (90%) of the title compound.

**N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-cytidine-3'-amidite**

N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-cytidine (74 g, 0.10 M) was dissolved in  $\text{CH}_2\text{Cl}_2$  (1 L). Tetrazole diisopropylamine (7.1 g) and 2-cyanoethoxy-tetra(isopropyl)-phosphite (40.5 mL, 0.123 M) were added with stirring, under a nitrogen atmosphere. The resulting mixture was stirred for 20 hours at room temperature (TLC showed the reaction to be 95% complete). The reaction mixture was extracted with saturated  $\text{NaHCO}_3$  (1x300 mL) and saturated  $\text{NaCl}$  (3x300 mL). The aqueous washes were back-extracted with  $\text{CH}_2\text{Cl}_2$  (300 mL), and the extracts were combined, dried over  $\text{MgSO}_4$  and concentrated. The residue obtained was chromatographed on a 1.5 kg silica column using EtOAc/hexane (3:1) as the eluting solvent. The pure fractions were combined to give 90.6 g (87%) of the title compound.

**2'-O-(Aminooxyethyl) nucleoside amidites and 2'-O-(dimethylaminooxyethyl) nucleoside amidites**

**2'-(Dimethylaminooxyethoxy) nucleoside amidites**

2'-(Dimethylaminooxyethoxy) nucleoside amidites [also known in the art as 2'-O-(dimethylaminooxyethyl) nucleoside amidites] are prepared as described in the following paragraphs.

Adenosine, cytidine and guanosine nucleoside amidites are prepared similarly to the thymidine (5-methyluridine) except the exocyclic amines are protected with a benzoyl moiety in the case of adenosine and cytidine and with isobutyryl in the case of guanosine.

**5'-O-tert-Butyldiphenylsilyl-O<sup>2</sup>-2'-anhydro-5-methyluridine**

O<sup>2</sup>-2'-anhydro-5-methyluridine (Pro. Bio. Sint., Varese, Italy, 100.0g, 0.416 mmol), dimethylaminopyridine (0.66g, 0.013eq, 0.0054mmol) were dissolved in dry pyridine (500 ml) at

-55-

ambient temperature under an argon atmosphere and with mechanical stirring. *tert*-Butyldiphenylchlorosilane (125.8g, 119.0mL, 1.1eq, 0.458mmol) was added in one portion. The reaction was stirred for 16 h at ambient temperature. TLC (Rf 0.22, ethyl acetate) indicated a complete reaction. The solution was concentrated under reduced pressure to a thick oil. This was partitioned between dichloromethane (1 L) and saturated sodium bicarbonate (2x1 L) and brine (1 L). The organic layer was dried over sodium sulfate and concentrated under reduced pressure to a thick oil. The oil was dissolved in a 1:1 mixture of ethyl acetate and ethyl ether (600mL) and the solution was cooled to -10°C. The resulting crystalline product was collected by filtration, washed with ethyl ether (3x200 mL) and dried (40°C, 1mm Hg, 24 h) to 149g (74.8%) of white solid. TLC and NMR were consistent with pure product.

**5'-O-*tert*-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine**

In a 2 L stainless steel, unstirred pressure reactor was added borane in tetrahydrofuran (1.0 M, 2.0 eq, 622 mL). In the fume hood and with manual stirring, ethylene glycol (350 mL, excess) was added cautiously at first until the evolution of hydrogen gas subsided. 5'-O-*tert*-Butyldiphenylsilyl-O<sup>2</sup>-2'-anhydro-5-methyluridine (149 g, 0.311 mol) and sodium bicarbonate (0.074 g, 0.003 eq) were added with manual stirring. The reactor was sealed and heated in an oil bath until an internal temperature of 160 °C was reached and then maintained for 16 h (pressure < 100 psig). The reaction vessel was cooled to ambient and opened. TLC (Rf 0.67 for desired product and Rf 0.82 for ara-T side product, ethyl acetate) indicated about 70% conversion to the product. In order to avoid additional side product formation, the reaction was stopped, concentrated under reduced pressure (10 to 1mm Hg) in a warm water bath (40-100°C) with the more extreme conditions used to remove the ethylene glycol. [Alternatively, once the low boiling solvent is gone, the remaining solution can be partitioned between ethyl acetate and water. The product will be in the organic phase.] The residue was purified by column chromatography (2kg silica gel,



-56-

ethyl acetate-hexanes gradient 1:1 to 4:1). The appropriate fractions were combined, stripped and dried to product as a white crisp foam (84g, 50%), contaminated starting material (17.4g) and pure reusable starting material 20g. The yield based on starting material less pure recovered starting material was 58%. TLC and NMR were consistent with 99% pure product.

**2'-O-([2-phthalimidoxy)ethyl]-5'-t-butyldiphenylsilyl-5-methyluridine**

5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine (20g, 36.98mmol) was mixed with triphenylphosphine (11.63g, 44.36mmol) and N-hydroxyphthalimide (7.24g, 44.36mmol). It was then dried over  $P_2O_5$  under high vacuum for two days at 40°C. The reaction mixture was flushed with argon and dry THF (369.8mL, Aldrich, sure seal bottle) was added to get a clear solution. Diethyl-azodicarboxylate (6.98mL, 44.36mmol) was added dropwise to the reaction mixture. The rate of addition is maintained such that resulting deep red coloration is just discharged before adding the next drop. After the addition was complete, the reaction was stirred for 4 hrs. By that time TLC showed the completion of the reaction (ethylacetate:hexane, 60:40). The solvent was evaporated in vacuum. Residue obtained was placed on a flash column and eluted with ethyl acetate:hexane (60:40), to get 2'-O-([2-phthalimidoxy)ethyl]-5'-t-butyldiphenylsilyl-5-methyluridine as white foam (21.819 g, 86%).

**5'-O-tert-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine**

2'-O-([2-phthalimidoxy)ethyl]-5'-t-butyldiphenylsilyl-5-methyluridine (3.1g, 4.5mmol) was dissolved in dry  $CH_2Cl_2$  (4.5mL) and methylhydrazine (300mL, 4.64mmol) was added dropwise at -10°C to 0°C. After 1 h the mixture was filtered, the filtrate was washed with ice cold  $CH_2Cl_2$  and the combined organic phase was washed with water, brine and dried over anhydrous  $Na_2SO_4$ . The solution was concentrated to get 2'-O-(aminooxyethyl) thymidine, which was then dissolved in MeOH (67.5mL). To this formaldehyde (20% aqueous solution, w/w, 1.1 eq.) was added and the resulting

-57-

mixture was stirred for 1 h. Solvent was removed under vacuum; residue chromatographed to get 5'-O-tert-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy) ethyl]-5-methyluridine as white foam (1.95 g, 78%).

5

**5'-O-tert-Butyldiphenylsilyl-2'-O-[N,N-dimethylaminooxyethyl]-5-methyluridine**

5'-O-tert-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine (1.77g, 3.12mmol) was dissolved in a solution of 1M pyridinium p-toluenesulfonate (PPTS) in dry MeOH (30.6mL). Sodium cyanoborohydride (0.39g, 6.13mmol) was added to this solution at 10°C under inert atmosphere. The reaction mixture was stirred for 10 minutes at 10°C. After that the reaction vessel was removed from the ice bath and stirred at room temperature for 2 h, the reaction monitored by TLC (5% MeOH in CH<sub>2</sub>Cl<sub>2</sub>). Aqueous NaHCO<sub>3</sub> solution (5%, 10mL) was added and extracted with ethyl acetate (2x20mL). Ethyl acetate phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, evaporated to dryness. Residue was dissolved in a solution of 1M PPTS in MeOH (30.6mL). Formaldehyde (20% w/w, 30mL, 3.37mmol) was added and the reaction mixture was stirred at room temperature for 10 minutes. Reaction mixture cooled to 10°C in an ice bath, sodium cyanoborohydride (0.39g, 6.13mmol) was added and reaction mixture stirred at 10°C for 10 minutes. After 10 minutes, the reaction mixture was removed from the ice bath and stirred at room temperature for 2 hrs. To the reaction mixture 5% NaHCO<sub>3</sub> (25mL) solution was added and extracted with ethyl acetate (2x25mL). Ethyl acetate layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and evaporated to dryness. The residue obtained was purified by flash column chromatography and eluted with 5% MeOH in CH<sub>2</sub>Cl<sub>2</sub>, to get 5'-O-tert-butyldiphenylsilyl-2'-O-[N,N-dimethylaminooxyethyl]-5-methyluridine as a white foam (14.6g, 80%).

35

**2'-O-(dimethylaminooxyethyl)-5-methyluridine**

Triethylamine trihydrofluoride (3.91mL, 24.0mmol) was dissolved in dry THF and triethylamine (1.67mL, 12mmol, dry, kept over KOH). This mixture of triethylamine-2HF was then

-58-

added to 5'-O-*tert*-butyldiphenylsilyl-2'-O-[N,N-dimethylaminoxyethyl]-5-methyluridine (1.40g, 2.4mmol) and stirred at room temperature for 24 hrs. Reaction was monitored by TLC (5% MeOH in CH<sub>2</sub>Cl<sub>2</sub>). Solvent was removed under vacuum and the residue placed on a flash column and eluted with 10% MeOH in CH<sub>2</sub>Cl<sub>2</sub> to get 2'-O-(dimethylaminoxyethyl)-5-methyluridine (766mg, 92.5%).

**5'-O-DMT-2'-O-(dimethylaminoxyethyl)-5-methyluridine**

2'-O-(dimethylaminoxyethyl)-5-methyluridine (750mg, 2.17mmol) was dried over P<sub>2</sub>O<sub>5</sub> under high vacuum overnight at 40°C. It was then co-evaporated with anhydrous pyridine (20mL). The residue obtained was dissolved in pyridine (11mL) under argon atmosphere. 4-dimethylaminopyridine (26.5mg, 2.60mmol), 4,4'-dimethoxytrityl chloride (880mg, 2.60mmol) was added to the mixture and the reaction mixture was stirred at room temperature until all of the starting material disappeared. Pyridine was removed under vacuum and the residue chromatographed and eluted with 10% MeOH in CH<sub>2</sub>Cl<sub>2</sub> (containing a few drops of pyridine) to get 5'-O-DMT-2'-O-(dimethylamino-oxyethyl)-5-methyluridine (1.13g, 80%).

**5'-O-DMT-2'-O-(2-N,N-dimethylaminoxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]**

5'-O-DMT-2'-O-(dimethylaminoxyethyl)-5-methyluridine (1.08g, 1.67mmol) was co-evaporated with toluene (20mL). To the residue N,N-diisopropylamine tetrazonide (0.29g, 1.67mmol) was added and dried over P<sub>2</sub>O<sub>5</sub> under high vacuum overnight at 40°C. Then the reaction mixture was dissolved in anhydrous acetonitrile (8.4mL) and 2-cyanoethyl-N,N,N<sup>1</sup>,N<sup>1</sup>-tetraisopropylphosphoramidite (2.12mL, 6.08mmol) was added. The reaction mixture was stirred at ambient temperature for 4 hrs under inert atmosphere. The progress of the reaction was monitored by TLC (hexane:ethyl acetate 1:1). The solvent was evaporated, then the residue was dissolved in ethyl acetate (70mL) and washed with 5% aqueous NaHCO<sub>3</sub> (40mL). Ethyl acetate layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated. Residue

-59-

obtained was chromatographed (ethyl acetate as eluent) to get 5'-O-DMT-2'-O-(2-N,N-dimethylaminoethoxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite] as a foam (1.04g, 74.9%).

5

**2'-(Aminooxyethoxy) nucleoside amidites**

2'-(Aminooxyethoxy) nucleoside amidites [also known in the art as 2'-O-(aminooxyethyl) nucleoside amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and  
10 thymidine nucleoside amidites are prepared similarly.

**N2-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]**

15 The 2'-O-aminooxyethyl guanosine analog may be obtained by selective 2'-O-alkylation of diaminopurine riboside. Multigram quantities of diaminopurine riboside may be purchased from Schering AG (Berlin) to provide 2'-O-(2-ethylacetyl) diaminopurine riboside along with a minor amount of the 3'-O-  
20 isomer. 2'-O-(2-ethylacetyl) diaminopurine riboside may be resolved and converted to 2'-O-(2-ethylacetyl)guanosine by treatment with adenosine deaminase. (McGee, D. P. C., Cook, P. D., Guinasso, C. J., WO 94/02501 A1 940203.) Standard protection procedures should afford 2'-O-(2-ethylacetyl)-5'-O-  
25 (4,4'-dimethoxytrityl)guanosine and 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine which may be reduced to provide 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-hydroxyethyl)-5'-O-(4,4'-dimethoxytrityl)guanosine. As before the hydroxyl group  
30 may be displaced by N-hydroxyphthalimide via a Mitsunobu reaction, and the protected nucleoside may phosphitylated as usual to yield 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-([2-phthalamidoxy]ethyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite].

35

**2'-dimethylaminoethoxyethoxy (2'-DMAEOE) nucleoside amidites**

2'-dimethylaminoethoxyethoxy nucleoside amidites (also known in the art as 2'-O-dimethylaminoethoxyethyl, i.e., 2'-O-

-60-

$\text{CH}_2\text{-O-CH}_2\text{-N}(\text{CH}_2)_2$ , or 2'-DMAEOE nucleoside amidites) are prepared as follows. Other nucleoside amidites are prepared similarly.

**2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine**

5        2[2-(Dimethylamino)ethoxy]ethanol (Aldrich, 6.66 g, 50 mmol) is slowly added to a solution of borane in tetrahydrofuran (1 M, 10 mL, 10 mmol) with stirring in a 100 mL bomb. Hydrogen gas evolves as the solid dissolves. O<sup>2</sup>-,2'-anhydro-5-methyluridine (1.2 g, 5 mmol), and sodium bicarbonate (2.5 mg) are added and the bomb is sealed, placed in an oil bath and heated to 155°C for 26 hours. The bomb is cooled to room temperature and opened. The crude solution is concentrated and the residue partitioned between water (200 mL) and hexanes (200 mL). The excess phenol is extracted into the hexane layer. The aqueous layer is extracted with ethyl acetate (3x200 mL) and the combined organic layers are washed once with water, dried over anhydrous sodium sulfate and concentrated. The residue is columned on silica gel using methanol/methylene chloride 1:20 (which has 2% triethylamine) as the eluent. As the column fractions are concentrated a colorless solid forms which is collected to give the title compound as a white solid.

**5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine**

25        To 0.5 g (1.3 mmol) of 2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine in anhydrous pyridine (8 mL), triethylamine (0.36 mL) and dimethoxytrityl chloride (DMT-Cl, 0.87 g, 2 eq.) are added and stirred for 1 hour. The reaction mixture is poured into water (200 mL) and extracted with  $\text{CH}_2\text{Cl}_2$  (2x200 mL). The combined  $\text{CH}_2\text{Cl}_2$  layers are washed with saturated  $\text{NaHCO}_3$  solution, followed by saturated  $\text{NaCl}$  solution and dried over anhydrous sodium sulfate. Evaporation of the solvent followed by silica gel chromatography using  $\text{MeOH}:\text{CH}_2\text{Cl}_2:\text{Et}_3\text{N}$  (20:1, v/v, with 1% triethylamine) gives the title compound.

35

-61-

**5'-O-Dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)-ethyl]-5-methyl uridine-3'-O-(cyanoethyl-N,N-diisopropyl)phosphoramidite**

Diisopropylaminotetrazolide (0.6 g) and 2-cyanoethoxy-N,N-diisopropyl phosphoramidite (1.1 mL, 2 eq.) are added to a solution of 5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyluridine (2.17 g, 3 mmol) dissolved in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) under an atmosphere of argon. The reaction mixture is stirred overnight and the solvent evaporated. The resulting residue is purified by silica gel flash column chromatography with ethyl acetate as the eluent to give the title compound.

**Example 2**

**15 Oligonucleotide synthesis**

Unsubstituted and substituted phosphodiester (P=O) oligonucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 380B) using standard phosphoramidite chemistry with oxidation by iodine.

20 Phosphorothioates (P=S) are synthesized as for the phosphodiester oligonucleotides except the standard oxidation bottle was replaced by 0.2 M solution of 3H-1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the stepwise thiation of the phosphite linkages. The thiation wait step was increased to 68 sec and was followed by the capping step. After cleavage from the CPG column and deblocking in concentrated ammonium hydroxide at 55°C (18 h), the oligonucleotides were purified by precipitating twice with 2.5 volumes of ethanol from a 0.5 M NaCl solution. Phosphinate oligonucleotides are prepared as described in U.S. Patent 5,508,270, herein incorporated by reference.

Alkyl phosphonate oligonucleotides are prepared as described in U.S. Patent 4,469,863, herein incorporated by reference.

35 3'-Deoxy-3'-methylene phosphonate oligonucleotides are prepared as described in U.S. Patents 5,610,289 or 5,625,050, herein incorporated by reference.

Phosphoramidite oligonucleotides are prepared as described in U.S. Patent, 5,256,775 or U.S. Patent 5,366,878, herein

-62-

incorporated by reference.

Alkylphosphonothioate oligonucleotides are prepared as described in published PCT applications PCT/US94/00902 and PCT/US93/06976 (published as WO 94/17093 and WO 94/02499, respectively), herein incorporated by reference.

3'-Deoxy-3'-amino phosphoramidate oligonucleotides are prepared as described in U.S. Patent 5,476,925, herein incorporated by reference.

Phosphotriester oligonucleotides are prepared as described in U.S. Patent 5,023,243, herein incorporated by reference.

Borano phosphate oligonucleotides are prepared as described in U.S. Patents 5,130,302 and 5,177,198, both herein incorporated by reference.

### **Example 3**

#### **Oligonucleoside Synthesis**

Methylenemethylimino linked oligonucleosides, also identified as MMI linked oligonucleosides, methylenedimethylhydrazo linked oligonucleosides, also identified as MDH linked oligonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified as amide-3 linked oligonucleosides, and methyleneaminocarbonyl linked oligonucleosides, also identified as amide-4 linked oligonucleosides, as well as mixed backbone compounds having, for instance, alternating MMI and P=O or P=S linkages are prepared as described in U.S. Patents 5,378,825, 5,386,023, 5,489,677, 5,602,240 and 5,610,289, all of which are herein incorporated by reference.

Formacetal and thioformacetal linked oligonucleosides are prepared as described in U.S. Patents 5,264,562 and 5,264,564, herein incorporated by reference.

Ethylene oxide linked oligonucleosides are prepared as described in U.S. Patent 5,223,618, herein incorporated by reference.

### **Example 4**

#### **PNA Synthesis**

Peptide nucleic acids (PNAs) are prepared in accordance with any of the various procedures referred to in Peptide

-63-

Nucleic Acids (PNA): Synthesis, Properties and Potential Applications, *Bioorganic & Medicinal Chemistry*, 1996, 4, 5-23. They may also be prepared in accordance with U.S. Patents 5,539,082, 5,700,922, and 5,719,262, herein incorporated by  
5 reference.

**Example 5****Synthesis of Chimeric Oligonucleotides**

Chimeric oligonucleotides, oligonucleosides or mixed  
10 oligonucleotides/oligonucleosides of the invention can be of several different types. These include a first type wherein the "gap" segment of linked nucleosides is positioned between 5' and 3' "wing" segments of linked nucleosides and a second "open end" type wherein the "gap" segment is located at either the 3' or  
15 the 5' terminus of the oligomeric compound. Oligonucleotides of the first type are also known in the art as "gapmers" or gapped oligonucleotides. Oligonucleotides of the second type are also known in the art as "hemimers" or "wingmers".

**[2'-O-Me]--[2'-deoxy]--[2'-O-Me] Chimeric Phosphorothioate**  
20 **Oligonucleotides**

Chimeric oligonucleotides having 2'-O-alkyl phosphorothioate and 2'-deoxy phosphorothioate oligonucleotide segments are synthesized using an Applied Biosystems automated DNA synthesizer Model 380B, as above. Oligonucleotides are  
25 synthesized using the automated synthesizer and 2'-deoxy-5'-dimethoxytrityl-3'-O-phosphoramidite for the DNA portion and 5'-dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite for 5' and 3' wings. The standard synthesis cycle is modified by increasing the wait step after the delivery of tetrazole and base to 600 s  
30 repeated four times for RNA and twice for 2'-O-methyl. The fully protected oligonucleotide is cleaved from the support and the phosphate group is deprotected in 3:1 ammonia/ethanol at room temperature overnight then lyophilized to dryness. Treatment in methanolic ammonia for 24 hrs at room temperature  
35 is then done to deprotect all bases and sample was again lyophilized to dryness. The pellet is resuspended in 1M TBAF in THF for 24 hrs at room temperature to deprotect the 2' positions. The reaction is then quenched with 1M TEAA and the sample is then reduced to 1/2 volume by rotovac before being



-64-

desalted on a G25 size exclusion column. The oligo recovered is then analyzed spectrophotometrically for yield and for purity by capillary electrophoresis and by mass spectrometry.

5        **[2'-O-(2-Methoxyethyl)]--[2'-deoxy]--[2'-O-(Methoxyethyl)]**  
         **Chimeric Phosphorothioate Oligonucleotides**  
         [2'-O-(2-methoxyethyl)]--[2'-deoxy]--[2'-O-(methoxyethyl)]  
chimeric phosphorothioate oligonucleotides were prepared as per  
the procedure above for the 2'-O-methyl chimeric  
10 oligonucleotide, with the substitution of 2'-O-(methoxyethyl)  
amidites for the 2'-O-methyl amidites.

**[2'-O-(2-Methoxyethyl)Phosphodiester]--[2'-deoxy Phosphoro-**  
         **thioate]--[2'-O-(2-Methoxyethyl) Phosphodiester] Chimeric**  
15        **Oligonucleotides**  
         [2'-O-(2-methoxyethyl phosphodiester)]--[2'-deoxy phosphoro-  
thioate]--[2'-O-(methoxyethyl) phosphodiester] chimeric  
oligonucleotides are prepared as per the above procedure for the  
2'-O-methyl chimeric oligonucleotide with the substitution of  
20 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites,  
oxidization with iodine to generate the phosphodiester  
internucleotide linkages within the wing portions of the  
chimeric structures and sulfurization utilizing 3, H-1,2  
benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) to generate  
25 the phosphorothioate internucleotide linkages for the center  
gap.

Other chimeric oligonucleotides, chimeric oligonucleosides  
and mixed chimeric oligonucleotides/oligonucleosides are  
synthesized according to United States patent 5,623,065, herein  
30 incorporated by reference.

#### **Example 6**

##### **Oligonucleotide Isolation**

After cleavage from the controlled pore glass column  
35 (Applied Biosystems) and deblocking in concentrated ammonium  
hydroxide at 55°C for 18 hours, the oligonucleotides or  
oligonucleosides are purified by precipitation twice out of 0.5  
M NaCl with 2.5 volumes ethanol. Synthesized oligonucleotides  
were analyzed by polyacrylamide gel electrophoresis on

-65-

denaturing gels and judged to be at least 85% full length material. The relative amounts of phosphorothioate and phosphodiester linkages obtained in synthesis were periodically checked by  $^{31}\text{P}$  nuclear magnetic resonance spectroscopy, and for some studies oligonucleotides were purified by HPLC, as described by Chiang et al., *J. Biol. Chem.* **1991**, 266, 18162-18171. Results obtained with HPLC-purified material were similar to those obtained with non-HPLC purified material.

#### 10 **Example 7**

##### **Oligonucleotide Synthesis - 96 Well Plate Format**

Oligonucleotides were synthesized via solid phase P(III) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a standard 96 well format. Phosphodiester internucleotide linkages were afforded by oxidation with aqueous iodine. Phosphorothioate internucleotide linkages were generated by sulfurization utilizing 3,4-dihydro-2H-benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) in anhydrous acetonitrile. Standard base-protected beta-cyanoethyldiisopropyl phosphoramidites were purchased from commercial vendors (e.g. PE-Applied Biosystems, Foster City, CA, or Pharmacia, Piscataway, NJ). Non-standard nucleosides are synthesized as per known literature or patented methods. They are utilized as base protected beta-cyanoethyldiisopropyl phosphoramidites.

Oligonucleotides were cleaved from support and deprotected with concentrated  $\text{NH}_4\text{OH}$  at elevated temperature (55-60°C) for 12-16 hours and the released product then dried in vacuo. The dried product was then re-suspended in sterile water to afford a master plate from which all analytical and test plate samples are then diluted utilizing robotic pipettors.

#### **Example 8**

##### **Oligonucleotide Analysis - 96 Well Plate Format**

The concentration of oligonucleotide in each well was assessed by dilution of samples and UV absorption spectroscopy. The full-length integrity of the individual products was evaluated by capillary electrophoresis (CE) in either the 96 well format (Beckman P/ACE<sup>TM</sup> MDQ) or, for individually prepared

-66-

samples, on a commercial CE apparatus (e.g., Beckman P/ACE™ 5000, ABI 270). Base and backbone composition was confirmed by mass analysis of the compounds utilizing electrospray-mass spectroscopy. All assay test plates were diluted from the master plate using single and multi-channel robotic pipettors. Plates were judged to be acceptable if at least 85% of the compounds on the plate were at least 85% full length.

**Example 9****10 Cell culture and oligonucleotide treatment**

The effect of antisense compounds on target nucleic acid expression can be tested in any of a variety of cell types provided that the target nucleic acid is present at measurable levels. This can be routinely determined using, for example, PCR or Northern blot analysis. The following 4 cell types are provided for illustrative purposes, but other cell types can be routinely used, provided that the target is expressed in the cell type chosen. This can be readily determined by methods routine in the art, for example Northern blot analysis, Ribonuclease protection assays, or RT-PCR.

**T-24 cells:**

The human transitional cell bladder carcinoma cell line T-24 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). T-24 cells were routinely cultured in complete McCoy's 5A basal media (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analysis, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

**A549 cells:**

-67-

The human lung carcinoma cell line A549 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). A549 cells were routinely cultured in DMEM basal media (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence.

#### NHDF cells:

Human neonatal dermal fibroblast (NHDF) were obtained from the Clonetics Corporation (Walkersville MD). NHDFs were routinely maintained in Fibroblast Growth Medium (Clonetics Corporation, Walkersville MD) supplemented as recommended by the supplier. Cells were maintained for up to 10 passages as recommended by the supplier.

#### HEK cells:

Human embryonic keratinocytes (HEK) were obtained from the Clonetics Corporation (Walkersville MD). HEKs were routinely maintained in Keratinocyte Growth Medium (Clonetics Corporation, Walkersville MD) formulated as recommended by the supplier. Cells were routinely maintained for up to 10 passages as recommended by the supplier.

#### Treatment with antisense compounds:

When cells reached 80% confluency, they were treated with oligonucleotide. For cells grown in 96-well plates, wells were washed once with 200  $\mu$ L OPTI-MEM<sup>TM</sup>-1 reduced-serum medium (Gibco BRL) and then treated with 130  $\mu$ L of OPTI-MEM<sup>TM</sup>-1 containing 3.75  $\mu$ g/mL LIPOFECTIN<sup>TM</sup> (Gibco BRL) and the desired concentration of oligonucleotide. After 4-7 hours of treatment, the medium was replaced with fresh medium. Cells were harvested 16-24 hours after oligonucleotide treatment.

The concentration of oligonucleotide used varies from cell line to cell line. To determine the optimal oligonucleotide concentration for a particular cell line, the cells are treated

-68-

with a positive control oligonucleotide at a range of concentrations. For human cells the positive control oligonucleotide is ISIS 13920, **TCCGTCATCGCTCCTCAGGG**, SEQ ID NO: 1, a 2'-O-methoxyethyl gapmer (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to human H-ras. For mouse or rat cells the positive control oligonucleotide is ISIS 15770, **ATGCATTCTGCCCCCAAGGA**, SEQ ID NO: 2, a 2'-O-methoxyethyl gapmer (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to both mouse and rat c-raf. The concentration of positive control oligonucleotide that results in 80% inhibition of c-Ha-ras (for ISIS 13920) or c-raf (for ISIS 15770) mRNA is then utilized as the screening concentration for new oligonucleotides in subsequent experiments for that cell line. If 80% inhibition is not achieved, the lowest concentration of positive control oligonucleotide that results in 60% inhibition of H-ras or c-raf mRNA is then utilized as the oligonucleotide screening concentration in subsequent experiments for that cell line. If 60% inhibition is not achieved, that particular cell line is deemed as unsuitable for oligonucleotide transfection experiments.

#### Example 10

#### Analysis of oligonucleotide inhibition of Protein Kinase R expression

Antisense modulation of Protein Kinase R expression can be assayed in a variety of ways known in the art. For example, Protein Kinase R mRNA levels can be quantitated by, e.g., Northern blot analysis, competitive polymerase chain reaction (PCR), or real-time PCR (RT-PCR). Real-time quantitative PCR is presently preferred. RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. Methods of RNA isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.1.1-4.2.9 and 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Northern blot analysis is routine in the art and is taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.2.1-4.2.9, John Wiley & Sons, Inc., 1996. Real-time quantitative (PCR) can be conveniently accomplished using the

-69-

commercially available ABI PRISM™ 7700 Sequence Detection System, available from PE-Applied Biosystems, Foster City, CA and used according to manufacturer's instructions.

Protein levels of Protein Kinase R can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), ELISA or fluorescence-activated cell sorting (FACS). Antibodies directed to Protein Kinase R can be identified and obtained from a variety of sources, such as the MSRS catalog of antibodies (Aerie Corporation, Birmingham, MI), or can be prepared via conventional antibody generation methods. Methods for preparation of polyclonal antisera are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.12.1-11.12.9, John Wiley & Sons, Inc., 1997. Preparation of monoclonal antibodies is taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.4.1-11.11.5, John Wiley & Sons, Inc., 1997.

Immunoprecipitation methods are standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 10.16.1-10.16.11, John Wiley & Sons, Inc., 1998. Western blot (immunoblot) analysis is standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 10.8.1-10.8.21, John Wiley & Sons, Inc., 1997. Enzyme-linked immunosorbent assays (ELISA) are standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.2.1-11.2.22, John Wiley & Sons, Inc., 1991.

### Example 11

#### Poly(A)+ mRNA isolation

Poly(A)+ mRNA was isolated according to Miura et al., *Clin. Chem.*, 1996, 42, 1758-1764. Other methods for poly(A)+ mRNA isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 µL cold PBS. 60 µL lysis buffer (10

-70-

mM Tris-HCl, pH 7.6, 1 mM EDTA, 0.5 M NaCl, 0.5% NP-40, 20 mM vanadyl-ribonucleoside complex) was added to each well, the plate was gently agitated and then incubated at room temperature for five minutes. 55  $\mu$ L of lysate was transferred to Oligo d(T) coated 96-well plates (AGCT Inc., Irvine CA). Plates were incubated for 60 minutes at room temperature, washed 3 times with 200  $\mu$ L of wash buffer (10 mM Tris-HCl pH 7.6, 1 mM EDTA, 0.3 M NaCl). After the final wash, the plate was blotted on paper towels to remove excess wash buffer and then air-dried for 5 minutes. 60  $\mu$ L of elution buffer (5 mM Tris-HCl pH 7.6), preheated to 70°C was added to each well, the plate was incubated on a 90°C hot plate for 5 minutes, and the eluate was then transferred to a fresh 96-well plate.

Cells grown on 100 mm or other standard plates may be treated similarly, using appropriate volumes of all solutions.

#### Example 12

##### Total RNA Isolation

Total RNA was isolated using an RNEASY 96™ kit and buffers purchased from Qiagen Inc. (Valencia CA) following the manufacturer's recommended procedures. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200  $\mu$ L cold PBS. 100  $\mu$ L Buffer RLT was added to each well and the plate vigorously agitated for 20 seconds. 100  $\mu$ L of 70% ethanol was then added to each well and the contents mixed by pipetting three times up and down. The samples were then transferred to the RNEASY 96™ well plate attached to a QIAVAC™ manifold fitted with a waste collection tray and attached to a vacuum source. Vacuum was applied for 15 seconds. 1 mL of Buffer RW1 was added to each well of the RNEASY 96™ plate and the vacuum again applied for 15 seconds. 1 mL of Buffer RPE was then added to each well of the RNEASY 96™ plate and the vacuum applied for a period of 15 seconds. The Buffer RPE wash was then repeated and the vacuum was applied for an additional 10 minutes. The plate was then removed from the QIAVAC™ manifold and blotted dry on paper towels. The plate was

-71-

then re-attached to the QIAVAC™ manifold fitted with a collection tube rack containing 1.2 mL collection tubes. RNA was then eluted by pipetting 60 µL water into each well, incubating 1 minute, and then applying the vacuum for 30  
5 seconds. The elution step was repeated with an additional 60 µL water.

The repetitive pipetting and elution steps may be automated using a QIAGEN Bio-Robot 9604 (Qiagen, Inc., Valencia CA). Essentially, after lysing of the cells on the culture plate, the  
10 plate is transferred to the robot deck where the pipetting, DNase treatment and elution steps are carried out.

### **Example 13**

#### **Real-time Quantitative PCR Analysis of Protein Kinase R mRNA**

##### **Levels**

Quantitation of Protein Kinase R mRNA levels was determined by real-time quantitative PCR using the ABI PRISM™ 7700 Sequence Detection System (PE-Applied Biosystems, Foster City, CA) according to manufacturer's instructions. This is a closed-  
20 tube, non-gel-based, fluorescence detection system which allows high-throughput quantitation of polymerase chain reaction (PCR) products in real-time. As opposed to standard PCR, in which amplification products are quantitated after the PCR is completed, products in real-time quantitative PCR are  
25 quantitated as they accumulate. This is accomplished by including in the PCR reaction an oligonucleotide probe that anneals specifically between the forward and reverse PCR primers, and contains two fluorescent dyes. A reporter dye (e.g., JOE, FAM, or VIC, obtained from either Operon  
30 Technologies Inc., Alameda, CA or PE-Applied Biosystems, Foster City, CA) is attached to the 5' end of the probe and a quencher dye (e.g., TAMRA, obtained from either Operon Technologies Inc., Alameda, CA or PE-Applied Biosystems, Foster City, CA) is attached to the 3' end of the probe. When the probe and dyes  
35 are intact, reporter dye emission is quenched by the proximity of the 3' quencher dye. During amplification, annealing of the probe to the target sequence creates a substrate that can be cleaved by the 5'-exonuclease activity of Taq polymerase.



-72-

During the extension phase of the PCR amplification cycle, cleavage of the probe by Taq polymerase releases the reporter dye from the remainder of the probe (and hence from the quencher moiety) and a sequence-specific fluorescent signal is generated.

5 With each cycle, additional reporter dye molecules are cleaved from their respective probes, and the fluorescence intensity is monitored at regular intervals by laser optics built into the ABI PRISM™ 7700 Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA  
10 from untreated control samples generates a standard curve that is used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples.

Prior to quantitative PCR analysis, primer-probe sets specific to the target gene being measured are evaluated for  
15 their ability to be "multiplexed" with a GAPDH amplification reaction. In multiplexing, both the target gene and the internal standard gene GAPDH are amplified concurrently in a single sample. In this analysis, mRNA isolated from untreated cells is serially diluted. Each dilution is amplified in the  
20 presence of primer-probe sets specific for GAPDH only, target gene only ("single-plexing"), or both (multiplexing). Following PCR amplification, standard curves of GAPDH and target mRNA signal as a function of dilution are generated from both the single-plexed and multiplexed samples. If both the slope and  
25 correlation coefficient of the GAPDH and target signals generated from the multiplexed samples fall within 10% of their corresponding values generated from the single-plexed samples, the primer-probe set specific for that target is deemed multiplexable. Other methods of PCR are also known in the art.

30 PCR reagents were obtained from PE-Applied Biosystems, Foster City, CA. RT-PCR reactions were carried out by adding 25 µL PCR cocktail (1x TAQMAN™ buffer A, 5.5 mM MgCl<sub>2</sub>, 300 µM each of dATP, dCTP and dGTP, 600 µM of dUTP, 100 nM each of forward primer, reverse primer, and probe, 20 Units RNase inhibitor,  
35 1.25 Units AMPLITAQ GOLD™, and 12.5 Units MuLV reverse transcriptase) to 96 well plates containing 25 µL total RNA solution. The RT reaction was carried out by incubation for 30

-73-

minutes at 48°C. Following a 10 minute incubation at 95°C to activate the AMPLITAQ GOLD™, 40 cycles of a two-step PCR protocol were carried out: 95°C for 15 seconds (denaturation) followed by 60°C for 1.5 minutes (annealing/extension).

5 Gene target quantities obtained by real time RT-PCR are normalized using either the expression level of GAPDH, a gene whose expression is constant, or by quantifying total RNA using RiboGreen™ (Molecular Probes, Inc. Eugene, OR). GAPDH expression is quantified by real time RT-PCR, by being run simultaneously  
10 with the target, multiplexing, or separately. Total RNA is quantified using RiboGreen™ RNA quantification reagent from Molecular Probes. Methods of RNA quantification by RiboGreen™ are taught in Jones, L.J., et al, *Analytical Biochemistry*, 1998, 265, 368-374.

15 In this assay, 175 µL of RiboGreen™ working reagent (RiboGreen™ reagent diluted 1:2865 in 10mM Tris-HCl, 1 mM EDTA, pH 7.5) is pipetted into a 96-well plate containing 25uL purified, cellular RNA. The plate is read in a CytoFluor 4000 (PE Applied Biosystems) with excitation at 480nm and emission at  
20 520nm.

Probes and primers to human Protein Kinase R were designed to hybridize to a human Protein Kinase R sequence, using published sequence information (GenBank accession number NM\_002759, incorporated herein as SEQ ID NO:3). For human  
25 Protein Kinase R the PCR primers were:  
forward primer: CAGAATTGACGGAAGACTTACGTTA (SEQ ID NO: 4)  
reverse primer: CATGATCAAGTTTTGCCAATGC (SEQ ID NO: 5) and the PCR probe was: FAM-CGCTCCGCCTTCTCGTTATTATATTTAACACG-TAMRA (SEQ ID NO: 6) where FAM (PE-Applied Biosystems, Foster City,  
30 CA) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye. For human GAPDH the PCR primers were:  
forward primer: GAAGGTGAAGGTCGGAGTC (SEQ ID NO: 7)  
reverse primer: GAAGATGGTGATGGGATTTTC (SEQ ID NO: 8) and the PCR  
35 probe was: 5' JOE-CAAGCTTCCCGTTCTCAGCC- TAMRA 3' (SEQ ID NO: 9) where JOE (PE-Applied Biosystems, Foster City, CA) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye.

-74-

**Example 14****Northern blot analysis of Protein Kinase R mRNA levels**

5       Eighteen hours after antisense treatment, cell monolayers were washed twice with cold PBS and lysed in 1 mL RNAZOL™ (TEL-TEST "B" Inc., Friendswood, TX). Total RNA was prepared following manufacturer's recommended protocols. Twenty micrograms of total RNA was fractionated by electrophoresis  
10       through 1.2% agarose gels containing 1.1% formaldehyde using a MOPS buffer system (AMRESCO, Inc. Solon, OH). RNA was transferred from the gel to HYBOND™-N+ nylon membranes (Amersham Pharmacia Biotech, Piscataway, NJ) by overnight capillary transfer using a Northern/Southern Transfer buffer system (TEL-  
15       TEST "B" Inc., Friendswood, TX). RNA transfer was confirmed by UV visualization. Membranes were fixed by UV cross-linking using a STRATALINKER™ UV Crosslinker 2400 (Stratagene, Inc, La Jolla, CA) and then probed using QUICKHYB™ hybridization solution (Stratagene, La Jolla, CA) using manufacturer's  
20       recommendations for stringent conditions.

To detect human Protein Kinase R, a human Protein Kinase R specific probe was prepared by PCR using the forward primer CAGAATTGACGGAAAGACTTACGTTA (SEQ ID NO: 4) and the reverse primer CATGATCAAGTTTTGCCAATGC (SEQ ID NO: 5). To normalize for  
25       variations in loading and transfer efficiency membranes were stripped and probed for human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, CA).

Hybridized membranes were visualized and quantitated using a PHOSPHORIMAGER™ and IMAGEQUANT™ Software V3.3 (Molecular  
30       Dynamics, Sunnyvale, CA). Data was normalized to GAPDH levels in untreated controls.

**Example 15**

**Antisense inhibition of human Protein Kinase R expression by  
35       chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap**

In accordance with the present invention, a series of oligonucleotides were designed to target different regions of

-75-

the human Protein Kinase R RNA, using published sequences (GenBank accession number NM\_002759, incorporated herein as SEQ ID NO: 3, residues 33001-86000 from GenBank accession number AC007899, incorporated herein as SEQ ID NO: 10, GenBank accession number AW468555, representing an EST suggesting an mRNA variant that extends from the 3' end of exon 3 into intron 3, the complement of which is incorporated herein as SEQ ID NO: 11, GenBank accession number AI417032, an EST suggesting an mRNA variant that extends from the 3' end of exon 2 into intron 2, incorporated herein as SEQ ID NO: 12, and GenBank accession number AW149070, representing an extension 3' from the end of SEQ ID NO: 3, the complement of which is incorporated herein as SEQ ID NO: 13). The oligonucleotides are shown in Table 1. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 1 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human Protein Kinase R mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments. If present, "N.D." indicates "no data".

Table 1

Inhibition of human Protein Kinase R mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	%INHIB	SEQ ID NO
139382	5'UTR	3	51	caagtgtggagctgaatgcc	40	14
139383	5'UTR	3	63	ctgtgggttctaccaagtgtg	59	15
139384	5'UTR	3	68	cgtgcctgtgggttctaccaa	32	16
139385	5'UTR	3	79	tctatgcttgtcgtgcctgt	65	17
139386	5'UTR	3	115	gacctcgatgcctcgatgaa	42	18
139387	5'UTR	3	151	tatgatagccagggtctcct	22	19
139388	5'UTR	3	169	ccagcgaagactaagggtcta	50	20
139389	5'UTR	3	172	ataccagcgaagactaagggt	70	21

-76-

139390	5'UTR	3	243	gctccagaaactggtaaaag	0	22
139391	5'UTR	3	269	caaatccaggaaggcaaact	12	23
139392	5'UTR	3	330	cagagaagcaaacctgagtc	62	24
139393	5'UTR	3	380	aaatgcacgcagataatcac	0	25
139394	5'UTR	3	384	tccaaaatgcacgcagataa	15	26
139395	5'UTR	3	410	ttcccgatctcctgggtggaa	55	27
139396	Start Codon	3	428	atcaccagccatttcttctt	10	28
139397	Coding	3	507	gcagttcttgatatttaagt	12	29
139398	Coding	3	521	aggtcctgaattaggcagtt	7	30
139399	Coding	3	553	ataacttgaaatgtaaacct	17	31
139400	Coding	3	559	tctattataacttgaaatgt	22	32
139401	Coding	3	586	ccttcaccttctggaaattc	50	33
139402	Coding	3	593	tgatctaccttcaccttctg	43	34
139403	Coding	3	629	agctaatttggctgcggcat	52	35
139404	Coding	3	634	tcaacagctaatttggctgc	0	36
139405	Coding	3	691	gaattcgttggtgtcaataa	37	37
139406	Coding	3	706	gataatccttctgaagaatt	47	38
139407	Coding	3	779	acactgttcataatttacag	48	39
139408	Coding	3	815	ataatgaaatccttctggcc	62	40
139409	Coding	3	856	cctgtaccaatactatattc	49	41
139410	Coding	3	864	tagtagaacctgtaccaata	45	42
139411	Coding	3	870	cctgttttagtagaacctgta	0	43
139412	Coding	3	875	tgcttcctgttttagtagaac	42	44
139413	Coding	3	995	taaagagttgctttgggact	35	45
139414	Coding	3	1019	ttcagaagcgagtgctgg	74	46
139415	Coding	3	1033	ccttcagatgatgattcaga	42	47
139416	Coding	3	1076	gtcactgttagaatttatct	72	48
139417	Coding	3	1090	gaactgtttaaactgtcact	66	49
139418	Coding	3	1148	tgccaaagatctttttgcct	23	50
139419	Coding	3	1177	tctttcatgtcaggaaggct	67	51
139420	Coding	3	1261	aaaacttggccaaatccacc	1	52
139421	Coding	3	1269	ttgctttgaaaacttggcca	79	53
139422	Coding	3	1276	ctgtgttttgctttgaaaac	29	54
139423	Coding	3	1305	gtttaataacgtaagtcttt	69	55
139424	Coding	3	1334	ctccgccttctcgttattat	33	56
139425	Coding	3	1529	tttatcacagaattccattt	24	57
139426	Coding	3	1543	tgttccaagggtccctttatc	11	58
139427	Coding	3	1660	agatctctatgaattaattt	29	59
139428	Coding	3	1674	tattacttggcttaagatct	56	60
139429	Coding	3	1685	tactaagaatatattacttg	20	61
139430	Coding	3	1803	gcgaagaaatctgttctggg	8	62
139431	Coding	3	1822	acttcctttccatagtcttg	45	63
139432	Coding	3	1847	aattagcccaagcgtaga	36	64
139433	Coding	3	1891	gatgtttcaaaagcagtgtc	0	65
139434	Coding	3	1897	aactttgatgtttcaaaagc	11	66
139435	Coding	3	1905	ctgtgaaaaactttgatgtt	48	67
139436	Coding	3	1973	gagtaatttctgtagaagag	34	68
139437	Coding	3	1976	tgagagtaatttctgtagaa	25	69
139438	Coding	3	2042	gcttttcttccacacagtca	23	70
139439	Stop Codon	3	2080	gaagggtctctaacaatgtgtg	68	71
139440	3'UTR	3	2092	gatactttttcagaagggtct	78	72
139441	3'UTR	3	2162	aaggtaaatatctattgata	39	73
139442	3'UTR	3	2220	ctgtttctgcagaaagatta	21	74
139443	3'UTR	3	2251	atgtttttgaagcaaaaaga	0	75
139444	3'UTR	3	2651	ttgattcattaatagtataa	0	76
139445	3'UTR	3	2684	gcggtagaaatttaataaat	9	77
139446	3'UTR	3	2743	ccagctggccttgtaagctat	46	78
139447	3'UTR	3	2764	tttaatgagtaccatatttc	60	79

-77-

139448	Intron2	10	8938	tatgagcaaactgaaattga	50	80
139449	Intron 3	10	9384	attgacttagatgatgccac	34	81
139450	Intron 10	10	22626	gttgaatgtaaaactcaa	2	82
139451	Intron 11	10	23227	cttggattgggagcaggcag	0	83
139452	Intron 11	10	27862	aactcctgacctcaggtgat	14	84
139453	Intron 11	10	28126	ctcaagtccatcatctcca	12	85
139454	mRNA variant	11	233	ttgtccttgcgatagtttgc	57	86
139455	mRNA variant	11	304	ccttcctgtgtccatgtgtt	30	87
139456	mRNA variant	11	402	tgcacccattaactcgtcat	17	88
139457	mRNA variant	12	333	tctgggaacaatacaatttg	1	89
139458	mRNA variant	12	443	caaatgagtgccataaaacc	0	90
139459	3'UTR	13	410	aatgccaaattgttttccga	43	91

As shown in Table 1, SEQ ID NOs 14, 15, 16, 17, 18, 20, 21, 24, 27, 33, 34, 35, 37, 38, 39, 40, 41, 42, 44, 45, 46, 47, 48, 49, 51, 53, 55, 56, 60, 63, 64, 67, 68, 71, 72, 73, 78, 79, 80, 81, 86, 87 and 91 demonstrated at least 30% inhibition of human Protein Kinase R expression in this assay and are therefore preferred. The target sites to which these preferred sequences are complementary are herein referred to as "active sites" and are therefore preferred sites for targeting by compounds of the present invention.

#### Example 16

##### Western blot analysis of Protein Kinase R protein levels

Western blot analysis (immunoblot analysis) is carried out using standard methods. Cells are harvested 16-20 h after oligonucleotide treatment, washed once with PBS, suspended in Laemmli buffer (100 ul/well), boiled for 5 minutes and loaded on a 16% SDS-PAGE gel. Gels are run for 1.5 hours at 150 V, and transferred to membrane for western blotting. Appropriate primary antibody directed to Protein Kinase R is used, with a radiolabelled or fluorescently labeled secondary antibody directed against the primary antibody species. Bands are visualized using a PHOSPHORIMAGER™ (Molecular Dynamics,

-78-

Sunnyvale CA).

-79-

**What is claimed is:**

5           1. A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding Protein Kinase R, wherein said compound specifically hybridizes with said nucleic acid molecule encoding Protein Kinase R and inhibits the expression of Protein Kinase R.

10           2. The compound of claim 1 which is an antisense oligonucleotide.

          3. The compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 14, 15, 16, 17, 18, 20, 21, 24, 27, 33, 34, 35, 37, 38, 39, 40, 41, 42, 44, 15 45, 46, 47, 48, 49, 51, 53, 55, 56, 60, 63, 64, 67, 68, 71, 72, 73, 78, 79, 80, 81, 86, 87 or 91.

          4. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

20           5. The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

          6. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

25           7. The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

          8. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

          9. The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

30           10. The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

          11. A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding Protein Kinase R.

          12. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

          13. The composition of claim 12 further comprising a colloidal dispersion system.



-80-

14. The composition of claim 12 wherein the compound is an antisense oligonucleotide.

15. A method of inhibiting the expression of Protein Kinase R in cells or tissues comprising contacting said cells or  
5 tissues with the compound of claim 1 so that expression of Protein Kinase R is inhibited.

16. A method of treating an animal having a disease or condition associated with Protein Kinase R comprising administering to said animal a therapeutically or  
10 prophylactically effective amount of the compound of claim 1 so that expression of Protein Kinase R is inhibited.

17. The method of claim 16 wherein the disease or condition results from an infection.

18. The method of claim 17 wherein the disease or  
15 condition is associated with apoptosis.

19. The method of claim 16 wherein the disease or condition is an autoimmune disorder.

20. A method of modulating the process of RNA-mediated interference (RNAi) in a cell or animal comprising administering  
20 to said cell or animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of Protein Kinase R is inhibited.

-1-

## SEQUENCE LISTING

<110> Isis Pharmaceuticals, Inc.  
 Donna T. Ward  
 Andrew T. Watt

<120> ANTISENSE MODULATION OF PROTEIN KINASE R EXPRESSION

<130> RTSP-0412

<150> 09/953,611

<151> 2001-09-13

<160> 91

<210> 1

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 1

tccgtcatcg ctcttcaggg

20

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 2

atgcattctg cccccaagga

20

<210> 3

<211> 2808

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (436) ... (2091)

<400> 3

gcggcggcgg cggcgcagtt tgctcatact ttgtgacttg cggtcacagt ggcattcagc 60

tccacacttg gtagaaccac aggcacgaca agcatagaaa catcctaaac aatcttcac 120

gaggcatcga ggtccatccc aataaaaatc aggagaccct ggctatcata gaccttagtc 180

ttcgctggta tactcgctgt ctgtcaacca gcgggttgact ttttttaagc cttctttttt 240

-2-

ctctttttacc agttttctgga gcaaattcag tttgccttcc tggatttgta aattgtaatg	300
acctcaaaac ttttagcagtt cttccatctg actcaggttt gcttctctgg cggctcttcag	360
aatcaacatc cacacttccg tgattatctg cgtgcatttt ggacaaagct tccaaccagg	420
atacggggaag aagaa atg gct ggt gat ctt tca gca ggt ttc ttc atg gag	471
Met Ala Gly Asp Leu Ser Ala Gly Phe Phe Met Glu	
1 5 10	
gaa ctt aat aca tac cgt cag aag cag gga gta gta ctt aaa tat caa	519
Glu Leu Asn Thr Tyr Arg Gln Lys Gln Gly Val Val Leu Lys Tyr Gln	
15 20 25	
gaa ctg cct aat tca gga cct cca cat gat agg agg ttt aca ttt caa	567
Glu Leu Pro Asn Ser Gly Pro Pro His Asp Arg Arg Phe Thr Phe Gln	
30 35 40	
gtt ata ata gat gga aga gaa ttt cca gaa ggt gaa ggt aga tca aag	615
Val Ile Ile Asp Gly Arg Glu Phe Pro Glu Gly Glu Gly Arg Ser Lys	
45 50 55 60	
aag gaa gca aaa aat gcc gca gcc aaa tta gct gtt gag ata ctt aat	663
Lys Glu Ala Lys Asn Ala Ala Ala Lys Leu Ala Val Glu Ile Leu Asn	
65 70 75	
aag gaa aag aag gca gtt agt cct tta tta ttg aca aca acg aat tct	711
Lys Glu Lys Lys Ala Val Ser Pro Leu Leu Leu Thr Thr Thr Asn Ser	
80 85 90	
tca gaa gga tta tcc atg ggg aat tac ata ggc ctt atc aat aga att	759
Ser Glu Gly Leu Ser Met Gly Asn Tyr Ile Gly Leu Ile Asn Arg Ile	
95 100 105	
gcc cag aag aaa aga cta act gta aat tat gaa cag tgt gca tcg ggg	807
Ala Gln Lys Lys Arg Leu Thr Val Asn Tyr Glu Gln Cys Ala Ser Gly	
110 115 120	
gtg cat ggg cca gaa gga ttt cat tat aaa tgc aaa atg gga cag aaa	855
Val His Gly Pro Glu Gly Phe His Tyr Lys Cys Lys Met Gly Gln Lys	
125 130 135 140	
gaa tat agt att ggt aca ggt tct act aaa cag gaa gca aaa caa ttg	903
Glu Tyr Ser Ile Gly Thr Gly Ser Thr Lys Gln Glu Ala Lys Gln Leu	
145 150 155	
gcc gct aaa ctt gca tat ctt cag ata tta tca gaa gaa acc tca gtg	951
Ala Ala Lys Leu Ala Tyr Leu Gln Ile Leu Ser Glu Glu Thr Ser Val	
160 165 170	
aaa tct gac tac ctg tcc tct ggt tct ttt gct act acg tgt gag tcc	999
Lys Ser Asp Tyr Leu Ser Ser Gly Ser Phe Ala Thr Thr Cys Glu Ser	
175 180 185	
caa agc aac tct tta gtg acc agc aca ctc gct tct gaa tca tca tct	1047
Gln Ser Asn Ser Leu Val Thr Ser Thr Leu Ala Ser Glu Ser Ser Ser	
190 195 200	
gaa ggt gac ttc tca gca gat aca tca gag ata aat tct aac agt gac	1095

-3-

Glu Gly Asp Phe Ser Ala Asp Thr Ser Glu Ile Asn Ser Asn Ser Asp 205 210 215 220	
agt tta aac agt tct tcg ttg ctt atg aat ggt ctc aga aat aat caa Ser Leu Asn Ser Ser Ser Leu Leu Met Asn Gly Leu Arg Asn Asn Gln 225 230 235	1143
agg aag gca aaa aga tct ttg gca ccc aga ttt gac ctt cct gac atg Arg Lys Ala Lys Arg Ser Leu Ala Pro Arg Phe Asp Leu Pro Asp Met 240 245 250	1191
aaa gaa aca aag tat act gtg gac aag agg ttt ggc atg gat ttt aaa Lys Glu Thr Lys Tyr Thr Val Asp Lys Arg Phe Gly Met Asp Phe Lys 255 260 265	1239
gaa ata gaa tta att ggc tca ggt gga ttt ggc caa gtt ttc aaa gca Glu Ile Glu Leu Ile Gly Ser Gly Gly Phe Gly Gln Val Phe Lys Ala 270 275 280	1287
aaa cac aga att gac gga aag act tac gtt att aaa cgt gtt aaa tat Lys His Arg Ile Asp Gly Lys Thr Tyr Val Ile Lys Arg Val Lys Tyr 285 290 295 300	1335
aat aac gag aag gcg gag cgt gaa gta aaa gca ttg gca aaa ctt gat Asn Asn Glu Lys Ala Glu Arg Glu Val Lys Ala Leu Ala Lys Leu Asp 305 310 315	1383
cat gta aat att gtt cac tac aat ggc tgt tgg gat gga ttt gat tat His Val Asn Ile Val His Tyr Asn Gly Cys Trp Asp Gly Phe Asp Tyr 320 325 330	1431
gat cct gag acc agt gat gat tct ctt gag agc agt gat tat gat cct Asp Pro Glu Thr Ser Asp Asp Ser Leu Glu Ser Ser Asp Tyr Asp Pro 335 340 345	1479
gag aac agc aaa aat agt tca agg tca aag act aag tgc ctt ttc atc Glu Asn Ser Lys Asn Ser Ser Arg Ser Lys Thr Lys Cys Leu Phe Ile 350 355 360	1527
caa atg gaa ttc tgt gat aaa ggg acc ttg gaa caa tgg att gaa aaa Gln Met Glu Phe Cys Asp Lys Gly Thr Leu Glu Gln Trp Ile Glu Lys 365 370 375 380	1575
aga aga ggc gag aaa cta gac aaa gtt ttg gct ttg gaa ctc ttt gaa Arg Arg Gly Glu Lys Leu Asp Lys Val Leu Ala Leu Glu Leu Phe Glu 385 390 395	1623
caa ata aca aaa ggg gtg gat tat ata cat tca aaa aaa tta att cat Gln Ile Thr Lys Gly Val Asp Tyr Ile His Ser Lys Lys Leu Ile His 400 405 410	1671
aga gat ctt aag cca agt aat ata ttc tta gta gat aca aaa caa gta Arg Asp Leu Lys Pro Ser Asn Ile Phe Leu Val Asp Thr Lys Gln Val 415 420 425	1719
aag att gga gac ttt gga ctt gta aca tct ctg aaa aat gat gga aag Lys Ile Gly Asp Phe Gly Leu Val Thr Ser Leu Lys Asn Asp Gly Lys 430 435 440	1767

-4-

cga aca agg agt aag gga act ttg cga tac atg agc cca gaa cag att 1815  
 Arg Thr Arg Ser Lys Gly Thr Leu Arg Tyr Met Ser Pro Glu Gln Ile  
 445 450 455 460  
  
 tct tcg caa gac tat gga aag gaa gtg gac ctc tac gct ttg ggg cta 1863  
 Ser Ser Gln Asp Tyr Gly Lys Glu Val Asp Leu Tyr Ala Leu Gly Leu  
 465 470 475  
  
 att ctt gct gaa ctt ctt cat gta tgt gac act gct ttt gaa aca tca 1911  
 Ile Leu Ala Glu Leu Leu His Val Cys Asp Thr Ala Phe Glu Thr Ser  
 480 485 490  
  
 aag ttt ttc aca gac cta cgg gat ggc atc atc tca gat ata ttt gat 1959  
 Lys Phe Phe Thr Asp Leu Arg Asp Gly Ile Ile Ser Asp Ile Phe Asp  
 495 500 505  
  
 aaa aaa gaa aaa act ctt cta cag aaa tta ctc tca aag aaa cct gag 2007  
 Lys Lys Glu Lys Thr Leu Leu Gln Lys Leu Leu Ser Lys Lys Pro Glu  
 510 515 520  
  
 gat cga cct aac aca tct gaa ata cta agg acc ttg act gtg tgg aag 2055  
 Asp Arg Pro Asn Thr Ser Glu Ile Leu Arg Thr Leu Thr Val Trp Lys  
 525 530 535 540  
  
 aaa agc cca gag aaa aat gaa cga cac aca tgt tag agcccttctg 2101  
 Lys Ser Pro Glu Lys Asn Glu Arg His Thr Cys  
 545 550  
  
 aaaaagtatc ctgcttctga tatgcagttt tccttaaatt atctaaaatc tgctagggaa 2161  
 tatcaataga tattttacott ttatttttaat gtttccttta attttttact atttttacta 2221  
 atcttttctgc agaaacagaa aggttttctt ctttttgctt caaaaacatt cttacatttt 2281  
 acttttttctt ggctcatctc tttattcttt tttttttttt taaagacaga gtctogctct 2341  
 gttgcccagg ctggagtgca atgacacagt cttggctcac tgcaacttct gcctottggg 2401  
 ttcaagtgat tctcctgcct cagcctcctg agtagctgga ttacaggcat gtgccacca 2461  
 cccaactaat ttttgtgttt ttaataaaga cagggtttca ccatgttggc caggctggtc 2521  
 tcaaactcct gacctcaagt aatccacctg cctcggcctc ccaaagtgct gggattacag 2581  
 ggatgagcca ccgcgcccag cctcatctct ttgttctaaa gatggaaaaa ccacccccaa 2641  
 attttctttt tatactatta atgaatcaat caattcatat ctatttatta aatttctacc 2701  
 gcttttaggc caaaaaaatg taagatcggt ctctgcctca catagcttac aagccagctg 2761  
 gagaaatag gtactcatta aaaaaaaaaa aaaagtgatg tacaacc 2808

&lt;210&gt; 4

&lt;211&gt; 26

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> PCR Primer

<400> 4

cagaattgac ggaaagactt acgtta

26

<210> 5

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 5

catgatcaag ttttgccaat gc

22

<210> 6

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Probe

<400> 6

cgctccgcct tctcggttatt atatttaaca cg

32

<210> 7

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 7

gaaggtgaag gtcggagtc

19

<210> 8

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 8

gaagatggtg atgggatttc

20

-6-

<210> 9  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> PCR Probe

<400> 9  
caagcttccc gttctcagcc

20

<210> 10  
<211> 53000  
<212> DNA  
<213> Homo sapiens

<220>

<221> intron  
<222> (1)...(1217)  
<223> Intron 1

<221> intron  
<222> (1298)...(8947)  
<223> Intron 2

<221> intron  
<222> (9349)...(10382)  
<223> Intron 3

<221> intron  
<222> (10518)...(11231)  
<223> Intron 4

<221> intron  
<222> (11353)...(16503)  
<223> Intron 5

<221> intron  
<222> (16653)...(18447)  
<223> Intron 6

<221> intron  
<222> (18575)...(19619)  
<223> Intron 7

<221> intron  
<222> (19697)...(19841)  
<223> Intron 8

<221> intron  
<222> (19936)...(21187)  
<223> Intron 9

<221> intron  
<222> (21223)...(22658)  
<223> Intron 10

- 7 -

<221> intron  
 <222> (22722) ... (31793)  
 <223> Intron 11

<221> intron  
 <222> (31917) ... (35540)  
 <223> Intron 12

<221> intron  
 <222> (35700) ... (38065)  
 <223> Intron 13

<221> intron  
 <222> (38247) ... (43348)  
 <223> Intron 14

<221> intron  
 <222> (43475) ... (48909)  
 <223> Intron 15

<221> intron  
 <222> (49012) ... (50677)  
 <223> Intron 16

<221> intron  
 <222> (50732) ... (53000)  
 <223> Intron 17

<400> 10  
 tttttttttt tgaattggag tccactctg tcaccagcaggc tggagtgtag tggcatgata 60  
 tcagctcact acaatctctg cctcccaggt tcaagcaatt ctccctgcct cagcctctgg 120  
 agtagctggg attacaggtg cctgccacca cgcccagcta atttttgtgt ttttttagtag 180  
 agacgggggt ttgccatgtt ggccaggctg gtccctgaact cctgacctca ggtgatccgc 240  
 ccgtctcagc ctcccaaatt tctgggatta caggcatgag ccaccgcgcc ggcctaggca 300  
 taatatattaa tgtatatatt aggtctgtct ttggaccacc ttctctctct atcccagcta 360  
 agatactgag agtacaaact cctgggttata attctaactc cgctgcttac tacctgtgtt 420  
 aatccaaatt ctctgtgcct caatactcat tagtcactgt gccaatgaac tctggaactc 480  
 tgtgtgactc tgggagtgtg tcgcagtccta tcaggtgagt agaatttcta taaatcgagg 540  
 actactgggtg ttggactatg gtaggaagct ccctggggta ctgtaggaag caggtgtctc 600  
 tatttagcag caggactggc ccacagggtgc ttttacagcg gctggcaagt gtctgctcat 660  
 gaatgaatgg atgggtggga gcggagtga ggagattacg ccccaggcc tctgatcccc 720  
 aggtctgtaa aggtgagggg gccgcgggtg ggcaagagg aaagagtgtc ttggtgttta 780  
 caggccccga cttgaactga atcctggctt tgccacttac gagcggcagg acccctgggt 840  
 gagttcattt actcagtttc ctctattgta gaatggagct ggtaagatcc atcttcccaa 900  
 cccacaccca aatatttgtg ttgagagtaa gtggaaccct tgattcgaga acctagtgcg 960  
 gccagcggac taggccagcg gagaacccta ggagccccgg gggcggggga tgggggtgca 1020  
 gggtcctggc cgtgcagggg cagcacgtgg gtgccaagcc cgctgccgg tgccaagccc 1080  
 gcccgcgggt gccaaagccc cccgccagtg cctctcgcgc gcactctgga tccagcgcca 1140  
 atttacccca atcccgtagc agacgagggc ttgtgcgaga gggggccggg cggctgcagg 1200  
 gaaggcggag tccaagggga aaacgaaact gagaaccagc tctcccgaag ccgcgggtct 1260  
 ccggccggcg gcggcgggcg cggcgggcgg ggcgcagggt agcagggcag ggggcagccg 1320  
 agggagcgcg gggagcgggg gccggggggc cacgtacgag gggctgcagg cccagccggg 1380  
 gcgggactcg ccaatcctgc gtcccagct caggacgcgg acgctgatcc gaagcccctg 1440  
 gccccggctg ggtcagcact gggagagcag gccaggtcc gcagcccggg tgtggggccc 1500  
 tcccaaatac cagggaaagg atcgtggagc ggggtgggga ctgaaagcca tttccttccc 1560  
 gtgaagaatt tttatcagtg caagtaacaa atatttccca ggcagcagtt gtggggcggg 1620  
 gtctagtggg agacgaatag gcctagtggc ttgacacatg gaaaatacgg aggcctgaaa 1680  
 tactcataga ctggctgaac aatctttggc taaaaatctc ttccgtggag agttgcagta 1740  
 gtttcccaat tgcctggccg cagttcctgt tccactccg tatectcacc cctgaacctc 1800



cacccccctac	ctcttctcca	cacctcagca	tctggaatgt	tcctttaagt	aagaaccaga	1860
ctctccccctg	ctccgacctt	ccccgtagct	ttcctgtctc	atcagaatcc	tataaacatt	1920
tattaagggt	cacaggcaag	gccccctcgca	ccccctactc	cggccacgct	ggcttccctg	1980
ctgttccttg	tgcacagcca	agcatcctcc	agcctctagg	cctttgcact	gcttgtttct	2040
tctttctgga	aagcttcttc	cccagataac	tgcattggga	aatccctccc	ttatcctgca	2100
ctgcttccca	tgccagctta	tcagagcagc	cttcttcaaa	caacctgcct	atacaagaaa	2160
ccccgctctg	cccttgctgt	tcccccttcc	actacttcgg	ttgtcaacat	agtagttatc	2220
acctggtgac	atcttcttct	ttttcttctt	tttttttttt	tttttgagac	agattctcac	2280
tctgtcgcca	ggcttgaatg	cagtggcacg	atctgggctc	actgcaacct	ctgcctctca	2340
ggttccaagcg	atcttcttcc	ctcagcctcc	caggtagctg	ggactacagg	tggccgccag	2400
cacagccaac	taattttttt	atctttagta	gagacagggt	ttcaccgtgt	tggccaggct	2460
gtatgtagtc	tgttgaaaag	gaagtggagg	catagccaaa	ataatttctg	ggcattagta	2520
agatggacaa	atattatctt	ttagtgtatg	tgttgagggt	ttcttccaga	tgagtgaata	2580
agatgtagaa	tctgtcccc	aaagagctca	ctaattagtt	taaaaagcag	tcagggtgtg	2640
ggtgaagggt	gggcaagggt	gagtggcaag	cccatactag	ctgacctctc	agcatcaaa	2700
aaggctgtgt	tgttcctgat	agatgagtgg	atattggtgg	gtacagagag	aatgcagata	2760
ttgcactata	aattgtagaga	aaagcagggt	acaagtcctg	gatggggtat	ctggagatat	2820
tttggtactc	actcattcat	tattgagcct	ggctccctac	ctgtagtaat	tcattgctct	2880
ttttggaaaa	tagttaaata	agcaatttta	ataaaggggg	tgagcactgt	ggaagagcct	2940
gtgaaggagt	gtctgggatt	ttgagctgaa	atctgtagga	agtagaaatt	gaccaggcca	3000
agacagcaga	aggaatagag	tcaagggcct	tttagggagg	agcagggttg	acagaggcag	3060
ttgggagttc	aggagagagt	ccatggtgga	agcgtgcttt	tgagaacctt	cattgtgtcc	3120
gtggaattta	aagccacaaa	cctggagggt	atcaccaggg	gagtgaagtc	aaagtagaaa	3180
gagcaagtct	aaggaccggg	cccagtgatg	ctagaatata	tagaaaagag	gaagtttaga	3240
ccatagaaaa	ggttaaaaaa	aaaaaaatag	aagaaaagaa	gttgaagatg	aaccaggaaa	3300
ggagacagaa	aaggagtagc	ttgtcagaac	agaagaaaac	caggcccagg	tgccatggct	3360
catgcctgta	atcgagcac	tttgggaggc	caagggtggg	ggatcacctg	aggctaggag	3420
tttgagacca	gcctggccaa	catggggaaa	ccccgtctct	actaaaaata	taaaaaatta	3480
gccgggctgt	gtggtgggct	cctgtaatcc	cagctactcg	gaatgctgag	gcaggagaat	3540
cgcttgaacc	cgggaggcag	agggtgcagc	gagccgagat	gccaccatca	cactccagcc	3600
tgggcaacaa	gagcgaaact	ctgtctcaaa	agaagaaaac	taggagagtg	ggtgtcttaa	3660
aagtccaagc	taagacaggg	agaggagggc	gaagaggatg	cgcaacccca	tcaaatgctg	3720
gttgtaagtc	aagtagagaa	ggactaagaa	ctgactactg	gatttagtga	tagggaagcc	3780
attggttaacc	tcgacaaaaa	caatttcagt	ggcttgtgga	gactgcatga	ttgaattgat	3840
gtttttttgt	ttgtttgttt	tgtttttgtt	tttttttttg	agacggagtt	tcgctcttgt	3900
tgcccaggct	ggagtgcatt	ggcacgatct	cagctcaccg	caacctccac	ctcctgggtt	3960
caagcgattc	tccttctctc	gcattcccag	tagctgggat	tacaggcatg	tgccaccacc	4020
ccggctaatt	ttgtatcttt	agtagagatg	gggtttctcc	atgttggtca	ggctgggtct	4080
gaagtcccga	cctcagggtg	tctgcccggc	ttggcctccc	aaagtgtctg	gattacaggt	4140
gtgagccacc	gcgcctggcc	actgaattga	tgttttaaaa	agatcatgat	gtggctgtat	4200
taaaaaagaa	aacagataat	aacaagtgtg	ggtaggagtg	tggagaaatt	agaacctctg	4260
tgcattgctg	gtggaaatgt	aacatgggtg	taaccactgt	ggaaaacaat	ttggtgattc	4320
atcacaaagt	taaacagaat	tatcatgtga	ttcaattcca	cttatatacc	acaaatatct	4380
agaagtaggg	acttaaacag	atatatgtat	accagtgttc	acagcagcat	gattcaagat	4440
ggccaaaagg	ttgaaataac	cagtgtccat	tcataaatga	atgcatgaac	aaaatatggt	4500
atatatacac	aacggaatat	tattcagcct	taaaaaggaa	aggaattctg	acatatgcta	4560
caacatagat	gaaccttgaa	gacattttgc	taagtgaatt	aaccagacac	aaaaggacaa	4620
atactgtttg	attccactta	tatgaggtag	ctagaacagg	caaattttca	gagacagaag	4680
agagattaga	aaatataaaa	aattaaccag	gcattgcccac	gcctatggtc	ccagctactc	4740
gggaggctga	ggtgggagga	tcgcttgagc	ccagagttca	aggctgcagt	aagctgtgat	4800
cacaccactg	cactccagcc	tgggcaacag	agcgagaccc	tgtctcaaaa	aaaaaaaaaa	4860
aaaaaaagat	tagcagagac	tgaaaggact	gggaaatggg	gagttactgt	ttaatgggta	4920
cacactttct	gttttgaaaag	attaagagtt	gtggatgtgg	atgtgggtgg	ggctacacaa	4980
cattgtgaat	gtacttaaaag	gcagggaatt	aatacattga	aaaatagtac	atctcatggt	5040
atgtgtatct	tatcacaaat	ttaaaacata	aaaaaaaaaa	tcacaatggg	tgcagggtag	5100
agaagggaatt	gaagttagctg	tcggaactgg	ttctgagatt	ctcacagcaa	tccaggaattg	5160
aggtggtgtt	ggcttgaact	aggatggtaa	gtgtagacat	ctttgagaag	tagaaagatt	5220
ttggtgacag	gacttagtta	tagattagaa	ggcaggggaga	ggaaatgtca	aggatgcctc	5280
ccagattgat	ggctttcaga	cttggataga	tgggtggactc	atctcctgtg	aaaggaaact	5340

tcaaaccagc	ttgggagaag	atcatatcatg	cagtacagga	tatttttgagt	ttaaagttcg	5400
ttcaagatgt	tcaagtggag	aatttggata	gagagatctg	aaactcagag	cggttcataa	5460
ggaatatgta	aacttttagag	gtaatggcgt	atagatgatc	actgaaatca	tggacgtgaa	5520
agaaatcacc	ttaaggagaa	agtatagagt	gaagagaaga	ggattgttgg	gccatgccag	5580
catttagagc	tacaaagatt	aagggtgtgt	aaaaagagtg	gcccggccag	gcgtggtggc	5640
ccacacctgt	aatcccagca	ctttgggagg	ctgaggctgg	tggatcactg	gagttcagga	5700
gttgagagacc	agcctggcca	acaccgggaa	acctcaaaaa	tacaaaaatt	agctgggcgt	5760
ggtggtgggc	acctgtagtc	ccatagtccc	agctacttga	gaggctgtgg	caggaaaatt	5820
gcttgaacct	gggaggcaga	tgctgcagtg	agctgagatc	atgttactgc	actccagcct	5880
gggcaacaga	gtgaggccct	gtctcaaaaa	caaaaaacag	aaagagtggc	cctggaagaa	5940
agaagatcaa	aagagctttc	caagaagaat	taagaggttt	acaggatctg	atctctgcct	6000
ttatggattt	accgattctg	gaagtttcat	ataaatggga	atcatacaat	atgtgtgaaa	6060
ttttatgtct	ggatttttca	ttttgcataa	tgtttttgag	gtttatccat	gtttttgttg	6120
ttgtggttgt	tgttttttga	gatggagtct	tcgtctctgc	gcgcaggctg	gagtgcagtg	6180
gcgcgatctc	agctcactgc	aagctccgcc	tgccgggttc	acgccattct	cctgcctcag	6240
cctcgcgagt	agctgggact	acaggcgcgc	gccaccgcgc	ccggctaatt	ttttgtattt	6300
ttagtggaga	cgaggtttca	ccgtggtctc	gatctcctga	cctcgtgatc	cgcccgcctc	6360
ggcctcccag	agtgttggga	gtacaggcat	gagccacggc	gcctggccta	tccatgttgt	6420
agcatgtatc	agtacttcat	tttttttgtg	actgaataat	attccgctgt	gtagatatat	6480
ttcacatttt	gttcaccatt	tatccgttga	tggaactctg	gtttgtttcc	accttttggc	6540
tattgttaac	agtgtctgta	tgtacattcc	tgtctaagtc	tttgtttgga	aacctgtttt	6600
ccaattcttt	gaaatatcta	ggaatggaat	tgctgagttt	tatgataatt	caaagtttac	6660
cttctagagg	aaccccagca	accgtattgt	tttacattct	tatcagcagt	gtttgagggg	6720
tccagtttct	ccatgtcctc	accaacactt	attttttatt	atttccctgat	tattattatt	6780
attgccatac	tagtgggtgt	gaaattgtat	ttagtgtggg	ttttgaattc	catttcttta	6840
atgactcatg	atgttgagta	tcttttcacg	tgcttatttg	cgatttacat	atttcttttg	6900
gagagatgtc	tgttcaagcc	cctttgccta	tttttttaat	tgggtgggtt	gtctttttgt	6960
tgttgagctg	taagaattct	ttatatatct	ggttactaga	ccctcatcag	atatatgatt	7020
tgtaaatatt	ctattctgta	gattgtcatt	tatttttctt	catagtgtcc	tttgatacac	7080
aaacgtttta	aatttttagt	aagcccaatt	tatctctgtt	ttcttttggt	gcttggtgctc	7140
ttgctgtcat	agctaaaatt	ttatcaccaa	atccaaagtc	atgaagatct	cccccatatt	7200
ttctttctaag	agttttatag	ttttcgcttg	tacatttata	ttttatatcc	tctaaatttt	7260
gtttataatt	taaatcattg	ctatagactt	ggtccagtga	gacctataaa	cagaggctct	7320
aattttactca	gtgggttaaat	tgtcctaaaa	ttgatttctg	caaaattcag	aggggagatt	7380
tttgggattt	catagagaaa	tctatatcca	tacagttaaa	tccttcatga	tttcatacac	7440
ttcacttttt	taaagtatta	aaactttttt	atttgaagaa	tacgtgggga	gaagagaaat	7500
atatttcagc	acttagatat	gtagattatt	tccaaaatag	tttaccactc	aactagtcac	7560
ttctgtgtaa	atcagttttc	cctgaagcaa	gcattgtgtt	gttcccggct	acaagcggtc	7620
ctcatttttg	atggtactgt	gggaccataa	aatgggcat	gcaaagcaat	cttaataatc	7680
aatggggaaa	atgatgattg	ttccatgacc	tttaaaattc	tgctaaaata	ttaaaactct	7740
taagggtcagt	tataaatgta	gaaaaaaatg	caaaaaaaat	ttaaaaatat	ttagtacact	7800
gtaatttaaa	acattaaaaa	tagaattaaa	gtgttttatt	tcattgtgaa	aactaagtag	7860
tttgaatagg	gattgccttt	tttttctgcc	aagtgaacta	tgatactgag	taagcatctt	7920
ttctattcat	ggcaaacgtg	catactcctt	ttaagtttgg	gtgagcttcc	agccttttat	7980
tgcttgtgct	ttcaatgttg	tgaagtattt	ctgtattcac	attaaatgct	ctttagtgtg	8040
aagtttggtt	tttttttttt	tttaccgtca	cttccctctg	gacatattta	tctttatttg	8100
aatcactttt	cttattttgt	ttgataagtt	tgcccttact	aagctcctat	gaatgcacag	8160
caggaagaac	attcccatga	tcagtgaact	cttctacaaa	tccatttatg	tttgattcaa	8220
atttcacttc	cagtgttata	atttttcggt	gctttgttgg	actttcatct	ttgttggtcca	8280
gttcttttoga	ttgttcactt	ctataaaaatg	tcaggtggag	gacaaagaga	cagtgttaact	8340
acgtgctctg	ctgtgagtga	actgattaac	agatgcacag	ggaccaacca	ctggaagaat	8400
ttgaaacaag	taacacgact	ggtcactgat	catgaagcat	atctgttatt	tacatcgtga	8460
tttgtagact	gaagaactag	cagagaagtt	tgtacttcct	gtaattactc	agagttatac	8520
tgtgtctacct	aaaattttta	cctaggttta	aacaacacca	gtttccttac	cagtttcctt	8580
tccttcctgg	taaggaaact	ggtattttaa	ctaaatctag	gtcactgaaa	tttgtgccat	8640
gggaaccgtg	cacattgagg	acctgcctac	accctacatg	tttatatttg	tccaggcagg	8700
cttaatgctg	actactgaga	aataggctat	ctgaatttat	atcaaatagt	gaatcttaaa	8760
gcaccaaga	tgaaaaattc	gtgcacattg	aggtgctttt	aaaatctttg	tcatttgaca	8820
atcaagctta	aaatgtatct	tagagtaacc	gaatttttaga	aataaagacc	tttaaaggcc	8880

ccatagtttg	ataccacaga	ttatccagca	tggtttataat	gaattatttc	tcctccttca	8940
atttcagttt	gctcatactt	tgtgacttgc	ggtcacagtg	gcattcagct	ccacacttgg	9000
tagaaccaca	ggcacgacaa	gcatagaaac	atcctaaaca	atcttcatcg	aggcatcgag	9060
gtccatccca	ataaaaatca	ggagaccctg	gctatcatag	accttagtct	tcgctggtat	9120
cactcgtctg	tctgaaccag	cggttgcatt	tttttaagcc	ttcttttttc	tcctttacca	9180
gtttctggag	caaattcagt	ttgccttctt	ggatttgtaa	attgtaatga	cctcaaaact	9240
ttagcagttc	ttccatctga	ctcaggtttg	cttctctggc	ggctctcaga	atcaacatcc	9300
acacttccgt	gattatctgc	gtgcattttg	gacaaagctt	ccaaccaggt	acaagcggtc	9360
ttccgaatth	tgcactcaga	aaagtggcat	catctaagtc	aattacatgc	aaattctggg	9420
gggctagttt	tttgtgtatg	ttaaatgggt	cacaacacga	cttctgtaaa	tcctcaaatc	9480
tgtcaatata	aatttttatg	tgatgaaagc	aaattgtatt	gttcctagaa	agtgtccttc	9540
cagttcttaag	ttgaagtaaa	agcatgtcat	ttgatgacaa	ttcttgcaac	atcttaaaac	9600
ctgtgtgaca	agtatagtag	gttttatggc	actcatttgt	agtacgaagc	tggactgcaa	9660
ctatcgatcc	atcattgttg	attctagcat	atcttctctg	ttttattttg	tctagagatc	9720
taggtcacgg	gctgatcacc	cttagcttga	gctctcctcc	gcctggcttc	cggcaggatc	9780
cacgtccaca	caggcacact	tgcttgcccg	ttcatttccc	agcctgtccc	catgctacca	9840
ctccacttca	cttattatat	atactctaaa	tccttttctt	ctcaacataa	aacattctac	9900
aatcctgcag	cctttttact	tttttaagca	ggtaggcaaa	catgtagttg	atactcagtg	9960
gaagcacaga	gcagagttaa	agagaaggac	cccctttcac	tgaccagttg	agtttttttt	10020
ctttccttta	ttttttaaaa	caatttcaaa	attgagatgg	ggtttcgcca	tggtgcccag	10080
gctgggtctcg	aactcctgag	ctcagggtgat	ccgccacact	tggctgggat	tataggcgtg	10140
agccaccaca	cctggccaag	ttgagttttt	aaagtagaaa	atcttgagaa	aattaacttt	10200
attgtgcagt	gaatgagaaa	gaaagaacgg	ttttgaaaga	aagtctctgc	atcttatgtga	10260
gactgagatg	agtcctataa	aggggagttc	ccccaacccc	tctgtctcct	aaactgcatt	10320
gggaaactca	gattaaatat	gttctgtgag	catcactcat	tcaaagtgtc	cttccattgt	10380
aggatacggg	aagaagaaat	ggctgggtgat	ctttcagcag	gtttcttcat	ggaggaactt	10440
aatacatacc	gtcagaagca	gggagtagta	cttaaatatc	aagaactgcc	taattcagga	10500
cctccacatg	ataggaggta	ggttgctata	aaaaatgata	tggcagccat	aaaaaatgat	10560
gagttcatgt	cctttgtagg	gacatggatg	aaagctgaaa	ccattattct	cagcaaaacta	10620
tcgcaaggac	aaaaaaacca	aacaccgcat	gttctcactc	ataggtgaga	actgagcaat	10680
gagaacacat	ggacacagga	aggggaacat	cacacaccag	ggactgttgt	gggggtggggg	10740
gaggggggag	ggatagcatt	aggagatata	cctaattgcta	aatgacgagt	taatgggtgc	10800
agcacacca	catggcacat	gtatacatat	gtaacctgca	cgttgtgcac	atgtacccta	10860
aaacttaaa	tataataata	ataaaattaa	aaaaaaaaga	aaaaagatat	gaccttataa	10920
atgtaagctg	ggggaatggc	aactctggca	caactttgag	gtcaacactt	tagtttttgtg	10980
agagtgtctc	tggcataaag	tgggaaccat	ggtaggagcca	cagttgactc	cagagagaaa	11040
agagggtaga	aacctttcca	tgcttcaaca	agacatgctg	ctttactgtt	tgagggtgact	11100
gcttaaatgc	tatattgaat	gtagggtcaa	accctcaaag	gtagtcatag	gaggtagtga	11160
tgactagagt	acttggtttt	agatagtgc	tgagttgtat	aatattttat	gaatattctc	11220
tttghtaatca	ggtttacatt	tcaagttata	atagatggaa	gagaattttcc	agaagggtgaa	11280
ggtagatcaa	agaaggaagc	aaaaaatgcc	gcagccaaat	tagctgttga	gatacttaat	11340
aaggaaaaga	aggtgagtga	ttgccttttt	tcctaataaa	tgggaacttg	caaatacatt	11400
ttctgtttct	ctctgtgaga	aaatactttc	atacagagta	aagccattca	cacgttccct	11460
tacattcaag	agtttggtta	agtcattcac	cctactttca	tttctatgaa	accctgagtg	11520
agagccacac	ctaggacacc	atgggcacaa	ctggataata	gttattttaga	gtgtcagcag	11580
cagttaaata	ctctaaagtt	gaacaaatat	ggaaagggtga	gaagtgttca	gtgggaaatg	11640
agctgacagg	ttctggggagg	agtccctctc	acctaataatga	ggaagtacag	taaaaaaggga	11700
aaaagagatg	aaagtgattg	tagggagaat	aatgtacagt	ggctactcac	tctctgtggg	11760
gaattggtac	caggactccc	tgtggatgcc	aaaattcact	gatgctcaag	tccttttatat	11820
aaaatggcat	agtattttaca	tataacctat	ttacatcttc	ccatatacag	ttatgcattg	11880
cttaacaagg	agaatacatt	gtgagaaatg	cacctttggg	caatttcttc	attgggcaaa	11940
catcatagag	gtacttacac	aatcctgaat	ggtacaacca	gtacacacct	aggctgtgtga	12000
gtatagctta	ttgctcctag	actacgaacc	tatacagcat	attattgtac	tgaatactgt	12060
agccaattgt	aacacaatgt	ttagtattca	tgtatctaaa	catatctaaa	cacagaaaaa	12120
gtacggtaaa	aatacagtat	aaaagacaaa	aggctgggct	tgggtggctca	cacctgtaat	12180
cctagcactt	tgggaagctg	aggcgggttg	atcacctgag	gtcaggagtt	gaaaaccagc	12240
ctggccaaca	tgggtgaaacc	ctgtctctac	taaaaatata	aaaaattagc	tgggctgtgt	12300
ggtggacgcc	tgtaatccca	gctacttggg	aggctgaggt	aggagaattg	cttgaaccgc	12360
ggagaaggag	gttgacagtga	gctgaggttg	tgccactgca	ctccagcctg	gggatccctat	12420

ctcaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aagacaagca	aaagtacacc	12480
catataaggc	acataccatg	cataaataga	gcttgagga	ctggaagttg	ccctgagttt	12540
gtcagcaagt	gggtggtgaa	tgaatgtgaa	ggcctagggc	attattgttt	accactgtag	12600
actttataaa	cactgtatag	ataagcaaca	ttcattttat	ttaaattttt	tttcttcaat	12660
aataaaattaa	ccttagctta	ctataactct	tttactttat	aaactttcta	tttttaacat	12720
tttcaactct	tccaaataac	acttagccta	aaacacaaac	gcggccaggc	gcggtgggtc	12780
atgcctgtaa	tcctggcact	ttgggaggcc	aaggcaggca	gatcacctga	ggtcaggagt	12840
ttaagatcag	cctggccaac	acggtgaaac	cctgtctcta	ctgaaaatac	aaaaatttag	12900
cgggcatggt	ggtgggcacc	tataattccg	gctacttggg	aggctgaggc	aggagaattg	12960
cttgaactca	ggaagcggag	gttgagtgaa	gccgagatcg	tgccactaca	ttccagcctg	13020
ggcgacaagg	caagactctg	tctcaaaaaa	aaacccacaa	aaccacaaac		13080
aaacacatag	tatggctgta	caaaaatatt	ttgtttcttt	acatgtttat	tctataagct	13140
tttttctatt	tttaaaattt	taaaactttt	tttttaactt	ttaaactttg	ttgtaaaaaa	13200
ttaaatcatg	gttgggcata	gcggttcatg	cctgggatgt	cgaggagcca	tgattgtgcc	13260
actgtactcc	agcctgggtg	acagagttag	accctgtctc	aaaacaaaaa	aaaacaaaaa	13320
aaaggctggg	tgtggtgggt	catgcctgta	gtcccagcac	tttggtaggt	caaggtaggt	13380
ggatcacttg	aatttgggag	tttgagatta	gcctaggcaa	catggtgaaa	ccctgtctgt	13440
actaaaaaca	caaaacatta	gccgggcttg	gtggcatgtg	cctgtagttc	cagctactca	13500
ggaggctagg	cgggaggatc	acgtgcctga	gaggtcaggg	ctgcagttag	ctgtgatctt	13560
ctgactgcac	tccagcctgg	gcaacagagc	aagaccctgt	ctcaaaaaaa	aaaaagaaag	13620
aaaaaaaaatt	acaacacaaa	cacacacatc	agcctaggcc	tacacagcgt	caggatcatc	13680
tacatcacca	tcttccacct	ccagattttg	tccctctgga	aagtgttcag	gagcaataac	13740
atacatggag	gtgtcatctc	ctattgtagc	aattccttct	tttggtattc	ctaccgaagg	13800
acctgcctga	ggctgtttta	cagtttactt	tttttttttt	aagtagaagg	agtaacttct	13860
aaaataatga	taaaaaaagt	atagtaaata	tataaaccag	taagttactt	atcattatcc	13920
agtattatgt	actatacata	attgtgtgtg	ctagactttt	ttataagact	gtagaacagt	13980
agatttgttt	acagtagtgt	caccacaaat	gtgtgagtaa	tgcatgtgtc	tgtaaccacg	14040
gagtttaaaa	ttatcctggg	caatatggcg	aaatgctgtc	tgtactaaaa	atatgaaatt	14100
tagccattac	agtggctatg	acctcattag	atgacagtaa	tttttttagct	ccattataat	14160
cttatgggac	cactgtcata	tatgcagtcc	attgttgacc	aaaatgtgat	tatgtagtac	14220
atgattatcc	tttagatcat	ctctagatta	cttataatat	ctctaataca	atgtaaatgc	14280
tatgtaaata	gtttttttgt	tgttgttgtt	gtcgtttttt	gagacagggt	cgtactctgt	14340
caccagggtc	ggagtgcagt	ggcatgatca	agggctactg	cagcctcaat	ctcccaggc	14400
tcagggtgatc	ctcccacctt	agcatcccaa	ctggctggga	ctacaggcac	gagccaccac	14460
acctggccaa	tttttgcatt	ttttgtagcg	atggagtctc	actatgttgc	ccaggctggt	14520
cttgaactcc	tggactcaag	caatctgccc	acctcagcct	cccaaagtgc	taggattgca	14580
ggcatgagcc	accacaccca	gctataagta	gttggttatgc	tgtattgttt	agggaataat	14640
acaagaaaaa	aaatctgcat	atatttagta	cagatgcaac	catcattttt	tttccaaata	14700
tttttgatcc	atgattgggt	gaatccaggg	atltgaaacc	cgtggatata	gcgagccaag	14760
tgtttacaga	gagcaggtaa	tgagaaacca	atatacatgt	gactgggtatc	ccggaataa	14820
agaacagagt	aaatagtgca	gaagaaaatg	atctgaagag	atttcagcag	acaatgttta	14880
tgaaataaag	aaagacttga	ctgcagatta	aaacaactta	atagatacag	gaaaatttag	14940
aaccacccag	accaacattg	attctttttt	tttttttttt	ttgagacaga	gtctcgctct	15000
gttgtccagg	ctggagtgca	gtggcacaa	cctctgcaa	cctccgcctc	ccatgttcaa	15060
gcaattctct	gcctcagcct	cctgagtagc	tgagattaca	ggcaccacc	accacggcca	15120
gctaattttt	tgatattttt	agtagagaca	gggtttcact	atgttggcca	ggctgggtgt	15180
taactcctga	cctcgtgatc	cactcgcttt	gggtctccaa	agtgtggga	ttacagggtg	15240
gagccaccgc	gcccggcccc	aacattgatt	cttatgaaag	tactgtgtct	cagagatgag	15300
gaaagaattt	tataagcatc	tagagagaag	aggaaaacta	tgtaaaatgt	aaaaattttt	15360
aaaatttcat	gctgtgcaca	gcaacattat	aaaccaggag	atagtgtagc	aatgcttata	15420
aaatgaaaca	tgaagtcatt	tacatttttag	acaccagagg	gccattctca	gatttggaag	15480
atgttgggaa	aattttaggt	tcaaggttct	ttcttgaaaa	atctacttaa	agataccctt	15540
ctaaccaatt	tttttttaac	tcaagcaaaa	gtgcaaaagta	taattattaa	tgaggtagaa	15600
aattgagtca	agaagttaga	aaaaacaaaa	aacagaatgt	tttaccacca	aaaagcagaa	15660
gaaagaaaat	aacaatgggt	gaaattacta	taaaagaaat	aaaaaataaa	aaaaaaagat	15720
caataaaacc	aaaagctagt	tttttgacaa	gattaataaa	atagcaaaac	tcagccgggt	15780
gtggtgggtc	acacctctaa	tcctagcatt	ttggaaggct	gaggcgggca	gataacttga	15840
gcttaggagt	tcgagaacag	cctgggcaat	atggccaaac	gctgtctcta	caaaaaatac	15900
aaaaaaatta	cccaggcatg	gtggtgtgtg	cctgtagtct	cagggtgctg	tgaggctgag	15960

acaggaagat	ggtttgaacc	caggaggtca	aggctgcagt	gagctgaggt	tgcaccactg	16020
cactctagcc	tgggtgacaa	agtgcacccc	tgtctgaaaa	aaattaaaaa	aatatcaaaa	16080
ctttggacaa	gattttttgtc	ggactaagaa	aaaaaggtag	agataataat	agtagaaatg	16140
atgctattat	attcatcttt	ttcattaagt	tatgatccag	tatacagctt	tactgtaata	16200
tctcttgcc	tgttttttga	gattagaaa	gggtatacaa	gctagaaagt	gttatagtac	16260
tttccaagga	caaacaagaa	aaagtgactt	ctttcctatt	gttaaaatct	atcttcgtcg	16320
atTTTTTct	ggtagaggga	gatacgtagt	cacacttttg	ctcaaggtaa	tataatagga	16380
aaatatataa	catccaagtt	gtctttcaaa	ttgctcattt	agtaatttta	ttagaagaat	16440
gattttttaa	aggttaaatc	tttgttgtca	tttatattaa	acaggaattt	tttttctttg	16500
taggcagtta	gtcctttatt	attgacaaca	acgaattctt	cagaaggatt	atccatgggg	16560
aattacatag	gccttatcaa	tagaattgcc	cagaagaaaa	gactaactgt	aaattatgaa	16620
cagtgtgcat	cgggggtgca	tggggccagaa	gggtaagaca	taattttggt	tttctttctg	16680
tttcattgta	tttaagcaat	aaagtgggtt	tattttcgtg	tctaattttc	cagaaatatg	16740
tgtcctttta	agcattctgt	atgcaagggt	ttacatgatt	gataagtaat	tggatttata	16800
atTTgtaatt	aaaatgctta	attgctgaag	ccatggaacc	catttaccat	aattgatcaa	16860
attagggtaa	tccttttatt	cagagaagta	gctggatggt	ttagtctgtg	gaacacccaa	16920
gagagtacag	gggtgccactg	ctcgaagaat	acagaaatct	tttcatcatt	gaggacatga	16980
tgggtgtaac	tgtctgaaaa	cctctctgcc	acatgtatag	aatcactctt	caccttgctc	17040
agatcaggga	gctctttgtc	caggtaattg	tccttcaaat	ttgattaaat	gaacaaatac	17100
catgtatcag	aaggaaatgag	ctttagccct	agactatgag	gagaccggga	tttgagggat	17160
ctgatgagac	agatgaacta	gagtttcaaa	gttactgaga	acatcaccag	tgagctaaga	17220
tgtgtgga	taggataaa	aatggattgg	aactgaaaaa	agcagaaatc	aaatgagtat	17280
gaggcaattg	tttttcaact	acaaccaacc	agttaaagag	aaagaagaaa	aaaaatatct	17340
acatggcaaa	tagttttaa	catcacttta	ggatacactt	ctatgaattg	actcagctat	17400
ttacagtc	ggcttttgag	ccaaaaccag	gaagagaaaa	atgttatagt	attcattgga	17460
atgaaatagt	caaaaagtga	tctgtgagtc	aatctcaata	attaagagat	gattttattt	17520
tctgtagctc	acttttttgg	tttctttaaa	ttatgctaac	attagatacc	taaaagaaag	17580
aagaaatctg	tttgcggggg	ggggcagtat	ctgaaaaaaa	taggagctat	agaaatgatc	17640
cagtcaacta	accagctat	ttaattcagg	gtctagcggg	gaagactcac	cctgtttgga	17700
tgtgtttctc	tcgatggctt	ccaacagaaa	cataaagcaa	aaggagtcca	aatactggaa	17760
tcatttttca	gtaatagata	gtaaccctgt	gatataaatt	gccatgtcca	ttgttttatc	17820
ccttaaaaa	agttattata	taattgtcca	agtatccttg	cctaaccaca	aatgtcctta	17880
catctaata	gaggagagt	tggactttag	tatagggaat	ctgcactgtg	gggattttct	17940
caaaattttt	tgcacatgag	cagatggcag	acaatggtga	agttagagca	gaatccatgc	18000
tttgctcttc	ccctacacta	taacctcata	gcttctcctg	tggaaagccta	ctttctctgc	18060
tggctttttc	cttcccattt	gagcacctct	gaaaaaattc	actggatctc	tttctttctt	18120
ttctacctcc	gtatcttttg	acctttgggg	aattaaaaaa	aaaaaatcac	cacttagtgc	18180
ctttgtgcca	gatctttcag	caaagcaaca	aaaaattaga	aattgcctgg	aaaatgcaag	18240
ctcagatgtc	agctgatcct	gggtattcag	agaaattggt	caggcatgtt	actgagggtt	18300
taaattatgc	aagatatgaa	ctataaatct	atctaataaa	ttggtgttat	cttaagatct	18360
ctgttaatat	gttatttttt	ttgaatccta	agttggattt	gctatatttt	tcagtgttgg	18420
ataagtacct	tctatgattt	ctcctagatt	tcattataaa	tgcaaaatgg	gacagaaaga	18480
atatagtatt	ggtacaggtt	ctactaaaca	ggaagcaaaa	caattggccg	ctaaacttgc	18540
atatcttcag	atattatcag	aagaaacctc	agtgggtacg	attgcctttg	gattaaattt	18600
ttatgtttta	aaattccctc	tgaagttgac	ttgaggttag	actgtgttaa	cattatgcca	18660
agacagccag	tgatttagca	aaatgattcc	tccattctgt	gtcgtaccga	tgagccatgc	18720
accatggggc	catgaggcct	cagaggggata	aaattttctg	tggcaactca	gggtagtttt	18780
taaactccag	gctgggctgg	gtgtgggtgg	tcacacctgt	aatcccagca	ctttgggagg	18840
ccaaggcagg	tggatctcct	gagttcagga	gttttttttt	tttttttttt	gagatggaat	18900
ctcgctctgt	tgcccaggct	agagtgcagt	ggcacgatct	cggctcactg	caacctccgc	18960
ctcccatggt	caagcaattc	tcctgcctca	gcctactgag	tagctgggac	tacaagcgcc	19020
tgctaccgtg	cccggcta	tttttatatt	tagtagagat	ggggtttcac	tatgttggcc	19080
aggctgggtc	tgaactcctg	acctcatgat	ccaccacact	cagcctccta	aagtgtctgg	19140
gtttacaggc	ttgagccact	gcacctggcc	gaactcagga	gtttcagacc	acctggccgg	19200
ggcaacacag	caaaaccatg	tcgctacaaa	aaaaaaaaaa	aattagacgg	gtgtgggtgg	19260
atgtacctgt	agtcctagct	actcaggagg	ctgaggcggg	aggattgcct	gagcctggga	19320
gatggagggt	gcagtgagcc	aagattgtgc	cactgcactt	caacctagac	aacagagcca	19380
gatcctgtct	gaaaagaaa	aaacaaacaa	aatatctgcc	ctgtgatcca	gaaaagtaaa	19440
ataaaaaata	aaataaaatc	cagaccaaac	atccaaaaaa	tgttattaat	cttgtaattg	19500

tttatgggttg	tggatttggg	aaatgtgttg	aaataaatgt	gatagtacat	agaaactgag	19560
cctctgtaga	gaaataatta	gttgatatta	agcctactaa	gggatacttt	ttctttcaga	19620
aatctgacta	cctgtcctct	ggttcctttg	ctactacgtg	tgagtcccaa	agcaactctt	19680
tagtgaccag	cacactgtaa	gtgtagacaa	acaattgaga	tacttaacat	attcatattt	19740
ctgtctgaaa	gacagatttt	tatgtttaag	gagaatttag	ggaaagaaat	aagtgataaa	19800
aacagaatta	ataaactaat	agttacaccc	ttttcttcta	gcgcttctga	atcatcatct	19860
gaagggtgact	tctcagcaga	tacatcagag	ataaattcta	acagtgcag	tttaaacagt	19920
tcttcgttgc	ttatggatatc	gtattagtct	cgaagcttcc	tacttaatct	tatttttctg	19980
tgcgttttct	catttaaaaa	taacttccag	tattccacca	taatttttat	attttttatc	20040
ttatgcactc	ttactaaatg	ataatacctc	agtagacttt	tttttttttt	ttttttgaga	20100
tggagtctcc	ctctgttgcc	caggctggag	tgcagtggg	agatcttggc	taattaccac	20160
ctccacctcc	tggttcaagc	gattctcctg	cctcagcctc	ctgagtagct	gggattacat	20220
gcgcgtgtac	cacacctggc	taatttttgt	acttttagta	gagacgggg	ttcaccatgt	20280
tgttcaggct	ggctctgaac	tcctgacctc	gtgttctgcc	cacctcggcc	ttcccaagt	20340
ctgggattac	aggcatgagc	caccgcgccc	ggctcggcag	ctttttgact	ttttttaaaa	20400
ttaagttcca	ttccttacct	ttccacacgt	cacttctgtc	tttctcact	catccttata	20460
ttttagtata	ttcctatgat	tttgcttttc	tctcctacca	atgggataat	atttaaagat	20520
tcactaatat	agttcgtttc	tgtttttaaa	aattagaatt	aaacttaaaa	gtaaacttga	20580
aatcagataa	tttttttaggc	tgggtcagtg	gcacatgcct	gtagcctgca	gcacttgaga	20640
ggccaaggta	ggaggatcgc	tttagccag	gagtttgaga	ccagcctagg	caacatagtg	20700
agaccctcat	cgcaaaaaa	aacaaaacaa	caaaaaccag	acaatttttt	tgtgcacata	20760
agcaggcaat	gttgaactta	gagcaaaatc	catgcttttg	gtgattagtg	ttacaagagt	20820
attctgttat	aaagaactac	aatcaataa	gaaaatggca	agcagctcag	tagaaaagtg	20880
tacaaaatgt	ataaacagat	attcagagaa	gagataccca	aatgggcaac	aaatatttaa	20940
agctgcttta	ctaggaatca	ggaaaattta	aatcaaaaac	attagatact	attttaaact	21000
cattagattg	gcaaaaagtt	aagtcttaca	atactaagtg	ttgatacagg	gcttgatgag	21060
agtacagaca	ttgatggact	aagaaattgg	tcagagagcc	atctagatat	acaggaggaa	21120
ggaaaacggg	aaaggaagat	gactgattta	gtcatctgaa	actatttctc	attttctttt	21180
gttatagaat	ggtctcagaa	ataatcaaag	gaaggcaaaa	aggtgagtat	cattatgcat	21240
tgaacatatt	ttgatctgaa	gttttatttc	agacttattt	attgttctta	atacttgtag	21300
agtattgtac	acccttattt	gagcagagtt	tcagaagcag	aaagcttgaa	atctataaac	21360
aaataatttt	agatgtgtcg	agaaatcttt	gactatgtgc	acatgctaca	ctgtaaacad	21420
aaagcacttt	gggggtatcg	ctagagtaat	taggttaagg	gcattatttt	gtacaagact	21480
ggcaagggaat	tgggctgttt	tcactgtaga	agtgttttca	agagaagtg	attattttgc	21540
agacaagtaa	ggttaaaata	gcataaaaac	ttggattaaa	aaaagggtcaa	atgctatgtc	21600
aattaactga	agagaaaggc	aaagatgtaa	atatagtcag	aaatgacagt	aagatggcag	21660
taggagccat	tatgagccac	cagtatattc	tgagcagtag	atagatgtat	tgaagaaaca	21720
tgggtcttga	tgtggatgct	tggatggaga	gaagagagtt	ctgcacatga	ggtgccctca	21780
gccacgatta	ctgtggcagt	caggagggat	gaggagaatg	tgtgagaaag	actgtaaagg	21840
aagagtggac	atgacttgag	ggaataggtt	ccccgtagct	gagtgaagc	atgaaggaga	21900
ggtaaaggag	aaaggatttg	aagattgctt	cactttgaac	aggatgcagt	caagaacctt	21960
ggcactaatg	gtgttaagga	agttaaggag	ttaagggtct	agagagaaga	cagcagtttg	22020
gatatgttta	gttttaggtg	gtatttaaac	ttccatttgc	aggtggctta	tcacagtaaa	22080
ggaataacag	ctaggatgag	ggtgtaagga	gatgtacttc	ctgaggtttt	gagtctggag	22140
gaggaaaagg	agaggttagt	gacgcaccaa	caatgagcac	tctaagggtg	aaaaaggaac	22200
cagaggaggg	atgaaaaagt	attagaggcc	agaggagaac	ggtaagtata	tagttttata	22260
aagaaaaaag	ttggctgggt	gctgtggctt	gcgctgtga	ttcccagcac	tttgggaggc	22320
caagggtggga	ggatggcttg	ggtccaggag	ttcgagacca	gactgggtaa	catgaagaga	22380
ccctgtctct	actaaaaata	aaaagaatta	gccaggtag	gtggcacatg	cctgtaatcc	22440
cagctacctg	ggaggctgag	gtgggaggat	ctcctctgag	cccagaattt	caaagttgta	22500
gtgagctatg	atcacaccac	tgcactccag	gctgggagat	ggggtgagac	cttgctctctg	22560
aagaaaaaaa	aagaaagaaa	aagggttaaca	ttaacactaa	ataagttata	tttgatttca	22620
attttatttg	agtttttacat	tcaactctta	atttttagat	ctttggcacc	cagatttgac	22680
cttcctgaca	tgaaagaaac	aaagtatact	gtggacaaga	ggtaagattt	taagtgtctga	22740
agaaagaaga	aggggtaatg	ctgtcgggtg	atgttttttg	tagttgtctg	tgaaatggcc	22800
atgatcctgt	cagttaaaaa	tatttgaata	agattaacta	cgcagggtaa	gaacaatagt	22860
cttaggctta	tcattaagag	ggggcccagg	aatgggatga	cccatattat	gattttgttc	22920
ccaaaccaag	aatctagttg	gttgttttga	tactccctta	gcttttttagc	cctttcttta	22980
agtttttcat	cagcgtttct	tactaggccc	aattgggtga	gataaaagca	acattcctca	23040

cccaatgaga	ggcagaggtc	ccttttttca	gccattatta	gatctagtcc	ccatctgttt	23100
tggaggacta	ctccagccga	ggagtctagt	ttgtcttgga	ctcttataat	gcttcaggct	23160
atatcttcta	aagaaccctg	taattctgtg	gaaagagctt	taaagtatgt	taagggagtg	23220
gccaatctgc	ctgctcccaa	tccaagtctg	gaggttatat	ccaaggcagc	cattaaagga	23280
atgacgtgga	tggccctcct	cttcctaacg	tattggatgg	atggaatggg	caaagggttg	23340
ctaggaggaa	ttagtccaat	ggagggagaa	agataaacta	gggtacaggt	tccagtcag	23400
ttagtgggga	gacaaagata	tgtgttggtg	ccactcacac	aaaaataag	cctttgtcat	23460
aaatacagtt	ggagatacag	aaagaaaaca	agtgaattaa	agatgggtgt	tttttctttc	23520
ctatggttca	ttactccagg	tggccaagga	ggaggtcaag	gagacacca	ctatagtagc	23580
gatataggaa	gagttatttt	ttacacattt	aatacgattt	gatgttgac	cattgcattg	23640
atgttgagcc	atggataaag	gtgggcgcta	ggggcagcac	aaattaggcc	agaggcattg	23700
gttgagggag	aggctgcaaa	acgaacaggt	tgcagaaatg	ctccattcgt	ttcaggtgat	23760
acttggtagt	caactcgggt	agtttgatgg	tcagcaggg	gtttaacaat	gataatgcgg	23820
ttgcattgg	taggtttaag	gatcttacac	ggaaatttcc	ctcagaggct	gaaaagcaaa	23880
gtgaggcttg	ttgtaaaagt	ggggtgtgtt	taattatggg	cccttcaatg	ggagggcctt	23940
gtggcttaag	gcgttgtagg	gagttgtaat	aggtttgaaa	taatgtgttg	gcctgattga	24000
ccttggaagt	gggataatcg	ccaaccagac	tgtcagctct	ttcaaaaaag	gaagctcctt	24060
tttggaagtt	atagattagg	gttacgtttt	ctgttaaaag	gtcatgaagg	ggtgtaggaa	24120
gggatgtata	agctgaagaa	gacagcgata	aacacatcca	gcattctgga	gcaaagggaag	24180
agttagcttg	cagcaagagg	ggttggtgtaa	ggtttataga	acgttctagt	ttgatagcag	24240
tgaggagtgg	ttgtatcgg	gaggttgatg	tgattaggga	atttagatag	aaagaaacaa	24300
caaaaggagg	aaaaagtttg	ggtaggaata	aagtcctgga	aggttccttg	aagccataaa	24360
tcccgtggaa	tagtaaggag	ctgatcagga	tgtataatga	gagtttcata	aggataccac	24420
tgaaggctcg	taacaaggct	agtttaggaag	caatgaaagt	ttgggagaga	aagagacata	24480
gctgcttagg	tgaatttctc	ttccttttcc	tcgggcattc	atgtgagatg	aagggaagtg	24540
gatcctgtgg	agacacaaga	gaggctgaag	gtggtttaga	tttgattgtt	tggatgtgta	24600
gtgaaggga	gtctgtgttc	ttgagagaag	tataatgaaa	ccagctgggg	agtccttggg	24660
gctttgctgc	tgtgggtgta	gtgaggaaga	tctggtaagg	ccccttccat	tttgggtgta	24720
gggggggaatt	gggggtaggg	ctgggacctt	ttaccagaac	ccagtttcc	gactgtaggga	24780
agggattaaa	ggagttgtat	tttgtcagca	tattcccaaa	tgaaatggca	gatgatatgc	24840
agaagaggag	aaatgagagg	ggttggttaga	ggtggggctt	gaccctgagg	tggaaacaaa	24900
ggagcatgag	ttcaaatact	tatgctcaaa	actcccatc	atgagttcaa	aggggatgag	24960
cattaaaggt	ttactgtaga	gtgcccgaat	ttttaggagg	gccaaagcta	gaagtgtaac	25020
ccagtcttta	tgtgtttgga	gtgagtacct	ggtgcgggtg	attttttagaa	tgccattcat	25080
tttttcaacc	tttctgaag	actgggggtg	ataggggatg	tgtagcttcc	aggtgattcg	25140
tagggcttgt	gcaagtgttt	gagtaatttg	agaaatgaat	tcaggaccat	tatcagattg	25200
aaaagaagga	ggcaccctga	acctggggat	gatttctgtt	attaatttgg	aggtgacagt	25260
cgaagctcat	ttgttggttt	tcggaaaagc	ctcaaccat	gccgaaaagg	tatcaaccag	25320
aacccaaaaga	aatcgaaacct	tttttactgg	gggcatatgg	gtaaaatcaa	tttcccagtc	25380
ttgtcttgga	aggtgtcccc	tggcttgatg	ggttggaana	gaaggagtc	cagtgttgga	25440
atggggtgaa	gctttctggc	aaatagagca	ttgatggaaa	atggctttca	actgttctct	25500
tatatctggg	gttatgtgta	tgtgggaact	taagaaatgt	tgtagagggg	aatggctagt	25560
gtgcaagagg	ttgtggatgt	cccataacag	agttgttttt	tgtttgtttg	ttttttgaga	25620
cagattcttg	ctctgtcacc	caggctggag	tgcaaggcca	cgatctcagc	tactgtcaat	25680
ctctgcctct	gggggttcaag	cgattctcct	gcctcagcct	cctgagtagc	tgggattaca	25740
ggcacgcacc	accatggctg	gctaattttg	tatttttagt	agagacaggg	tttcaccatg	25800
ttgatcaggc	tgggtctcaaa	ctcctgacct	cgtgatccgc	ccgcctcagc	ctcccaaagt	25860
gttgggatta	caggcgtgac	taccgcacct	ggccaagagt	tgttttttca	gggtcaggta	25920
ggactaat	gttttgtatg	acagtatggg	agtttgaatt	gtgccccgc	tgtgagtagt	25980
tgttgtat	ggtgtttggg	ataaaagggg	atatgttgtg	tgaggggaaa	tagatactag	26040
agaattggat	ggttggttga	ggtgtgtttt	gccaatagt	cagcctcacg	gttccctaaa	26100
gaaatgtggc	ttttatctga	ttgaagtcct	ttgcaatggg	taactgcagc	cttttttggg	26160
agtagagctg	cctttagtag	acaatggatt	agttttccat	taatgatagg	agttccctta	26220
gctgtgagat	agccccactt	gctccaaatt	tgggcatttg	aatggttgat	gttataaaca	26280
tatttagaat	tgggtgtata	tattaaactg	tgtgtttttt	gctagggtta	atgctttcat	26340
tagggcaact	aattctgctt	gttggggagga	tgtgccccaa	ggcaaggggg	cagcctctac	26400
aactcttcta	ggtggaagac	agtgggtatc	atcacaatat	ctctcagtga	ctgcataatc	26460
tgcttggcgg	ggaggggttt	ttgatgcgct	gccatctata	aatcaatctg	gggctccctt	26520
tatgtgagtg	gaagtaagg	ggtaaaacac	ggcaagagaa	ctttcaatta	gatcagagca	26580



tgagtgttgg	tcaggggtcca	aatcagtggt	tgaagataaa	agagtagcag	gattaggagt	26640
gagcatctgt	gaagagagat	ggaggggtga	atgtagggtc	tgcatgtgag	aggatgagat	26700
ggaggtgagc	gccttatggc	tgagcatatc	ttatagactg	tgagaagaaa	acacctgaag	26760
agggttcata	aatgtgagtt	tgtgcctcag	ggataattaa	agaggctgtg	gacaaaattt	26820
ttaagcaaa	gggcccaggt	ttgtaaatgg	ggtctagtgt	ttttgaagaa	tatgccactg	26880
gttggaggga	atctcccatg	gattgggcta	atagtcacag	ggcctgatta	tgagaactgt	26940
gtaaatatag	atgaaaaggt	cttagggggt	ttggaaggcc	taaagtgggg	gcctgtaata	27000
aggcacattt	taggtgacag	aaagcatgat	aaaggctctg	ggtaggagtg	agtgggtgat	27060
caagatttcc	tcttgtgtgt	tcataaagag	gtttagtgat	agtggcaaaa	tttgctatct	27120
ataatcagaa	atatcccat	aatttgagga	aagaaaataa	gtcccttttt	gtcttaggaa	27180
atgggacttg	ttaaatgcct	tgctttcatg	ctagtggaa	ttccctggta	tttggagtta	27240
tgattaatcc	tagctatgaa	acgtttggag	aggttaaatt	gggtcttctt	tttggatata	27300
tggtaccac	attcagccaa	aaaatttaaa	agcctggctg	tgtgttgaat	acagtgttct	27360
agagaggggc	tgcaaaagag	taaattgtcc	acatatgaa	gcaaaacact	gggttgtaga	27420
ggtagttggg	aaaggtccaa	tcaaagtgcc	tgaccgaaat	agtgagggtc	gtccctaaac	27480
ccctggggga	agacagtcca	ggtgagttgt	tgggagtagc	ctgtgtcagc	gtcagtccaa	27540
gtaaaagcaa	aaaggttttg	agaggaggaa	gatagaggga	taatataaaa	ggcatctttg	27600
aggtctaatt	cagagaaata	gctagtattg	ggaagaattt	gcaatatgag	gatatagggg	27660
tttgggacaa	caggacaaac	agaacagtag	tggagttatt	tgttgcaaat	cctgaaccag	27720
tctataggag	ccatctgggt	ttgtaatggg	gagaatagga	gtattgtggg	gagaatgggt	27780
ggggattaaa	atattggcag	ccaggccagg	tgggtgcctc	acgctgttaa	tccgagcact	27840
ttgggaggcc	aaggcggtg	gatcacctga	ggtcaggagt	tcaagaccag	tctaggccaa	27900
catggggaaa	ccccatctct	actaaaaata	caaaaattag	ttgggcatgg	tggcacacac	27960
ctatagtccc	agctactcaa	gaggctgagg	caggagaatt	acttgaatct	gggaggcagg	28020
agttgcagtg	agccaagatt	gcgccattga	gctccagcct	gggtgacaag	agcaagactc	28080
catctcaaaa	aaataaaaata	aaataaaaata	tgggcagcca	aaagtgggga	gatgatggac	28140
ttgagtcccc	atagtccatt	aggggatatt	tgtggaccac	tatttgacat	ttaggatcct	28200
tcattgaaat	ttgaattgga	gaatgggtgg	tagctaaccat	gggggagtc	gtgttccata	28260
ctatgggatt	tacagggtcg	aggaatttgg	gatttaagtc	tgtttgatata	ggaatgtctg	28320
aggaaggggt	ctgttcttga	gatgataata	aataggggta	gctttgggtg	agggttgata	28380
aatgaatgat	tcgtccccgt	ttgtgtagga	tgtcccttcc	tagtaaagga	gtgggggaat	28440
gaggaatgac	caagaaagag	tgagtgaggg	tgactccctg	aaatgagcaa	tatagaggca	28500
gtgttttgta	tggggtttct	tgtatgccct	tcattccatc	aacagaaaca	aatgaacatt	28560
ctaattgggc	ttgggtattca	gttaatgcc	gtagacttgc	cccagtatcc	aaaagaaagg	28620
aaataatctt	accagatacc	gtcccaatta	acctgggttt	tgtggactca	ctagatgtgg	28680
gggcgaagga	tgccgggtac	cctcagtcct	ccgttgtcag	caccaacagt	gaagagattt	28740
cctcctgtaa	tgtttggggg	gcttcattat	gagtggtacc	cgaatgggga	agggtgtccct	28800
gttgagggca	ttccatcgtc	cagtgtcccc	aaagactgca	agttgggcat	ggtttggtgg	28860
gaggccaggg	gataggacaa	gccttttccc	agtgtccagg	gttgccctat	tgaaaacaga	28920
ctcctggaga	ggtgggggag	tttccctttg	ggttattagg	aggctttcgt	ataactgact	28980
tttggacagc	agaggcaagc	atctgggtatt	ttaaatggag	atgtttgtcc	tcttgaattt	29040
ttgttcctc	atctctgttg	ttaaagacat	ggaaggtcgc	atttaggagc	tcccaccaag	29100
atgtctgggg	gccctcctct	aatttttcta	attttttccg	aatatctggg	gtggattggg	29160
aaataaattg	gaggtagaga	aaagtttgac	cttctctaga	ttctgggtcc	aaattggtat	29220
attttagcat	agcttcagtg	agggtgtgata	agaaaagggc	agggttttac	tggtgtctct	29280
gtgtaatttc	tctgagcttt	tcataattaa	ctgccttatg	ggcatttttg	tccatgccc	29340
tgaggagaca	ggtaatcatg	tgggtctctc	acctgatgcc	attgtctccc	tgttggcaag	29400
tcccatctgg	gcctctatgg	gggactgc	cattggccac	tggattttgt	ataggggctt	29460
tattatggag	ttattataat	caaggggaac	ttaaagtagt	ggtgcttgtc	caagatggta	29520
atgtcctctg	tctgtcaaag	atggaactgt	gaaatagaat	ttgtttaaag	atgtgttgtt	29580
cattcaacag	aagtttcttg	agggcccat	ataaggctaa	attatacttc	caccggaaca	29640
gtttaattga	cattgcacta	tccggcgcac	gattgatcat	gtctcttgga	gaagtaatat	29700
ctagacagat	ccaaatggaa	tgtggtaatt	gtagatcttt	gtgatgctta	tgtggatttc	29760
tctgacatct	atacaagtta	ttaatattga	aaacaagtac	tcctgtaaat	cagtatttaa	29820
aaaaataact	tctgtgggaa	ttagaattga	tccacttgta	tctgttttct	actttctagc	29880
tccatatcag	atttcacttg	aaaaaaagtc	tactctgctg	tagacaatat	gtttggattt	29940
aaaatgaaat	gtctgaaacg	atggagacct	gtttgcatca	gtggggcggg	tcattcaata	30000
taaaacttta	aaaaacaata	cggaatcaaa	agtttattaa	gcaccaata	tagaattggc	30060
actgtgctgg	gcacaggtt	tatggtagga	acaaataaaa	tgggtccctgt	tgtcatggag	30120



- 16 -

tttcatgggg	atgaccgact	ttaaataaat	aattacatga	acaggccaag	cacagtggct	30180
catgcctgtt	atcccagcac	tttgggaggg	tgaggcggat	ggatcacttg	aggtcaggag	30240
ttcgagacca	gcctggccaa	catggtgaaa	ccccatctgt	actaaaaata	caaaaattag	30300
cagggtgtcgt	ggcatgcacc	tgtagtctca	gctacttttg	aggctgaggc	aggagaatcg	30360
cttgaacctg	gagggtggag	gttgcagtga	gcggagatcg	caccactgta	ttccagcctg	30420
ggtgacagaa	cgagactctg	tctcaaaaaa	aaaaaaaaaa	aaattgcagg	aacaaactat	30480
ggtcagagct	gtgaaaggaa	agcaatggca	tgagagagaa	tggaagcagg	ggtgaggcga	30540
ggtttctctg	gggtcacagt	tgtggggagg	cctgatggat	gagtgggcac	agagcagtg	30600
gtgctaggtg	gaaggaagg	cgtatgagaa	ggtaaagatg	gaaaagggtga	tgtgaaagt	30660
cgagaacaga	cagaagagt	tgtgctttga	gtgcaatgag	gaggggcaca	gtgccatgag	30720
atgaggtatg	tgagggagg	aggggcctcc	tcatattggca	ccttataggc	catttaagg	30780
ctttttgttt	ttgtggaatg	caaagggttg	ctgttggagg	gtttcagcaa	cagagagaca	30840
tggccagact	cagttttcat	ccctctgggt	gctgcatgga	tcatagattg	gagtggggga	30900
agagaggaag	tggggatcca	gttaacgagg	tactgctatg	gcctaattga	agcatggact	30960
ggggtgaaga	tgttggaggc	agaggaaagc	gggtggatac	cagcaatgtg	ttttggagg	31020
agaattgaca	ggtcttaatg	atggaacacg	aagcttgagg	gagaagagaa	aaccaagtag	31080
aaacctaggc	aggcttagag	cgtatgcccc	tttctcttat	aaaagcttga	tgatagtagc	31140
tgtggagcac	aatatagcag	ttcctttgaa	cattttgtat	ttgtgatagg	atttttatca	31200
tggctttttt	tttttttttt	tttttttttt	tttttttctg	tttttttgag	atggagtttc	31260
attcttgtcg	cccaggctgg	agtgcagtgg	tgtgatcttg	gctcactgca	acctctgcct	31320
cccagattca	agcaattctc	ctgcctcagc	cttccaagta	gctgggatta	caggcactcg	31380
ccaccacacc	tggetaattt	ttgtattttt	agtagagacg	gggttttcacc	atgttggcca	31440
ggctgggtctt	gaactcctga	cttcagggtga	tccacctgcc	ttggcctcct	gaagtgcctg	31500
tattacgggc	atgagccatg	gcacctggac	ttatcatgac	ttttgaaaag	ccaggagttg	31560
actgtgactg	cctgggggtga	tatgttacgt	tagacttggc	ctgggaggag	tgagaggtc	31620
actctttgtg	agtcaagagt	ttctgccaag	tggatctttc	ttattcagaa	ggagagaatc	31680
aaatttgttt	tattgtccat	ttcacaagtg	acattaaagg	gaaaggagt	gggaggcggg	31740
ggggtggggg	ttgagcatga	aatgtcaaaa	taacagtgg	ttttatcttt	aagggttggc	31800
atggatttta	aagaaataga	attaattggc	tcagggtggat	ttggccaagt	tttcaaagca	31860
aaacacagaa	ttgacggaaa	gacttacgtt	attaaacgtg	ttaaatataa	taacgagtaa	31920
gtagtaaatg	tttacatttt	tttgaatggc	aagggtacgt	gaatctgcac	tattcttttt	31980
tatgcttctc	tcttctttat	tagggatatca	tttatttctt	tctgatcctc	attaaacatt	32040
tcattctacc	aagaggagt	tggcttactc	cgagatgatc	tcactttact	gtgggttatt	32100
caataaaaat	ggatatacca	ttgatcatcc	ttttgggtgct	atcttcagaa	ctgaagctat	32160
agagtcattt	gcttttaaagt	gacatgcaaa	ttcatgaaat	gctccgtatt	ttaaaaaccg	32220
tggcaccaga	tagaacctat	cattacccac	aaaatagggt	atctttgaga	tgttctagt	32280
ttaccttctt	attttataga	tgaggaaact	aagatccaga	gatgtgaagt	gattttgtct	32340
aagataaaaag	ctagatggta	attgttctct	ggttgtctgt	tattgtataa	ggcactgctc	32400
caaaatgcag	tgttataaaa	cagcaattta	ttgttgtctc	taatgggtcc	atgggttgat	32460
tgtgctcatc	tggacaattc	tcacttgggg	tctcagaggg	atttgcagtc	agtagtcac	32520
tgaacacctg	actacagcct	atcttaggct	ggatattccaa	gctggctagc	agttgacacc	32580
ggctgtgggc	tggaaagtta	gctgggactg	tcaatcagaa	tacctccaca	tggcctccct	32640
atggggattg	ggcttcttac	aacttgggtg	ctgggtttca	agaaggattg	ttcccagaac	32700
aagtcattca	aaagatcagg	agtgaagtgg	aaggcttctt	ttgacctaat	ctgaggagt	32760
ccagaacgtc	actaccatca	agttatat	gttaaacaa	tcactgaagc	cagcttagat	32820
tcaaggggag	gccaaatagg	ccctaccccg	taatttgtca	ttctagggga	tgagttctaa	32880
gaatattatt	tagggactgg	gtgtgggtgg	tcacgcctgt	aatcccagca	ctttggggag	32940
ccgtggcagg	cggatcacct	gaggtcagga	gttcgagacc	agcctcacca	acatggagaa	33000
acctctctct	actgaaaata	caaaattagc	tgggtgtgat	ggcgcatgcc	tgtaattctca	33060
gcttctcgag	aggctgagtc	agaagaattg	cttgaacccg	ggaggcggag	cttgtgggtga	33120
gcccagatca	tgccattgca	ctccagcctg	ggcaacaaaa	gcgaaactcc	ctctcaaaaa	33180
aaaaataaaa	taaaaataat	aaaaagaata	ctatttaggg	aggctgaggt	gagtggatca	33240
cttgagccca	ggagtttgag	actagcctgg	ggcaacatgg	caaaactcca	cctctacaaa	33300
aaatacagta	attaggccgg	tgtggtagcc	acgcctgtag	tctcagctac	ttcagaagct	33360
gagggtgggag	gaccattttga	gcccagtagg	tggaggctgc	agtgagccat	ggtcacacca	33420
ctgcactaca	gcctgggtga	cagagtgaga	ccctatctcc	aaaaaaaaaa	aaagaatgtt	33480
attcaaatta	tggattttata	tccaagaaga	tataaatcac	agtgctattc	attaacagta	33540
aaaagttaga	acaacaaaaa	tatccagcag	taaagaaatg	agtatatata	ttttgttctg	33600
tcccctgatc	gatggctgtt	ttgcagccat	taaaaatgac	tggctggggc	aggcatgggtg	33660

gctcacgcct	gtaatcccag	cacttttggga	ggccaagaca	ggcagatcac	gaggtcaaga	33720
gactgaggcc	atctggccaa	catggtgaaa	ctctgtctct	actaaaaata	caaaaattag	33780
ctgggcatgg	cagcgtagcg	ctgtagtccc	agctacttgg	gaggctgagg	caggagaatc	33840
gcttgaaccc	aggaggcgga	ggttgcagtg	agccaagatc	gcgccattgc	actccagcct	33900
gggcgacaaa	gcaagactct	tctcaaaaaa	aatgactggc	tgggtgcagt	ggctcaggcc	33960
tgtaatccta	ccactttgag	aggccaaggc	tgggtggatca	cttgagggtca	ggagtgcgag	34020
accaacctgg	gcaacatgga	gaaaccctgt	ctctacaaaa	aataataaaa	ctagccaagt	34080
gtggtgggtg	gtgcctgtgg	tcctagctac	tagggaggct	gaggtaggag	gatcgcttga	34140
gccctagggg	tggaggttgc	agtggagccaa	cattgccact	gcaactccagc	ctgggtgaca	34200
gagtggagac	ctgtctcaaa	aaaaaaaagg	agaatctaaa	ataacattat	tttaggattg	34260
tcaaagatc	agtaattttt	tttatttttg	caaatttgtg	tcatatactt	taaaacttct	34320
tgcattaaaa	aataaaaattg	taaaatgatt	attcttctct	atctttgaaa	tctccaattt	34380
atttactgca	cttagcatgg	aattttctta	ggtcttggca	acacatccct	gtaaagcctt	34440
ccaccatttc	accttctctg	cataagttat	cctctttgtg	tatatattgcc	acacattgaa	34500
aatcctgaat	taggtacttc	acactgcctg	ggttacctag	ccttgctgcc	taaatgtggt	34560
ttgcttgtga	aatacaaaga	ttttaacaca	aatctaagca	aaacataatg	tatgatttag	34620
ctatgaaaaa	ttgcaactgg	tgggtccatt	ggctcatgct	tgcaatccca	gcactttggg	34680
aggctgaggc	agggtggattg	ctagatccca	ggagtttgag	accagcatgg	gcagcgtggc	34740
aaaaccccat	ctctacagaa	aatagaaaaa	attagatggg	tgtgggtggg	tgctcctgtg	34800
gtcccagcta	ctcaggagac	tgaggtggga	gaattgtttg	aggctagaag	gttgaggctg	34860
caatgagcca	agattgtgcc	actgcactcc	aacctgggtg	acagagcaag	actctgtctc	34920
aataaaaata	ataaattaat	taaaatgaca	tcactggcat	ttcaagagta	ctacagatga	34980
tttttaaatt	gtctgatgct	tggcattaag	tcgctgcctt	ttattttatt	attttttgag	35040
acagagtctt	gctcttttgc	ccaggctgga	gtgcagtggg	gcaactcttg	ctcactgcaa	35100
cctccgcctc	ctggattcaa	gcgattctcc	tgccctcagc	tcccaagtag	ctgggattac	35160
agacatgcgc	cactgtgccc	agctaaaatt	tttgtatttt	tagtagagat	gggggtttcac	35220
catgttgggc	aggctgggtc	tgaactcctg	acctcgatg	ccgcccacct	tcgcctccca	35280
aagtgtgggg	attacaggcc	tgagccaccg	cgcccggcca	ctgcctttta	ttttatcttg	35340
agagtggaaa	ctgctatggt	ttttttcagt	atgttcactt	tttccttttg	aatgtcctgg	35400
cttccattct	aaaactatgt	gagaaccaca	gcaatggttt	aataagggaa	tgtagacagt	35460
tgtctattac	atgaggtggt	ttgtgggtgt	tatgagggat	gtacactgac	actgccatgt	35520
tcctgtttcc	ttttaactag	gaaggcggag	cgtgaagtaa	aagcattggc	aaaacttgat	35580
catgtaaata	ttgttacta	caatggctgt	tgggatggat	ttgattatga	tcctgagacc	35640
agtgatgatt	ctcttgagag	cagtgattat	gatcctgaga	acagcaaaaa	tagttcaagg	35700
taactaaaaa	taaattctca	tagccataat	aggatggaag	gaaattgtta	tttactatgt	35760
atgggcccact	ggataaggct	attaatcatc	acgattaatt	atcacaattc	cctctgagag	35820
acactgttat	ctctccattc	cgaaggtaag	gagaaagtga	aaatctcttc	cttgctcctc	35880
ctcttgctgc	agacttgctc	tcacaaccct	ctgttacatc	ctcagctgtc	tgcaaaatct	35940
caggttcage	tttcctgact	ccattgtttc	atggagagcc	ttgttcacgt	gccggcttca	36000
gcgcaggctg	tttaagtgtg	gtcttgtgaa	gagagtttta	acatatagat	gctgcatctg	36060
ggggctccct	cctcagctac	caacactttt	ctgtccctct	cttaggctgt	gattgggtgtg	36120
gtgcggtcag	agggctctct	tggaatgtaa	ctataccact	tatgctgggg	tgggtggggag	36180
tgaaaatatt	tttaagacca	caagctgaga	tgggggcacc	ctcatgtttt	atgtcagtta	36240
agccattatg	aaacaactgg	agatcctaaa	gagctggcat	ctgtctttga	aagtcaccca	36300
acctattatg	gggacagtcc	tctcactaaa	atcctgaggc	caatggggtc	ccattcattc	36360
atttttctct	gccccacctc	catctccatg	tcgtgtaagt	gagaacatta	tcacagttc	36420
aggagtattt	gaccgtcagc	atacaggact	tcagctttca	gcaaattctt	ggctacctct	36480
tcctgttttc	aagctgacat	atatacaaa	aatataaatg	aatattgagg	ctaacttaat	36540
tcagaaaaaa	aataaaacgt	ggttagcaaa	aaaaaaaaaa	aaaaaaatca	agcctccaat	36600
ttatgtatct	tagtaatttg	ttggcacttc	tcttagagta	ccttccctat	tgtttttaggt	36660
ttgctttccc	tttactctct	cctattagac	tattatcccc	gtgacggcaa	ggatatagtg	36720
tctaactgat	tttctcatct	ctaggtgcct	ttcatgctta	gtagatcaat	ggtgaattaa	36780
aaggtttcaa	agttacttta	tataataatg	aaatttagtt	tcctgcattg	tattcatggt	36840
cctattttcta	tctgttagca	atgggtgattg	cagatcttca	gcaatgaaga	atgggtggct	36900
catttttttt	ttcttctcgt	tttttttttt	tttttttttt	ttgagacggt	gtctcgactc	36960
gtcgcacagg	ctggagtgcg	gtgggtgcaat	cttggtcac	tgcaagctct	gctcccgga	37020
ttcacagtat	tctcctgcct	cagtctcctg	agtagctggg	actacaggcg	cccgcacca	37080
cgcccggtta	attttttgta	tttttagtag	agacgggatt	tcaccgtgtt	agccaggatg	37140
gtcttgatct	cctgacctcg	tgatccaccc	gcctcggcct	cccaaagtgc	tgggattaca	37200

tgcgtgagcc	accgcgcccc	gcctcttctt	tttttttttt	tgagacagag	tcttactcta	37260
tgcgtcatgc	gggagcacia	tggcgtgatc	tcagcttact	gcaatctctg	ccttctgggt	37320
tcaaattgatt	ctcgtgcctc	atcctcccga	gtagctgaga	ctacaggtgc	cgcgccacca	37380
cacccagcta	atTTTTgtgt	tttttagtaga	gatgggggtt	cgccatgctg	cccaggctgg	37440
tctcaaactc	ctgagctcaa	gcaatccgcc	agtctcggcc	tcccaagggtg	ctaggattat	37500
aggcgtgagc	caccgtgccc	agcccagctc	atattttata	aattagctaa	acaaataaag	37560
ctctggacat	ccgggaactt	atgattgaaa	taaaaaatgg	cctattatat	tttgattcaa	37620
atttgtttat	tatatTTtaga	tttctatttt	gtgacatgtt	ttgggggtct	ttttttttct	37680
tttttttttt	ttttttgtga	gacggaatct	cgctctgtca	cccaggctgg	agtgcagtgg	37740
cgtgatctcg	gtcactgca	agctccgcct	acggggttca	cgccattctc	ttgcctcagc	37800
ctccccggag	tagctgggac	tacaggcgcc	cgccaccacg	cctggctaata	tttttgtatt	37860
tttagtagag	acgggggtttc	accgtgggtct	cgatctcctg	acctcgtgat	ccgcccgcct	37920
cggcctccca	aagtgttttt	gggggttctta	agaagataag	gtataagctt	ttaaaaagtt	37980
atgaaaaact	ttaaaaagtt	ataaaaaatt	ttttataaat	ttatatTTtat	tgttactttt	38040
aacatactgt	gaatttttata	cccagggtcaa	agactaagtg	ccttttctatc	caaatggaat	38100
tctgtgataa	agggaccttg	gaacaatgga	ttgaaaaaag	aagaggcgag	aaactagaca	38160
aagttttggc	tttggaactc	tttgaacaaa	taacaaaagg	ggtggattat	atacattcaa	38220
aaaaattaat	tcatagagat	cttaaggtaa	gtggaaaatg	tactttatta	attgatatat	38280
atataatata	gtaatttttaa	aatatatctt	ctcagctggg	cacagtggct	cacgcctata	38340
atctcaacac	tttgggaggc	tgaggcaggc	agatcatctg	aggctcatgag	ttcgaaacca	38400
gtctggccaa	catggtgaaa	ccgtgtctct	actaaaaata	caaaaattag	ctgggcatgg	38460
tggcgtgccc	ctgtaatccc	agctactcgg	gaggctgagg	caggagattc	gcttgaacct	38520
gggagggtgga	ggttgcagtg	agccaagatt	gtgccactgc	actccagcct	agggtgaagag	38580
tgagacttgt	ctcaaaaaaa	aaaattatat	atataataaa	aataagatag	atagatatat	38640
atttttttct	ctagtttttag	aatagtgggt	gattgatagt	tatgagaaaa	tggtatctga	38700
acatttccat	gcaaataatt	actgtgactg	gcacagccaa	ctggctgctc	tgcccctgtt	38760
cctcctgcct	cctctaagtg	actcagcttt	atttgagagg	cagaggggac	tctgttgact	38820
gttgctttag	gaatatgggt	ccctaattctc	tcagtattta	ctcgcgaggg	ctgtcacagc	38880
tactgggtcc	agagtctaata	actgtcttgg	ttaagcattt	caaccccatg	attggaaaat	38940
tgcggtaate	ccggactggg	aaagtgtatc	atcccttagt	atttttcattt	tcctctggct	39000
tttatgggtcc	ggacaaggag	tttccctatt	ttttacttct	cattaaaaatg	acagaagggtg	39060
agagacagaa	tagcccttca	cagcccttcc	tccattccct	attccctgtg	acttgcctaa	39120
gcctgtcaca	agctggccgt	cctgaatcct	gtccctggac	ccttgctcat	gttcttctct	39180
ctcatgggac	actcttctgc	ctgccccctt	tggttgtaat	tcctttactg	agcctttcct	39240
gatcactctg	gaactgcctt	tttctgttct	aggcagaagt	accttatTTta	tggtggctatc	39300
tgcttatccc	acccctctaa	aacagcaagg	aataagggaat	gaaacaaaaa	aattccttga	39360
gagaaataag	ttcccatata	cacagttgtt	tattgggctc	agagaggaat	gagtagccct	39420
taaaagggtat	tgcttccgtg	gtctgcccag	gggctggatg	tctgatgcat	tggtgttttg	39480
agtctgtctg	gttcccaatat	gtctcttcta	caatatctga	agttgttctt	tgaagggtgga	39540
acattgtcag	aactattttca	aaaggataaa	tgtagagttg	gttatgcttt	cactttggga	39600
taaatcatat	atatagttaa	ataacaaata	agcacaatta	tttctatata	aaataaattg	39660
caaataaatg	cagaagtgtg	ggcattaagc	tcctagtctc	cagaatgaat	tagcaaaatt	39720
ctgactgggtg	cctaccact	tacctgccaa	ctatgcccc	caccgtgtgt	gccctgtgtc	39780
atggactgat	cttttcttgt	gtctatttgc	agagaatttt	tactctggct	gcagttgctc	39840
aagggtcaga	ctttattatt	cttcttaaat	ttttaatttt	tatttttttt	tgagacaagg	39900
tcttgctctt	ttgcccaggc	tggagtgcag	tggcacaaatc	acggctcatt	acagccttga	39960
cctcctgggc	tcaagcagtc	ctccacacct	agcctcccgt	atagctggga	ccacagggtgt	40020
acaccaccac	acctggccat	ttttgtgtgt	tttttttttg	tagagacagg	gtctcaccat	40080
gtttccgagg	ctgggtctcaa	acttttagac	tcaagtgat	cctcctgcct	cagcctccca	40140
aagtgtggc	attccagggtg	tgtccactg	cacccggcct	caagctttga	tactgagact	40200
tctttcatct	tctataactt	ttcaggctct	cactactaca	gttggttgatt	tctctcctct	40260
aagaaaagat	acaatgaagg	tgtacaattt	tgggggttgtg	ttttgcaaaa	tagcagctgt	40320
agggtggtttt	gccagagaat	ggtctttacc	taacacagcc	cctcttaca	aagtctccaa	40380
gtgtttacca	ctttctgttg	gaatcttagg	aactagacca	aaggcgctgg	gaagggtacat	40440
aggggtttct	ggagtgaagg	cttcttgtgc	aaggctgctt	ctctctaaaa	tgttcagtct	40500
cctaaagccc	aggctctgggt	catcctcagc	ctgagcatca	gtcctgttcc	tgtgcctcct	40560
agggtgaagtt	tgcatccctt	ttatatgatc	tacagcccta	tattttgtct	aatcatatta	40620
taactgatta	gacaaaaatgt	ggcattattg	tttttatttc	ttttgtgttt	tacaagggtct	40680
cactctgttg	cccaggctgg	agtgcagttg	tatgatctca	gctcactgca	gcctggacct	40740

cctaggetca	agcaatcctc	ccacctcggc	ccccacata	gctgggacta	cagggtgcagg	40800
ctaccaaggc	aggctaattt	ttgacatttt	gtggagacag	gatttttgcca	tgttgccctg	40860
gttggtctcg	aactcctgag	ctcaagtgat	ctgccgacct	tggettccca	aaagtgtggg	40920
attacaggca	tgagccacca	taccagctt	ctttttcttt	tctttttttc	ttttttcttt	40980
tttttttttt	tttgagacag	agtctcctct	gttgcccagg	ctggagtga	gtggagtgat	41040
ctcggctcac	tgcagcctct	gactcctggg	ttcacgagat	tctcctgctg	cagcctctcg	41100
agtatctggg	attacaggcg	cctgccatga	tgcccagata	attttttgta	tttttagtag	41160
agacagggtt	tcaccatgtt	ggcaagggtg	gccttggact	gatgggccc	cgctgtctgc	41220
ccgcttcagc	ctcccaaagt	gctgggatta	cagggtgtgac	tcaccacgcc	ctgcccactt	41280
tttcttttga	atgaactaca	aaaagtgatc	tgatattttc	actagatagc	ctcatccagc	41340
ttagatattt	acacggcttc	acaaattcaa	ttttctgttt	cttagagtca	ggtgatagcc	41400
ttatgtggga	ctagcagttt	cacttgcaat	cctgacatat	tcctacacat	tgcaacttga	41460
acatagcata	ggaatgtttt	ctctccacat	ccactccaca	tctgtctaca	gctttccatc	41520
tgtattactg	gtgttaggct	ccaatctgac	tggttaattga	attctaatac	aaactgcta	41580
tgctgtatga	gccgtcatct	caagctggct	tctcggaagc	tcctccttca	gccttccctg	41640
ggcttatggt	ctcttccttc	ttaggtcctt	actaggtagg	ccctctcata	agtgtgttat	41700
cccgtagagt	ctgtgtgttt	agcctaagat	tgtattaaaa	gtccagcctt	ttcaaaaata	41760
gcaaaatatt	aattttctca	tcaactacct	tctgtttttt	gtggtcttta	gaatatgggt	41820
cagtagagct	gggtgtgggtg	gcctgtggtc	ccagctactt	gggaggctga	ggtgggagga	41880
tcgcttgagc	tgaggaagtc	aaggctgcag	tgagccatga	tcatgccact	gaaatccatc	41940
ctggataaca	aaatgagaca	ctgtctcaaa	aacaaacaaa	aataatatgt	gtcaatacct	42000
cctatgggct	gggcgtgggtg	gctcatgcct	gtaacctcag	cactttggga	ggctgaggtg	42060
agcagattgc	ttgaggtcag	gagtttgaga	ccaatctggc	caacatgggtg	aaaatctgtc	42120
tctactaaaa	atacaaaaaa	attagccaag	cgttgtggca	catgcctgta	atcccagctc	42180
ctcgggaggc	tgaggcagga	gaattgcttg	aaccaggaa	gcagagggtg	tggtgagccg	42240
agatcatgcc	actacactcc	atcctgggtg	acagagcgag	gctccatctt	acaaaacaaa	42300
acaaaacaaa	acacctccct	taaaaaaaaa	aaatctgctt	aaagaattgc	atggataaaa	42360
atatttcaga	gctagtattt	agcttccagt	taacttggta	tgctttcatg	tggaagggga	42420
tgtgttttgt	aagaagttgt	cagaggcttg	gagaaaaagc	ccccaaagag	aattctgcac	42480
aggctaactc	gcactattgt	tgggaatgga	cccatccga	gaatctcaaa	gttgaagggtg	42540
atcttaagga	tgtctgcttc	agtcacctatc	agatcatgga	ctcatatttg	caacatttcc	42600
tcaagtgggt	gttcagccct	atcttgggat	ggggaactgt	ctaactccca	ttctttggac	42660
aacactatta	ggatattagg	atatttttaa	gctaactctt	aggctatttc	cacctatag	42720
tcctggatct	tttcccttgg	accatgcaga	gtgaatccac	cttgacgtg	acagcttttc	42780
agatattcga	gggcagctgt	gccagagcc	acctctgggtg	tcagctaaga	aatccttact	42840
tctgtccagg	cgtggtggct	catgcctgta	atcccagcac	tttgggaggc	caagggtgggt	42900
ggatcatgag	gtcaggagat	cgagaccatc	ctggctaaca	cggtgaaacc	ctgtctctac	42960
taaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	ctagccgggc	atggtggcgg	gtgcctgtag	43020
tcccagctac	tcgggagggt	gaggcaggag	aatggcatga	acccaggagg	cggagcttgc	43080
agtgaaccga	gatagcacca	ctgcactcca	gcttgggtga	cagagcgaga	ctccggccca	43140
aaagaaaaaa	aaaaaaaaag	aaatcctgac	ttctttcagc	tggcatttta	aagacgagtc	43200
atattaaatt	ccctgatttt	ggctacctgt	gtaagggtaa	aggctctata	aataatataa	43260
aaatagtctt	ttctgtatat	aattaagaca	tgtggtaata	gtatgttaag	ttggtacatg	43320
taagttaaat	tttttttttt	catagccaag	taatatattc	ttagtagata	caaaaacagt	43380
aaagattgga	gactttggac	ttgtaacatc	tctgaaaaat	gatggaaaagc	gaacaaggag	43440
taagggaact	ttgcgataca	tgagcccaga	acaggtaagg	tctctttcct	gtctgtctat	43500
attttacttc	ttttattttg	aaaattataa	aaagagtaga	cactacttat	ataattaaaa	43560
ctgtacagaa	gtatatacta	aaaattttcc	ttaccattct	tttctacccc	tattcttctt	43620
atcagtttat	tctttatcct	tttagataat	tttctgagtt	ataaaaacat	acaaacacaa	43680
atatacacc	agattttttt	tacagaaaca	tatatatgtg	tacatttttt	caaggactta	43740
ttttgttatt	ttgtgactat	atagcataat	ttctccatat	tagttcaaat	agatctgcca	43800
cattcttttt	ttacaactg	tattatattt	caaaatatgg	agataccata	atttaactat	43860
ttttttaaat	ttaatatttt	ttgttgttgt	tcttattttg	ttttagagac	agggctctgc	43920
tctgtcaccc	aggctggagt	gcagtagtat	gattattgct	cactgcagcc	tcaaaatctt	43980
gggctcaagc	aatcttccca	cctcagcctc	ctgagtagct	aggactctag	aggcacatac	44040
cactgtgccc	agctaattat	ttttattttt	attaattatt	tatttactta	tttattgtag	44100
agacaaggtc	tcactatggt	tcccagggtg	tatttaacta	ttttcttatac	gaagggtatt	44160
tctttagggt	gtttacaact	tcatacaact	agacattcct	ccttattttg	ggtcccaaga	44220
acaaataatt	ctgtgataat	ctgtgttaga	cttcttgagg	taaagtgatt	gaatagattg	44280

accagtgc	at	ttcaaaacttta	attgctggtt	aattgtcatt	ctaaaaaaag	tgattcta	44340
aatactgt	cc	cgtcaaaaatg	tatgagaata	ctgcacatc	atactctcca	gtgatcag	44400
ttgggtag	tg	tggtgaatta	ggagtatc	gctattttag	tttgtat	ccagatt	44460
agtaagg	tat	gcccctct	catatat	cttaaacatt	ttctgcaaat	tctctact	44520
tatcct	ttcc	caat	ttctca	taattaag	ctcatt	ttct	44580
tgatctata	t	tggtgttga	tcccgat	gttaactata	ttatagaatt	tttctc	44640
attgttact	tt	ctttgtttat	aatgacatt	gtggtactgc	agct	tttt	44700
ttttttgaga	t	tgaggtttg	ctcttg	caaggctgga	gtgcaatggc	atgatctcag	44760
ctcactgcaa		caacctctgc	ctcccgggt	caagcaattc	tcctgcctca	gtctcccaag	44820
tagctgggat		tatagg	gcc	caccaccatg	cccagctaag	tttgtat	44880
cgggtttcac		catgctggc	aggctggt	caaactcctg	acctcaggta	atccaccac	44940
cttggcctcc		caaagtgtg	ggattacaga	cgtgagccac	caaaccagc	actgcagctt	45000
ttaaattgtc		atat	ttatca	atacggctgc	taggtttctc	at	45060
tattacaaga		ttatgaaaat	at	tttttgggt	tttactaaca	taaaaattaa	45120
aattaact	tt	tgtttatgta	tgagaaagga	atctaacttg	at	tttccccg	45180
cagttgcttc		atcactacgt	gttaagcagt	taattattta	aatgctat	taaggaaaat	45240
tcatagagac		agaaagtgga	acagagggtta	tctggaagaa	gggaggaatg	ggaacttctt	45300
gtttaatggg		tatagcttct	gtttggggtg	atgaaaagtt	ctggaaatag	atagtgggtga	45360
tggttataca		acattgtgaa	ggtagttaat	gccactgaat	tgtaggcata	aaaatggtta	45420
aaagggtaaa		ttttatgtta	tgtctat	accacaataa	aatattattt	tatcatatat	45480
aaaattccca		cacattcata	gatgtgtt	tggaactttgt	tctgtttcct	taatttattt	45540
tatatttctc		tctttaatat	tatgctat	agattattgt	agcattataa	actaggctt	45600
agtatttgaa		cagcaggacc	tgccacatta	ttcttcaatt	taaaaatgct	ctcagctatt	45660
cacatttaca		attccaaatg	aactctgtaa	tcacattgtc	atcttccata	actggttttg	45720
aggttttgat		agcaattgca	tcaaatttga	ggattcaggt	gaggaacatt	gatattcttca	45780
tatatttgag		acttctccaa	aattgggtatt	ttctctcact	tattcgagtc	ctccatcagt	45840
cagcttttgc		cagactatgc	tgtggtaaca	aatgacccca	gtttcttagt	ggtgcagaaa	45900
ataccaagg		tctatttctt	gctcacatga	caagtcggca	gcagtcctggc	tggtgcag	45960
tttgctctga		gtgtctcctt	cattccaaaga	cccaggctgt	aggaaaaatg	ctatctgagt	46020
cactgccgtc		ctcaaggcag	aaagcaatgg	cagaaccttg	tgatggcttt	tacatgttct	46080
gctcagcagt		ggcatacatc	actaaacatc	attgccaga	gcaaaatgca	tggtccagct	46140
caaggcaatg		agggtggaga	agagtaatcc	tctcactagg	aggccagtc	agcattgggg	46200
gcaatcatac		aacctacctc	agagccactt	ttatactgtt	caaaatctat	atatatatat	46260
atatagagag		agagagagag	agatttatta	tgatatatat	atatatatat	atatatatat	46320
atata	ttttt	ttttttttt	tttgagacag	ggtcttgctt	ttcaccagg	ctggagtaca	46380
gtggcacaat		catagctcac	cactgcgcag	cctcgacctc	cttggctcag	gtgacctcc	46440
tgctcagcc		ccctcagtag	caggactaca	ggctcaaacc	accaacacct	ggctaatttt	46500
ttttgtatt		ttttgtagag	actgggtttc	accatgttgc	ctaggctgg	ctcgaattcc	46560
tggtgttaag		cgatccacct	gtcttgacct	cccaaagtac	taggattaca	ggaatgagcc	46620
acggcgctg		gtcatattgt	ttatattttt	gaagctttct	ccagaatctg	tattgcattt	46680
tgctattaaa		atgagattcc	atgcttgaac	ccgggaggtg	gaggttgag	tgagctgaga	46740
tcgcgccatt		gcaactgcagc	ctggtcaaca	ggaatgagac	tccatctgaa	gaaaaaa	46800
aaaaaagaaa		agaaattcca	tatctcta	ttgttattag	tgtagccgtt	aattttaaaa	46860
atata	ctct	ttat	tttttaa	ttgtggtaaa	atatacaaac	ataaaattta	46920
catt	ttttaag	tgtatagttt	agtggcggtta	aatgtgttca	cattgttgtg	ctttcatcac	46980
caccatacat		ccacagatta	cttttcattt	tgcaaaactg	aaactttaca	cccgtaaag	47040
aactcctatt		ctcctctccc	tacagcccaa	tcaactacca	ttctactttc	tgtctgtata	47100
tttgactatt		ctagatgcct	catgtaagtg	gaatcgtaag	gtatttacc	ttttgttact	47160
ggcttatttt		actcagcata	atatcctcaa	gatatatcca	tggtgtaaca	tgtcagaatt	47220
tctttttaag		gctgactaat	gaattccatt	gtatgtatac	accacatttt	gtttgtcctt	47280
ttatccatca		atgggacactt	agggttgcttc	caccttttga	ctgtggtgaa	taatgctgct	47340
gatgaacatg		ggtgtacagc	tggtgagttt	taaatatttg	tctcatatat	agtctcatta	47400
tttgaatgtg		at	ttttttttt	gggttgattg	cttttatttt	ttaccttttg	47460
cctattttaa		tttctgattt	gtaaatgccc	gttaaagatt	at	ttttgtctga	47520
ttcaaaatat		ctctactatt	ttgtcatcca	agaatagata	tactgagcta	tctgatggtt	47580
tgagagtcta		gaatggagaa	ggcatgtact	ttttcctttt	ggggagccag	ttggcataaa	47640
aaatatagaa		cacaataggc	cagtggctct	ctttaacttc	ctgctgcttt	cagtatctcc	47700
tgcatcctgt		attgctgccc	tcacactatt	tggttaaaaa	cattcatcat	tgtactttac	47760
tttttattat		gtgtgtgtgg	tttttttttc	catttaaaaa	ccttttgttg	gctgggtgca	47820

gtggctcatg	cctgtaatcc	caacactttg	ggaggctgag	gtgggcagat	cacctcaggt	47880
caaggggttt	gagaccagcc	tggccaagat	gttgaaactc	catctccact	aaaaaaacaa	47940
aaatacagaa	atacaaaact	acaaaaatga	gccaggcgtg	gtggcacgtg	cctggagtcc	48000
cagctactct	ggaggctgag	gcaggagaac	tgcttgaacc	tgggaggttg	gggctgctgt	48060
gagccgagac	cacgccactg	cattccagcc	tggtgacagc	gggactccgt	ctcaaaaaaa	48120
aaaaaggcaa	cattttgttg	aggaacaatt	tatacagtat	aaaatgcaca	gatcttaagt	48180
gtatattttt	tcgttttgac	aaatgcatac	acctctgtaa	cttataagac	tataaagata	48240
tagaacattt	tgctccttca	agctcctttc	cagtcagtg	ctcctcccca	ctgatcagaa	48300
gaaaccagca	ctctgagttc	tatcaccata	gcttagttct	tcccgttttt	gaccttcata	48360
tgaatggaat	catacagtag	gtactctttg	tatttaattt	cttcattcaa	aataatatct	48420
tctggaaaaa	ctttgttgct	cataccagca	gagaattcct	ttttattgct	gagtcgtagt	48480
ccattgtatg	aatatgccac	aacatgttta	tccattcttc	tggttggtgc	ctttgagttg	48540
tttccagtta	tggaaatattg	tgaataaata	cgctatgaac	agttgcaatg	caagccgcct	48600
actgggtgct	attttaactg	ctttacctgc	tgcatctcac	tctcacaatc	aaactctgtg	48660
gttgatactg	ttgttatcct	tgttttataa	ctgagattat	tcccatgttg	atcgtttaatt	48720
tacacagagg	attcagctat	tcggcggtac	agatttgaac	ctaggcagtc	agactccaca	48780
gattttgcta	ataaatagac	attgttttgt	ggtgtaagat	gttttggtca	aataactttt	48840
ttgggcttta	gaaggctgga	tatttatgta	aggagcataa	caaaggtaaa	tctatttttg	48900
tctcttttaga	tttcttcgca	agactatgga	aagggaagtgg	acctctacgc	tttggggcta	48960
attcttgctg	aacttcttca	tgtatgtgac	actgcttttg	aaacatcaaa	ggtaaaatta	49020
tctcaaagaa	agaattaaac	aagaaaaatt	actgactacc	accttcagag	tgctgctgca	49080
gacagttctt	gccctcacgt	gaggatgggc	ttgagcatat	tagtatctga	ctgcaaatga	49140
aatatgaatt	ttctgtcttt	caaggtttgg	cagagaccaa	acactttctt	aaagacccaa	49200
aactttgatc	ttccctggaa	ggtagtacat	ctcataagac	ttgtaagact	tgtcagtcag	49260
taacattttta	ttgattgact	gctttgtgta	agacactgtg	ctaagtgtcg	taagggttgc	49320
aaaaataaac	aagccttggc	tgggcgcggt	ggctcacccc	tgtaatccca	gctttgagag	49380
gccaaaggcag	gcagatcact	tgaagtcagg	tgctcgagac	cagcctggcc	aacgtggtga	49440
aatctcatct	ctactaaaaa	tacaaaaatt	agctgggtgt	gggtggtgcac	acctgtaatc	49500
ccaactactc	agggggctga	ggcaggagaa	tcgcttgaac	ctgggaggcg	gaggttgcag	49560
tgagccaaga	tcacaccact	gcactccagc	ctgggtgaca	gagtgacatt	ccatctctaa	49620
ataaataaat	ataaaagcc	ttgttctcaa	ggagcttatt	ttctaaaagg	gaagataata	49680
taagagaatg	ccataagcat	tttaggagaa	ggcatgaagt	ctgtggaagc	agctgggagg	49740
gagatctttc	cagctgtagg	gacttaggtt	tcattggagac	atctaagctg	ggctctgaag	49800
gatctgttgg	cttctaatag	tccaaaacag	aaaagttgat	tctagcatgg	aggcgggaat	49860
gtacagagtg	tatttgggga	cagcaggcag	tgtaagttgt	attggagtat	ataagttaca	49920
aggaagtagt	ggttggtgag	gctagaaaga	taggttgggc	taacttgagg	aaaaaatgtg	49980
gaccttcttg	cttagacagt	ggggagtcac	taaaggcagt	aggcaagtgg	atatcctact	50040
cttttttttt	ttttttttga	gatagagttt	cactttttatt	gccagggtcg	gagtgcaatg	50100
gcgcgatctt	ggctcactgt	aacttctgcc	tcccagggttc	aagcaattct	cctgcctcag	50160
cctccaaggt	aactgggact	acaggcgtgc	accaccatgc	ctggttaatt	tttttgtatt	50220
tagtagagat	ggggtttcac	catgttggtc	aggctgggtc	cgaactcctg	acctctggca	50280
atccaccgcc	ctcggcctcc	cagagtgttg	ggattacagg	tgtagccac	tgcacccagc	50340
tggatacctt	actcttaagc	tcaggaaagg	gaactttcct	ggagtcaata	accttatcct	50400
ctgtaaaaca	gttagaagta	cctatcactt	agggttccaa	aatgcatgaa	gggagattgt	50460
aaagatgatg	cacttaacac	ttcatgtcgt	aatgcaagga	tggttattag	attgggggta	50520
gtgtaggaga	gagggaaatcc	tgtttgcttc	ttggctaaag	agactttccc	aaaaaatctg	50580
gaaatcctt	acatttcagg	tattcctcag	ccttttagttc	tgtctttcct	cccaagtaaa	50640
taatttccta	atatacacct	atcatttttt	tttccagttt	ttcacagacc	tacgggatgg	50700
catcatctca	gatataattg	ataaaaaaga	agtaagcact	tgaaaatcat	cagaatttta	50760
tttatttcaa	tgttttattt	cttactattg	actctcactg	tcattgcaga	aaactcttct	50820
acagaaatta	ctctcaaaga	aacctgagga	tcgacctaac	acatctgaaa	tactaaggac	50880
cttgactgtg	tggaagaaaa	gcccagagaa	aaatgaacga	cacacatgtt	agagcccttc	50940
tgaaaaagta	tcctgcttct	gatatgcagt	tttccttaaa	ttatctaaaa	tctgctaggg	51000
aatatcaata	gatatttacc	ttttatttta	atgtttcctt	taatttttta	ctattttttac	51060
taatctttct	gcagaaacag	aaagggtttc	ttctttttgc	ttcaaaaaca	ttcttacatt	51120
ttactttttc	ctggctcatc	tctttattct	tttttttttt	ttaaagacag	agtctcgctc	51180
tgttgcccg	gctggagtgc	aatgacacag	tottggctca	ctgcaacttc	tgctctctgg	51240
gttcaagtga	ttctcctgcc	tcagcctcct	gagtagctgg	attacaggca	tgtgccaccc	51300
acccaactaa	tttttgtgtt	tttaataaag	acagggtttc	acctgtttgg	ccaggctggg	51360

-22-

```

ctcaaactcc tgacctcaag taatccacct gcctcggcct cccaaagtgc tgggattaca 51420
gggatgagcc accgcgcccc gcctcatctc tttgttctaa agatggaaaa accacccccca 51480
aattttcttt ttatactatt aatgaatcaa tcaattcata tctattttatt aaattttctac 51540
cgcttttagg ccaaaaaaat gtaagatcgt tctctgcctc acatagctta caagccagct 51600
ggagaaatat ggtactcatt aaaaaaaaaa aaaaaagtga tgtacaacca cttcggaaaa 51660
caatttgcca ttatctagta aagttgaatc catgtatacc cacatagcta tcaattctat 51720
tcctacatac gtgcttacaa gaatgtccat aaaaccctgt ttataatagc caaaagaaca 51780
gggaacaacc ataatgcaca tcaaaagaag aatggattaa aaaaattata ttcacacaca 51840
ggagtactat atagtattga aaacaattga agtacagcta aatgtaataa cgtaacacaa 51900
tacaactctc agaaacataa tgttaagcga acaaagcagg ttttcagaaa atatatgcag 51960
aataattcca tttatataaa gttccagagc atgcaaaact aaatcatttt gtataaaaaa 52020
cccaacaatat gtgatgagac aataatggga aggaaggga tgagaaatat taaattctgg 52080
atggtgggta tctttgaggg aggggaatga tgtgattggg gaaatggact ttcaaaggta 52140
atggtaactt ccttaagctg gatggtaggt ccactagtgt ttgctgcata gttataacct 52200
ttatcttaaa tacattttgt atctattgta acaaccactt taaagacaac cgtgctgtaa 52260
ggcagtagct aaaaacagaa aatagtccat cgggaagggt aagatggctt tctgctgagc 52320
acagggctag aagtgcagac ccagtgggct tccaactat atgccagggt gttagatgag 52380
tagagaggag accaccagg aagtctggac aaggggtctg gcatgagctc tggagaagat 52440
atatttgagg aacatgggg atgctagttt gttgtctga attgctgtag agaagataat 52500
ttaaattgca tcttagaaga cgaccctgag ggtgaatttc aacttagggc aattgtttta 52560
gtttgtttct tattggttta aatggatact tgaagctgga taatttataa ggaaaagaga 52620
tttatatgac ttacagttct gcaggctgta caagaaacat ggcaccagca tctgcttctt 52680
ccccggctgc ttccactcat ggtggaagg gaaggggagc cggatgtgca gagatcatat 52740
ggcaagagag gaagcaagag agcgaggag aaggtgccag gctcttttta aataaccggc 52800
tcttgaggga actaatagat tgagaactcc ttgcttctcc tccccagcac accccacccc 52860
cagggacggc attaatgtat tcatgagggg tcttccccca tgacccaaac acctcccatc 52920
aggccccacc tccaacactg ggatcaaatt tcaacatgag attttggggg acaaacatgc 52980
aaactatagc agcaaccagc                                     53000

```

&lt;210&gt; 11

&lt;211&gt; 508

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(508)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 11

```

aggatacggg aagaagaaat ggctggtgat ctttcagcag gtttcttcat ggaggaaactt 60
aatacatacc gtcagaagca gggagtagta cttaaataac aaganctgcc taattcagga 120
cctccacatg ataggaggta ggttgctata aaaaatgata tggcagccat aaanaatgat 180
gagttcatgt cttttgtagg gacatggatg aagctggaaa ccattattct cagcaacta 240
tcgcaaggac aaaaaaacca aacaccgcat gttctcactc atagggtgaga actgagcaat 300
gagaacacat ggacacagga aggggaacat cacacaccag ggactgttgt ggggtggggg 360
gaggggggag ggatagcatt aggagatata cctaatagcta aatgacgagt taatgggtgc 420
agcacaccaa catggcacat gtatacatat gtaacctgca cgttgtgcac atgtacccta 480
aaacttaag tataataata ataaaatt                                     508

```

&lt;210&gt; 12

&lt;211&gt; 492

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

-23-

<400> 12  
 accagtttct ggagcaaatt cagtttgcct tcctggattc gtaaattgta atgacctcaa 60  
 agcttttagca gttcttccat ctgactcagg ttctcttttc tggcgggtctt cagtatcaac 120  
 atccacactt ccattgatta tctgtgtgca ttttggacaa agcttccaac caggtacaag 180  
 ctgtcttcca aatttagcac tcagaaaagt ggcacatctt aagtcaatta catgcaaatt 240  
 ttttggctaa tttcttgtgt atgttaaattt ggtcacaaca tgacttctgt aaatcctcaa 300  
 atctgtcaat gtaaattttt acatgatgaa agcaaattgt attgttccca gaaagtgtca 360  
 ttccagttct aagttgaagt aaaagcatat catttgatga caattcttgc aaagtcttaa 420  
 aacctgtgtg acgagtatag taggttttat ggcaactcatt tgtagtacga agctggactc 480  
 caactgaaca tg 492

<210> 13  
 <211> 458  
 <212> DNA  
 <213> Homo sapiens

<220>

<400> 13  
 ccatttatac tctactctca gtatggatta ttaatgtatt ttaatattct gtttaggccc 60  
 actaaggcaa aatagcccca aaacaagact gacaaaaatc tgaaaaacta atgaggatta 120  
 ttaagctaaa acctgggaaa taggaggctt aaaattgact gccaggctgg gattacaggg 180  
 atgagccacc gcgcccagcc tcactctctt gttctaaaga tggaaaaacc acccccaaatt 240  
 tttcttttta tactattaaa gaatcaatca attcatatct atttattaaa tttctaccgc 300  
 ttttaggcca aaaaaatgta agatcgttct ctgcctcaca tagcttaca gccagctgga 360  
 gaaatatggt actcattaaa aaaaaaaaaa aaagtgatgt acaaccactt cggaaaacaa 420  
 tttggcatta tctagtaaag ttgaatccat gtataccc 458

<210> 14  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 14  
 caagtgtgga gctgaatgcc 20



-24-

<210> 15  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 15  
ctgtggttct accaagtgtg 20

<210> 16  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 16  
cgtgcctgtg gttctaccaa 20

<210> 17  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 17  
tctatgcttg tcgtgcctgt 20

<210> 18  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 18  
gacctgatg cctcgatgaa 20

<210> 19  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

-25-

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 19

tatgatagcc aggtctcct

20

&lt;210&gt; 20

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 20

ccagcgaaga ctaaggtcta

20

&lt;210&gt; 21

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 21

ataccagcga agactaaggt

20

&lt;210&gt; 22

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 22

gctccagaaa ctggtaaaag

20

&lt;210&gt; 23

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 23

caaattccagg aaggcaaact

20

&lt;210&gt; 24

-26-

<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 24  
cagagaagca aacctgagtc 20

<210> 25  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 25  
aaatgcacgc agataatcac 20

<210> 26  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 26  
tccaaaatgc acgcagataa 20

<210> 27  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 27  
ttcccgatatc ctggttgga 20

<210> 28  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 28  
atcaccagcc atttcttctt 20

<210> 29  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 29  
gcagttcttg atatttaagt 20

<210> 30  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 30  
aggctcctgaa ttaggcagtt 20

<210> 31  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 31  
ataacttgaa atgtaaacct 20

<210> 32  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 32  
tctattataa cttgaaatgt 20

<210> 33  
<211> 20

-28-

<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 33  
ccttcacctt ctggaaattc 20

<210> 34  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 34  
tgatctacct tcaccttctg 20

<210> 35  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 35  
agctaatttg gctgcggcat 20

<210> 36  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 36  
tcaacagcta atttggtgc 20

<210> 37  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

-29-

<400> 37  
gaattcgttg ttgtcaataa 20

<210> 38  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 38  
gataatcctt ctgaagaatt 20

<210> 39  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 39  
acactgttca taatttacag 20

<210> 40  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 40  
ataatgaaat ccttctggcc 20

<210> 41  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 41  
cctgtaccaa tactatattc 20

<210> 42  
<211> 20  
<212> DNA

-30-

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 42

tagtagaacc tgtaccaata

20

&lt;210&gt; 43

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 43

cctgttttagt agaacctgta

20

&lt;210&gt; 44

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 44

tgcttcctgt ttagtagaac

20

&lt;210&gt; 45

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 45

taaagagttg ctttgggact

20

&lt;210&gt; 46

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 46

-31-

ttcagaagcg agtgtgctgg 20

<210> 47  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 47  
ccttcagatg atgattcaga 20

<210> 48  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 48  
gtcactgtta gaatttatct 20

<210> 49  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 49  
gaactgttta aactgtcact 20

<210> 50  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 50  
tgccaaagat ctttttgctt 20

<210> 51  
<211> 20  
<212> DNA  
<213> Artificial Sequence



<220>

<223> Antisense Oligonucleotide

<400> 51

tctttcatgt caggaaggtc

20

<210> 52

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 52

aaaacttggc caaatccacc

20

<210> 53

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 53

ttgctttgaa aacttggcca

20

<210> 54

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 54

ctgtgttttg ctttgaaaac

20

<210> 55

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 55

gtttaataac gtaagtcttt

20

- 33 -

<210> 56  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 56  
ctccgccttc tcggtattat 20

<210> 57  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 57  
tttatcacag aattccattt 20

<210> 58  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 58  
tgttccaagg tccctttatc 20

<210> 59  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 59  
agatctctat gaattaattt 20

<210> 60  
<211> 20  
<212> DNA  
<213> Artificial Sequence

-34-

<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 60  
tattacttgg cttaagatct 20

<210> 61  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 61  
tactaagaat atattacttg 20

<210> 62  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 62  
gcgaagaaat ctgttctggg 20

<210> 63  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 63  
acttcctttc catagtcttg 20

<210> 64  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

-35-

<400> 64  
aattagcccc aaagcgtaga 20

<210> 65  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 65  
gatgtttcaa aagcagtgtc 20

<210> 66  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 66  
aactttgatg tttcaaaagc 20

<210> 67  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 67  
ctgtgaaaaa ctttgatgtt 20

<210> 68  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 68  
gagtaatttc tgtagaagag 20

<210> 69  
<211> 20  
<212> DNA

-36-

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 69

tgagagtaat ttctgtagaa

20

&lt;210&gt; 70

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 70

gcttttcttc cacacagtca

20

&lt;210&gt; 71

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 71

gaagggtct aacatgtgtg

20

&lt;210&gt; 72

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 72

gatacttttt cagaagggt

20

&lt;210&gt; 73

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 73

-37-

aaggtaaata tctattgata

20

&lt;210&gt; 74

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 74

ctgttttctgc agaaagatta

20

&lt;210&gt; 75

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 75

atgtttttga agcaaaaaga

20

&lt;210&gt; 76

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 76

ttgattcatt aatagtataa

20

&lt;210&gt; 77

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 77

gcggtagaaa tttaataaat

20

&lt;210&gt; 78

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 78

ccagctggct tgtaagctat

20

<210> 79

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 79

tttaatgagt accatatttc

20

<210> 80

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 80

tatgagcaaa ctgaaattga

20

<210> 81

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 81

attgacttag atgatgccac

20

<210> 82

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 82

gttgaatgta aaactcaaat

20

<210> 83  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 83  
cttggattgg gagcaggcag 20

<210> 84  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 84  
aactcctgac ctcaggtgat 20

<210> 85  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 85  
ctcaagtcca tcatctccca 20

<210> 86  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 86  
ttgtccttgc gatagtttgc 20

<210> 87  
<211> 20  
<212> DNA  
<213> Artificial Sequence



-40-

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 87

ccttcctgtg tccatgtgtt

20

&lt;210&gt; 88

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 88

tgcacccatt aactcgtcac

20

&lt;210&gt; 89

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 89

tctgggaaca atacaatttg

20

&lt;210&gt; 90

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 90

caaagagtg ccataaaacc

20

&lt;210&gt; 91

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 91

aatgccaaat tgttttccga

20

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
20 March 2003 (20.03.2003)

PCT

(10) International Publication Number  
**WO 2003/022222 A3**

(51) International Patent Classification<sup>7</sup>: **A01N 43/04**,  
C12Q 1/68, C12P 19/34, C12N 15/63, 15/88, C07H 21/02,  
21/04

(21) International Application Number:  
PCT/US2002/028870

(22) International Filing Date:  
11 September 2002 (11.09.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/953,611 13 September 2001 (13.09.2001) US

(71) Applicant: **ISIS PHARMACEUTICALS, INC.**  
[US/US]; 2292 Faraday Avenue, Carlsbad, CA 92008  
(US).

(72) Inventors: **WARD, Donna, T.**; 41349 Magnolia Street,  
Murrieta, CA 92562 (US). **WATT, Andrew, T.**; 1500 Shad-  
owridge Drive, Apartment 154, Vista, CA 92083 (US).

(74) Agents: **LICATA, Jane, Massey et al.**; Licata & Tyrrel  
P.C., 66 E. Main Street, Marlton, NJ 08053 (US).

(81) Designated States (*national*): AE, AG, AI., AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GI,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN,  
YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,  
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

(88) Date of publication of the international search report:  
3 February 2005

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: ANTISENSE MODULATION OF PROTEIN KINASE R EXPRESSION

(57) **Abstract:** Antisense compounds, compositions and methods are provided for modulating the expression of Protein Kinase R. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Protein Kinase R. Methods of using these compounds for modulation of Protein Kinase R expression and for treatment of diseases associated with expression of Protein Kinase R are provided.



WO 2003/022222 A3